id	sid	tid	token	lemma	pos
dpc-3517	1	1	dermatology	dermatology	NOUN
dpc-3517	1	2	:	:	PUNCT
dpc-3517	1	3	practical	practical	ADJ
dpc-3517	1	4	and	and	CCONJ
dpc-3517	1	5	conceptual	conceptual	ADJ
dpc-3517	1	6	original	original	ADJ
dpc-3517	1	7	article	article	NOUN
dpc-3517	1	8	|	|	ADV
dpc-3517	1	9	dermatol	dermatol	ADJ
dpc-3517	1	10	pract	pract	NOUN
dpc-3517	1	11	concept	concept	NOUN
dpc-3517	1	12	.	.	PUNCT
dpc-3517	2	1	2024;14(1):e2024026	2024;14(1):e2024026	NUM
dpc-3517	2	2	1	1	NUM
dpc-3517	2	3	pembrolizumab	pembrolizumab	NOUN
dpc-3517	2	4	versus	versus	ADP
dpc-3517	2	5	high	high	ADV
dpc-3517	2	6	-	-	PUNCT
dpc-3517	2	7	dose	dose	NOUN
dpc-3517	2	8	interferon	interferon	NOUN
dpc-3517	2	9	-	-	PUNCT
dpc-3517	2	10	α2b	α2b	NOUN
dpc-3517	2	11	as	as	ADP
dpc-3517	2	12	adjuvant	adjuvant	ADJ
dpc-3517	2	13	therapy	therapy	NOUN
dpc-3517	2	14	for	for	ADP
dpc-3517	2	15	pediatric	pediatric	ADJ
dpc-3517	2	16	melanoma	melanoma	NOUN
dpc-3517	2	17	:	:	PUNCT
dpc-3517	2	18	a	a	DET
dpc-3517	2	19	retrospective	retrospective	ADJ
dpc-3517	2	20	study	study	NOUN
dpc-3517	2	21	yu	yu	PROPN
dpc-3517	2	22	du1	du1	PROPN
dpc-3517	2	23	,	,	PUNCT
dpc-3517	2	24	zhonghui	zhonghui	PROPN
dpc-3517	2	25	qi1	qi1	PROPN
dpc-3517	2	26	,	,	PUNCT
dpc-3517	2	27	xianbin	xianbin	PROPN
dpc-3517	2	28	liang2	liang2	PROPN
dpc-3517	2	29	,	,	PUNCT
dpc-3517	2	30	jie	jie	PROPN
dpc-3517	2	31	dai1	dai1	PROPN
dpc-3517	2	32	,	,	PUNCT
dpc-3517	2	33	xiaoting	xiaoting	PROPN
dpc-3517	2	34	wei1	wei1	PROPN
dpc-3517	2	35	,	,	PUNCT
dpc-3517	2	36	xue	xue	PROPN
dpc-3517	2	37	bai1	bai1	PROPN
dpc-3517	2	38	,	,	PUNCT
dpc-3517	2	39	lili	lili	PROPN
dpc-3517	2	40	mao1	mao1	PROPN
dpc-3517	2	41	,	,	PUNCT
dpc-3517	2	42	zhihong	zhihong	PROPN
dpc-3517	2	43	chi1	chi1	PROPN
dpc-3517	2	44	,	,	PUNCT
dpc-3517	2	45	chuanliang	chuanliang	PROPN
dpc-3517	2	46	cui1	cui1	PROPN
dpc-3517	2	47	,	,	PUNCT
dpc-3517	2	48	bin	bin	PROPN
dpc-3517	2	49	lian1	lian1	PROPN
dpc-3517	2	50	,	,	PUNCT
dpc-3517	2	51	bixia	bixia	PROPN
dpc-3517	2	52	tang1	tang1	PROPN
dpc-3517	2	53	,	,	PUNCT
dpc-3517	2	54	xuan	xuan	PROPN
dpc-3517	2	55	wang1	wang1	PROPN
dpc-3517	2	56	,	,	PUNCT
dpc-3517	2	57	yu	yu	PROPN
dpc-3517	2	58	chen3	chen3	PROPN
dpc-3517	2	59	,	,	PUNCT
dpc-3517	2	60	jun	jun	PROPN
dpc-3517	2	61	 	 	SPACE
dpc-3517	2	62	guo1	guo1	PROPN
dpc-3517	2	63	,	,	PUNCT
dpc-3517	2	64	 	 	SPACE
dpc-3517	2	65	lu	lu	NOUN
dpc-3517	2	66	si1	si1	VERB
dpc-3517	2	67	1	1	NUM
dpc-3517	2	68	key	key	ADJ
dpc-3517	2	69	laboratory	laboratory	NOUN
dpc-3517	2	70	of	of	ADP
dpc-3517	2	71	carcinogenesis	carcinogenesis	NOUN
dpc-3517	2	72	and	and	CCONJ
dpc-3517	2	73	translational	translational	ADJ
dpc-3517	2	74	research	research	NOUN
dpc-3517	2	75	(	(	PUNCT
dpc-3517	2	76	ministry	ministry	NOUN
dpc-3517	2	77	of	of	ADP
dpc-3517	2	78	education	education	PROPN
dpc-3517	2	79	,	,	PUNCT
dpc-3517	2	80	beijing	beijing	PROPN
dpc-3517	2	81	)	)	PUNCT
dpc-3517	2	82	,	,	PUNCT
dpc-3517	2	83	department	department	NOUN
dpc-3517	2	84	of	of	ADP
dpc-3517	2	85	melanoma	melanoma	PROPN
dpc-3517	2	86	and	and	CCONJ
dpc-3517	2	87	sarcoma	sarcoma	NOUN
dpc-3517	2	88	,	,	PUNCT
dpc-3517	2	89	peking	peking	NOUN
dpc-3517	2	90	university	university	NOUN
dpc-3517	2	91	cancer	cancer	NOUN
dpc-3517	2	92	hospital	hospital	NOUN
dpc-3517	2	93	and	and	CCONJ
dpc-3517	2	94	institute	institute	PROPN
dpc-3517	2	95	,	,	PUNCT
dpc-3517	2	96	beijing	beijing	PROPN
dpc-3517	2	97	,	,	PUNCT
dpc-3517	2	98	china	china	PROPN
dpc-3517	2	99	2	2	NUM
dpc-3517	2	100	department	department	NOUN
dpc-3517	2	101	of	of	ADP
dpc-3517	2	102	oncology	oncology	NOUN
dpc-3517	2	103	,	,	PUNCT
dpc-3517	2	104	the	the	DET
dpc-3517	2	105	third	third	ADJ
dpc-3517	2	106	people	people	NOUN
dpc-3517	2	107	’s	’s	PART
dpc-3517	2	108	hospital	hospital	NOUN
dpc-3517	2	109	of	of	ADP
dpc-3517	2	110	zhengzhou	zhengzhou	PROPN
dpc-3517	2	111	,	,	PUNCT
dpc-3517	2	112	zhengzhou	zhengzhou	PROPN
dpc-3517	2	113	,	,	PUNCT
dpc-3517	2	114	china	china	PROPN
dpc-3517	2	115	3	3	NUM
dpc-3517	2	116	department	department	PROPN
dpc-3517	2	117	of	of	ADP
dpc-3517	2	118	medical	medical	ADJ
dpc-3517	2	119	oncology	oncology	NOUN
dpc-3517	2	120	,	,	PUNCT
dpc-3517	2	121	fujian	fujian	ADJ
dpc-3517	2	122	cancer	cancer	NOUN
dpc-3517	2	123	hospital	hospital	PROPN
dpc-3517	2	124	and	and	CCONJ
dpc-3517	2	125	fujian	fujian	PROPN
dpc-3517	2	126	medical	medical	PROPN
dpc-3517	2	127	university	university	PROPN
dpc-3517	2	128	cancer	cancer	NOUN
dpc-3517	2	129	hospital	hospital	NOUN
dpc-3517	2	130	,	,	PUNCT
dpc-3517	2	131	fuzhou	fuzhou	PROPN
dpc-3517	2	132	,	,	PUNCT
dpc-3517	2	133	fujian	fujian	PROPN
dpc-3517	2	134	province	province	PROPN
dpc-3517	2	135	,	,	PUNCT
dpc-3517	2	136	china	china	PROPN
dpc-3517	2	137	key	key	ADJ
dpc-3517	2	138	words	word	NOUN
dpc-3517	2	139	:	:	PUNCT
dpc-3517	2	140	pd-1	pd-1	ADJ
dpc-3517	2	141	,	,	PUNCT
dpc-3517	2	142	interferon	interferon	ADJ
dpc-3517	2	143	,	,	PUNCT
dpc-3517	2	144	children	child	NOUN
dpc-3517	2	145	,	,	PUNCT
dpc-3517	2	146	adolescents	adolescent	NOUN
dpc-3517	2	147	,	,	PUNCT
dpc-3517	2	148	melanoma	melanoma	PROPN
dpc-3517	2	149	citation	citation	NOUN
dpc-3517	2	150	:	:	PUNCT
dpc-3517	2	151	du	du	PROPN
dpc-3517	2	152	y	y	PROPN
dpc-3517	2	153	,	,	PUNCT
dpc-3517	2	154	qi	qi	PROPN
dpc-3517	2	155	z	z	PROPN
dpc-3517	2	156	,	,	PUNCT
dpc-3517	2	157	liang	liang	PROPN
dpc-3517	2	158	x	x	PROPN
dpc-3517	2	159	,	,	PUNCT
dpc-3517	2	160	et	et	PROPN
dpc-3517	2	161	al	al	PROPN
dpc-3517	2	162	.	.	PROPN
dpc-3517	2	163	pembrolizumab	pembrolizumab	NOUN
dpc-3517	2	164	versus	versus	ADP
dpc-3517	2	165	high	high	ADV
dpc-3517	2	166	-	-	PUNCT
dpc-3517	2	167	dose	dose	NOUN
dpc-3517	2	168	interferon	interferon	NOUN
dpc-3517	2	169	-	-	PUNCT
dpc-3517	2	170	α2b	α2b	NOUN
dpc-3517	2	171	as	as	ADP
dpc-3517	2	172	adjuvant	adjuvant	ADJ
dpc-3517	2	173	therapy	therapy	NOUN
dpc-3517	2	174	for	for	ADP
dpc-3517	2	175	pediatric	pediatric	ADJ
dpc-3517	2	176	melanoma	melanoma	NOUN
dpc-3517	2	177	:	:	PUNCT
dpc-3517	2	178	a	a	DET
dpc-3517	2	179	 	 	SPACE
dpc-3517	2	180	retrospective	retrospective	ADJ
dpc-3517	2	181	study	study	NOUN
dpc-3517	2	182	.	.	PUNCT
dpc-3517	3	1	dermatol	dermatol	NOUN
dpc-3517	3	2	pract	pract	PROPN
dpc-3517	3	3	concept	concept	NOUN
dpc-3517	3	4	.	.	PUNCT
dpc-3517	4	1	2024;14(1):e2024026	2024;14(1):e2024026	X
dpc-3517	4	2	.	.	PUNCT
dpc-3517	4	3	doi	doi	NOUN
dpc-3517	4	4	:	:	PUNCT
dpc-3517	4	5	https://doi.org/10.5826/dpc.1401a26	https://doi.org/10.5826/dpc.1401a26	NOUN
dpc-3517	4	6	accepted	accept	VERB
dpc-3517	4	7	:	:	PUNCT
dpc-3517	4	8	july	july	PROPN
dpc-3517	4	9	16	16	NUM
dpc-3517	4	10	,	,	PUNCT
dpc-3517	4	11	2023	2023	NUM
dpc-3517	4	12	;	;	PUNCT
dpc-3517	4	13	published	publish	VERB
dpc-3517	4	14	:	:	PUNCT
dpc-3517	4	15	january	january	PROPN
dpc-3517	4	16	2024	2024	NUM
dpc-3517	4	17	copyright	copyright	NOUN
dpc-3517	4	18	:	:	PUNCT
dpc-3517	5	1	©	©	PROPN
dpc-3517	5	2	2024	2024	NUM
dpc-3517	5	3	du	du	X
dpc-3517	5	4	et	et	PROPN
dpc-3517	5	5	al	al	PROPN
dpc-3517	5	6	.	.	PUNCT
dpc-3517	6	1	this	this	PRON
dpc-3517	6	2	is	be	AUX
dpc-3517	6	3	an	an	DET
dpc-3517	6	4	open	open	ADJ
dpc-3517	6	5	-	-	PUNCT
dpc-3517	6	6	access	access	NOUN
dpc-3517	6	7	article	article	NOUN
dpc-3517	6	8	distributed	distribute	VERB
dpc-3517	6	9	under	under	ADP
dpc-3517	6	10	the	the	DET
dpc-3517	6	11	terms	term	NOUN
dpc-3517	6	12	of	of	ADP
dpc-3517	6	13	the	the	DET
dpc-3517	6	14	creative	creative	ADJ
dpc-3517	6	15	commons	common	NOUN
dpc-3517	6	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-3517	6	17	license	license	NOUN
dpc-3517	6	18	(	(	PUNCT
dpc-3517	6	19	by	by	ADP
dpc-3517	6	20	-	-	PUNCT
dpc-3517	6	21	nc-4.0	nc-4.0	NOUN
dpc-3517	6	22	)	)	PUNCT
dpc-3517	6	23	,	,	PUNCT
dpc-3517	6	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-3517	6	25	,	,	PUNCT
dpc-3517	6	26	which	which	PRON
dpc-3517	6	27	permits	permit	VERB
dpc-3517	6	28	unrestricted	unrestricted	ADJ
dpc-3517	6	29	noncommercial	noncommercial	ADJ
dpc-3517	6	30	use	use	NOUN
dpc-3517	6	31	,	,	PUNCT
dpc-3517	6	32	distribution	distribution	NOUN
dpc-3517	6	33	,	,	PUNCT
dpc-3517	6	34	and	and	CCONJ
dpc-3517	6	35	reproduction	reproduction	NOUN
dpc-3517	6	36	in	in	ADP
dpc-3517	6	37	any	any	DET
dpc-3517	6	38	medium	medium	NOUN
dpc-3517	6	39	,	,	PUNCT
dpc-3517	6	40	provided	provide	VERB
dpc-3517	6	41	the	the	DET
dpc-3517	6	42	original	original	ADJ
dpc-3517	6	43	authors	author	NOUN
dpc-3517	6	44	and	and	CCONJ
dpc-3517	6	45	source	source	NOUN
dpc-3517	6	46	are	be	AUX
dpc-3517	6	47	credited	credit	VERB
dpc-3517	6	48	.	.	PUNCT
dpc-3517	7	1	funding	funding	NOUN
dpc-3517	7	2	:	:	PUNCT
dpc-3517	7	3	none	none	NOUN
dpc-3517	7	4	.	.	PUNCT
dpc-3517	8	1	competing	compete	VERB
dpc-3517	8	2	interests	interest	NOUN
dpc-3517	8	3	:	:	PUNCT
dpc-3517	8	4	none	none	NOUN
dpc-3517	8	5	.	.	PUNCT
dpc-3517	9	1	authorship	authorship	NOUN
dpc-3517	9	2	:	:	PUNCT
dpc-3517	9	3	yu	yu	PROPN
dpc-3517	9	4	du	du	PROPN
dpc-3517	9	5	,	,	PUNCT
dpc-3517	9	6	zhonghui	zhonghui	PROPN
dpc-3517	9	7	qi	qi	PROPN
dpc-3517	9	8	and	and	CCONJ
dpc-3517	9	9	xianbin	xianbin	PROPN
dpc-3517	9	10	liang	liang	PROPN
dpc-3517	9	11	contributed	contribute	VERB
dpc-3517	9	12	equally	equally	ADV
dpc-3517	9	13	to	to	ADP
dpc-3517	9	14	this	this	DET
dpc-3517	9	15	work	work	NOUN
dpc-3517	9	16	.	.	PUNCT
dpc-3517	10	1	all	all	DET
dpc-3517	10	2	authors	author	NOUN
dpc-3517	10	3	have	have	AUX
dpc-3517	10	4	contributed	contribute	VERB
dpc-3517	10	5	significantly	significantly	ADV
dpc-3517	10	6	to	to	ADP
dpc-3517	10	7	this	this	DET
dpc-3517	10	8	publication	publication	NOUN
dpc-3517	10	9	.	.	PUNCT
dpc-3517	11	1	introduction	introduction	NOUN
dpc-3517	11	2	:	:	PUNCT
dpc-3517	11	3	pembrolizumab	pembrolizumab	NOUN
dpc-3517	11	4	is	be	AUX
dpc-3517	11	5	well	well	ADV
dpc-3517	11	6	-	-	PUNCT
dpc-3517	11	7	tolerated	tolerate	VERB
dpc-3517	11	8	in	in	ADP
dpc-3517	11	9	pediatric	pediatric	ADJ
dpc-3517	11	10	patients	patient	NOUN
dpc-3517	11	11	with	with	ADP
dpc-3517	11	12	advanced	advanced	ADJ
dpc-3517	11	13	tumors	tumor	NOUN
dpc-3517	11	14	,	,	PUNCT
dpc-3517	11	15	consistent	consistent	ADJ
dpc-3517	11	16	with	with	ADP
dpc-3517	11	17	results	result	NOUN
dpc-3517	11	18	in	in	ADP
dpc-3517	11	19	adults	adult	NOUN
dpc-3517	11	20	.	.	PUNCT
dpc-3517	12	1	however	however	ADV
dpc-3517	12	2	,	,	PUNCT
dpc-3517	12	3	information	information	NOUN
dpc-3517	12	4	on	on	ADP
dpc-3517	12	5	the	the	DET
dpc-3517	12	6	safety	safety	NOUN
dpc-3517	12	7	and	and	CCONJ
dpc-3517	12	8	efficacy	efficacy	NOUN
dpc-3517	12	9	of	of	ADP
dpc-3517	12	10	adjuvant	adjuvant	ADJ
dpc-3517	12	11	pembrolizumab	pembrolizumab	NOUN
dpc-3517	12	12	in	in	ADP
dpc-3517	12	13	children	child	NOUN
dpc-3517	12	14	and	and	CCONJ
dpc-3517	12	15	adolescents	adolescent	NOUN
dpc-3517	12	16	with	with	ADP
dpc-3517	12	17	melanoma	melanoma	NOUN
dpc-3517	12	18	is	be	AUX
dpc-3517	12	19	lacking	lack	VERB
dpc-3517	12	20	.	.	PUNCT
dpc-3517	13	1	objectives	objective	NOUN
dpc-3517	13	2	:	:	PUNCT
dpc-3517	13	3	to	to	PART
dpc-3517	13	4	compare	compare	VERB
dpc-3517	13	5	pembrolizumab	pembrolizumab	NOUN
dpc-3517	13	6	versus	versus	ADP
dpc-3517	13	7	high	high	ADV
dpc-3517	13	8	-	-	PUNCT
dpc-3517	13	9	dose	dose	NOUN
dpc-3517	13	10	interferon	interferon	NOUN
dpc-3517	13	11	-	-	PUNCT
dpc-3517	13	12	α2b	α2b	NOUN
dpc-3517	13	13	(	(	PUNCT
dpc-3517	13	14	hdi	hdi	PROPN
dpc-3517	13	15	)	)	PUNCT
dpc-3517	13	16	as	as	ADP
dpc-3517	13	17	adjuvant	adjuvant	ADJ
dpc-3517	13	18	therapy	therapy	NOUN
dpc-3517	13	19	in	in	ADP
dpc-3517	13	20	pediatric	pediatric	ADJ
dpc-3517	13	21	patients	patient	NOUN
dpc-3517	13	22	with	with	ADP
dpc-3517	13	23	melanoma	melanoma	NOUN
dpc-3517	13	24	.	.	PUNCT
dpc-3517	14	1	methods	method	NOUN
dpc-3517	14	2	:	:	PUNCT
dpc-3517	14	3	we	we	PRON
dpc-3517	14	4	performed	perform	VERB
dpc-3517	14	5	a	a	DET
dpc-3517	14	6	retrospective	retrospective	ADJ
dpc-3517	14	7	study	study	NOUN
dpc-3517	14	8	of	of	ADP
dpc-3517	14	9	pediatric	pediatric	ADJ
dpc-3517	14	10	patients	patient	NOUN
dpc-3517	14	11	diagnosed	diagnose	VERB
dpc-3517	14	12	with	with	ADP
dpc-3517	14	13	melanoma	melanoma	NOUN
dpc-3517	14	14	between	between	ADP
dpc-3517	14	15	january	january	PROPN
dpc-3517	14	16	2008	2008	NUM
dpc-3517	14	17	and	and	CCONJ
dpc-3517	14	18	april	april	PROPN
dpc-3517	14	19	2022	2022	NUM
dpc-3517	14	20	.	.	PUNCT
dpc-3517	15	1	relapse	relapse	NOUN
dpc-3517	15	2	-	-	PUNCT
dpc-3517	15	3	free	free	ADJ
dpc-3517	15	4	survival	survival	NOUN
dpc-3517	15	5	(	(	PUNCT
dpc-3517	15	6	rfs	rfs	PROPN
dpc-3517	15	7	)	)	PUNCT
dpc-3517	15	8	and	and	CCONJ
dpc-3517	15	9	the	the	DET
dpc-3517	15	10	1	1	NUM
dpc-3517	15	11	-	-	PUNCT
dpc-3517	15	12	year	year	NOUN
dpc-3517	15	13	rfs	rfs	NOUN
dpc-3517	15	14	rate	rate	NOUN
dpc-3517	15	15	were	be	AUX
dpc-3517	15	16	compared	compare	VERB
dpc-3517	15	17	between	between	ADP
dpc-3517	15	18	patients	patient	NOUN
dpc-3517	15	19	receiving	receive	VERB
dpc-3517	15	20	adjuvant	adjuvant	ADJ
dpc-3517	15	21	pembrolizumab	pembrolizumab	NOUN
dpc-3517	15	22	or	or	CCONJ
dpc-3517	15	23	hdi	hdi	PROPN
dpc-3517	15	24	.	.	PUNCT
dpc-3517	16	1	results	result	NOUN
dpc-3517	16	2	:	:	PUNCT
dpc-3517	16	3	seventy	seventy	NUM
dpc-3517	16	4	-	-	PUNCT
dpc-3517	16	5	five	five	NUM
dpc-3517	16	6	pediatric	pediatric	ADJ
dpc-3517	16	7	patients	patient	NOUN
dpc-3517	16	8	with	with	ADP
dpc-3517	16	9	melanoma	melanoma	NOUN
dpc-3517	16	10	were	be	AUX
dpc-3517	16	11	screened	screen	VERB
dpc-3517	16	12	from	from	ADP
dpc-3517	16	13	a	a	DET
dpc-3517	16	14	database	database	NOUN
dpc-3517	16	15	of	of	ADP
dpc-3517	16	16	6,013	6,013	NUM
dpc-3517	16	17	patients	patient	NOUN
dpc-3517	16	18	.	.	PUNCT
dpc-3517	17	1	twenty	twenty	NUM
dpc-3517	17	2	-	-	PUNCT
dpc-3517	17	3	four	four	NUM
dpc-3517	17	4	patients	patient	NOUN
dpc-3517	17	5	were	be	AUX
dpc-3517	17	6	finally	finally	ADV
dpc-3517	17	7	enrolled	enrol	VERB
dpc-3517	17	8	,	,	PUNCT
dpc-3517	17	9	of	of	ADP
dpc-3517	17	10	whom	whom	PRON
dpc-3517	17	11	9	9	NUM
dpc-3517	17	12	received	receive	VERB
dpc-3517	17	13	pembrolizumab	pembrolizumab	NOUN
dpc-3517	17	14	and	and	CCONJ
dpc-3517	17	15	15	15	NUM
dpc-3517	17	16	received	receive	VERB
dpc-3517	17	17	hdi	hdi	PROPN
dpc-3517	17	18	as	as	ADP
dpc-3517	17	19	adjuvant	adjuvant	ADJ
dpc-3517	17	20	therapy	therapy	NOUN
dpc-3517	17	21	.	.	PUNCT
dpc-3517	18	1	by	by	ADP
dpc-3517	18	2	august	august	PROPN
dpc-3517	18	3	31	31	NUM
dpc-3517	18	4	,	,	PUNCT
dpc-3517	18	5	2022	2022	NUM
dpc-3517	18	6	,	,	PUNCT
dpc-3517	18	7	the	the	DET
dpc-3517	18	8	median	median	ADJ
dpc-3517	18	9	follow	follow	VERB
dpc-3517	18	10	-	-	PUNCT
dpc-3517	18	11	up	up	NOUN
dpc-3517	18	12	times	time	NOUN
dpc-3517	18	13	were	be	AUX
dpc-3517	18	14	23.6	23.6	NUM
dpc-3517	18	15	months	month	NOUN
dpc-3517	18	16	and	and	CCONJ
dpc-3517	18	17	98.7	98.7	NUM
dpc-3517	18	18	months	month	NOUN
dpc-3517	18	19	in	in	ADP
dpc-3517	18	20	the	the	DET
dpc-3517	18	21	pembrolizumab	pembrolizumab	NOUN
dpc-3517	18	22	and	and	CCONJ
dpc-3517	18	23	hdi	hdi	PROPN
dpc-3517	18	24	groups	group	NOUN
dpc-3517	18	25	,	,	PUNCT
dpc-3517	18	26	respectively	respectively	ADV
dpc-3517	18	27	.	.	PUNCT
dpc-3517	19	1	there	there	PRON
dpc-3517	19	2	was	be	VERB
dpc-3517	19	3	no	no	DET
dpc-3517	19	4	significant	significant	ADJ
dpc-3517	19	5	difference	difference	NOUN
dpc-3517	19	6	in	in	ADP
dpc-3517	19	7	median	median	ADJ
dpc-3517	19	8	rfs	rfs	NOUN
dpc-3517	19	9	between	between	ADP
dpc-3517	19	10	two	two	NUM
dpc-3517	19	11	groups	group	NOUN
dpc-3517	19	12	(	(	PUNCT
dpc-3517	19	13	not	not	PART
dpc-3517	19	14	reached	reach	VERB
dpc-3517	19	15	versus	versus	ADP
dpc-3517	19	16	38.7	38.7	NUM
dpc-3517	19	17	months	month	NOUN
dpc-3517	19	18	,	,	PUNCT
dpc-3517	19	19	p	p	X
dpc-3517	19	20	=	=	NOUN
dpc-3517	19	21	0.11	0.11	NUM
dpc-3517	19	22	)	)	PUNCT
dpc-3517	19	23	.	.	PUNCT
dpc-3517	20	1	the	the	DET
dpc-3517	20	2	median	median	ADJ
dpc-3517	20	3	overall	overall	ADJ
dpc-3517	20	4	survival	survival	NOUN
dpc-3517	20	5	was	be	AUX
dpc-3517	20	6	not	not	PART
dpc-3517	20	7	reached	reach	VERB
dpc-3517	20	8	in	in	ADP
dpc-3517	20	9	either	either	DET
dpc-3517	20	10	group	group	NOUN
dpc-3517	20	11	.	.	PUNCT
dpc-3517	21	1	the	the	DET
dpc-3517	21	2	1	1	NUM
dpc-3517	21	3	-	-	PUNCT
dpc-3517	21	4	year	year	NOUN
dpc-3517	21	5	rfs	rfs	NOUN
dpc-3517	21	6	rates	rate	NOUN
dpc-3517	21	7	were	be	AUX
dpc-3517	21	8	88.9	88.9	NUM
dpc-3517	21	9	%	%	NOUN
dpc-3517	21	10	and	and	CCONJ
dpc-3517	21	11	66.7	66.7	NUM
dpc-3517	21	12	%	%	NOUN
dpc-3517	21	13	in	in	ADP
dpc-3517	21	14	the	the	DET
dpc-3517	21	15	pembrolizumab	pembrolizumab	NOUN
dpc-3517	21	16	and	and	CCONJ
dpc-3517	21	17	hdi	hdi	PROPN
dpc-3517	21	18	groups	group	NOUN
dpc-3517	21	19	,	,	PUNCT
dpc-3517	21	20	respectively	respectively	ADV
dpc-3517	21	21	.	.	PUNCT
dpc-3517	22	1	all	all	DET
dpc-3517	22	2	adverse	adverse	ADJ
dpc-3517	22	3	events	event	NOUN
dpc-3517	22	4	in	in	ADP
dpc-3517	22	5	the	the	DET
dpc-3517	22	6	pembrolizumab	pembrolizumab	NOUN
dpc-3517	22	7	group	group	NOUN
dpc-3517	22	8	were	be	AUX
dpc-3517	22	9	grade	grade	NOUN
dpc-3517	22	10	1	1	NUM
dpc-3517	22	11	or	or	CCONJ
dpc-3517	22	12	2	2	NUM
dpc-3517	22	13	,	,	PUNCT
dpc-3517	22	14	but	but	CCONJ
dpc-3517	22	15	grade	grade	NOUN
dpc-3517	22	16	3–5	3–5	NUM
dpc-3517	22	17	adverse	adverse	ADJ
dpc-3517	22	18	events	event	NOUN
dpc-3517	22	19	occurred	occur	VERB
dpc-3517	22	20	in	in	ADP
dpc-3517	22	21	two	two	NUM
dpc-3517	22	22	(	(	PUNCT
dpc-3517	22	23	13	13	NUM
dpc-3517	22	24	%	%	NOUN
dpc-3517	22	25	)	)	PUNCT
dpc-3517	22	26	patients	patient	NOUN
dpc-3517	22	27	receiving	receive	VERB
dpc-3517	22	28	hdi	hdi	PROPN
dpc-3517	22	29	.	.	PUNCT
dpc-3517	23	1	abstract	abstract	ADJ
dpc-3517	23	2	2	2	NUM
dpc-3517	23	3	original	original	ADJ
dpc-3517	23	4	article	article	NOUN
dpc-3517	23	5	|	|	ADV
dpc-3517	23	6	dermatol	dermatol	ADJ
dpc-3517	23	7	pract	pract	NOUN
dpc-3517	23	8	concept	concept	NOUN
dpc-3517	23	9	.	.	PUNCT
dpc-3517	24	1	2024;14(1):e2024026	2024;14(1):e2024026	NUM
dpc-3517	24	2	corresponding	corresponding	ADJ
dpc-3517	24	3	author	author	NOUN
dpc-3517	24	4	:	:	PUNCT
dpc-3517	24	5	lu	lu	PROPN
dpc-3517	24	6	si	si	PROPN
dpc-3517	24	7	,	,	PUNCT
dpc-3517	24	8	department	department	NOUN
dpc-3517	24	9	of	of	ADP
dpc-3517	24	10	melanoma	melanoma	PROPN
dpc-3517	24	11	and	and	CCONJ
dpc-3517	24	12	sarcoma	sarcoma	NOUN
dpc-3517	24	13	,	,	PUNCT
dpc-3517	24	14	peking	peking	NOUN
dpc-3517	24	15	university	university	NOUN
dpc-3517	24	16	cancer	cancer	NOUN
dpc-3517	24	17	hospital	hospital	NOUN
dpc-3517	24	18	and	and	CCONJ
dpc-3517	24	19	institute	institute	PROPN
dpc-3517	24	20	,	,	PUNCT
dpc-3517	24	21	no	no	INTJ
dpc-3517	24	22	.	.	PROPN
dpc-3517	24	23	52	52	NUM
dpc-3517	24	24	fucheng	fucheng	PROPN
dpc-3517	24	25	road	road	NOUN
dpc-3517	24	26	,	,	PUNCT
dpc-3517	24	27	haidian	haidian	PROPN
dpc-3517	24	28	district	district	PROPN
dpc-3517	24	29	,	,	PUNCT
dpc-3517	24	30	beijing	beijing	PROPN
dpc-3517	24	31	,	,	PUNCT
dpc-3517	24	32	100142	100142	NUM
dpc-3517	24	33	,	,	PUNCT
dpc-3517	24	34	china	china	PROPN
dpc-3517	24	35	.	.	PUNCT
dpc-3517	25	1	e	e	X
dpc-3517	25	2	-	-	NOUN
dpc-3517	25	3	mail	mail	NOUN
dpc-3517	25	4	:	:	PUNCT
dpc-3517	25	5	silu15_silu@126.com	silu15_silu@126.com	PROPN
dpc-3517	25	6	.	.	PUNCT
dpc-3517	26	1	introduction	introduction	NOUN
dpc-3517	26	2	melanoma	melanoma	NOUN
dpc-3517	26	3	is	be	AUX
dpc-3517	26	4	a	a	DET
dpc-3517	26	5	rare	rare	ADJ
dpc-3517	26	6	disease	disease	NOUN
dpc-3517	26	7	in	in	ADP
dpc-3517	26	8	the	the	DET
dpc-3517	26	9	pediatric	pediatric	ADJ
dpc-3517	26	10	population	population	NOUN
dpc-3517	26	11	compared	compare	VERB
dpc-3517	26	12	with	with	ADP
dpc-3517	26	13	its	its	PRON
dpc-3517	26	14	incidence	incidence	NOUN
dpc-3517	26	15	in	in	ADP
dpc-3517	26	16	adults	adult	NOUN
dpc-3517	26	17	,	,	PUNCT
dpc-3517	26	18	with	with	ADP
dpc-3517	26	19	an	an	DET
dpc-3517	26	20	incidence	incidence	NOUN
dpc-3517	26	21	of	of	ADP
dpc-3517	26	22	0.7–0.8	0.7–0.8	NOUN
dpc-3517	26	23	per	per	ADP
dpc-3517	26	24	million	million	NUM
dpc-3517	26	25	per	per	ADP
dpc-3517	26	26	year	year	NOUN
dpc-3517	26	27	in	in	ADP
dpc-3517	26	28	the	the	DET
dpc-3517	26	29	first	first	ADJ
dpc-3517	26	30	decade	decade	NOUN
dpc-3517	26	31	of	of	ADP
dpc-3517	26	32	life	life	NOUN
dpc-3517	26	33	,	,	PUNCT
dpc-3517	26	34	rising	rise	VERB
dpc-3517	26	35	to	to	ADP
dpc-3517	26	36	>	>	X
dpc-3517	26	37	10	10	NUM
dpc-3517	26	38	per	per	ADP
dpc-3517	26	39	million	million	NUM
dpc-3517	26	40	per	per	ADP
dpc-3517	26	41	year	year	NOUN
dpc-3517	26	42	in	in	ADP
dpc-3517	26	43	adolescents	adolescent	NOUN
dpc-3517	26	44	aged	age	VERB
dpc-3517	26	45	15–19	15–19	NOUN
dpc-3517	26	46	  	  	SPACE
dpc-3517	26	47	years	year	NOUN
dpc-3517	26	48	[	[	X
dpc-3517	26	49	1	1	NUM
dpc-3517	26	50	]	]	PUNCT
dpc-3517	26	51	.	.	PUNCT
dpc-3517	27	1	there	there	PRON
dpc-3517	27	2	are	be	VERB
dpc-3517	27	3	three	three	NUM
dpc-3517	27	4	subtypes	subtype	NOUN
dpc-3517	27	5	of	of	ADP
dpc-3517	27	6	pediatric	pediatric	ADJ
dpc-3517	27	7	melanoma	melanoma	NOUN
dpc-3517	27	8	:	:	PUNCT
dpc-3517	27	9	spitzoid	spitzoid	ADJ
dpc-3517	27	10	melanoma	melanoma	NOUN
dpc-3517	27	11	,	,	PUNCT
dpc-3517	27	12	melanoma	melanoma	NOUN
dpc-3517	27	13	arising	arise	VERB
dpc-3517	27	14	in	in	ADP
dpc-3517	27	15	a	a	DET
dpc-3517	27	16	congenital	congenital	ADJ
dpc-3517	27	17	melanocytic	melanocytic	ADJ
dpc-3517	27	18	nevus	nevus	NOUN
dpc-3517	27	19	,	,	PUNCT
dpc-3517	27	20	and	and	CCONJ
dpc-3517	27	21	conventional	conventional	ADJ
dpc-3517	27	22	(	(	PUNCT
dpc-3517	27	23	also	also	ADV
dpc-3517	27	24	known	know	VERB
dpc-3517	27	25	as	as	ADP
dpc-3517	27	26	adult	adult	NOUN
dpc-3517	27	27	-	-	PUNCT
dpc-3517	27	28	type	type	NOUN
dpc-3517	27	29	)	)	PUNCT
dpc-3517	27	30	melanoma	melanoma	NOUN
dpc-3517	28	1	[	[	X
dpc-3517	28	2	2	2	NUM
dpc-3517	28	3	]	]	PUNCT
dpc-3517	28	4	.	.	PUNCT
dpc-3517	29	1	spitzoid	spitzoid	ADJ
dpc-3517	29	2	melanoma	melanoma	PROPN
dpc-3517	29	3	is	be	AUX
dpc-3517	29	4	one	one	NUM
dpc-3517	29	5	of	of	ADP
dpc-3517	29	6	the	the	DET
dpc-3517	29	7	most	most	ADV
dpc-3517	29	8	common	common	ADJ
dpc-3517	29	9	subtypes	subtype	NOUN
dpc-3517	29	10	of	of	ADP
dpc-3517	29	11	pediatric	pediatric	ADJ
dpc-3517	29	12	melanoma	melanoma	NOUN
dpc-3517	29	13	,	,	PUNCT
dpc-3517	29	14	showing	show	VERB
dpc-3517	29	15	distinct	distinct	ADJ
dpc-3517	29	16	histopathological	histopathological	ADJ
dpc-3517	29	17	and	and	CCONJ
dpc-3517	29	18	genetic	genetic	ADJ
dpc-3517	29	19	patterns	pattern	NOUN
dpc-3517	29	20	compared	compare	VERB
dpc-3517	29	21	with	with	ADP
dpc-3517	29	22	adult	adult	NOUN
dpc-3517	29	23	melanoma	melanoma	NOUN
dpc-3517	29	24	,	,	PUNCT
dpc-3517	29	25	including	include	VERB
dpc-3517	29	26	a	a	DET
dpc-3517	29	27	greater	great	ADJ
dpc-3517	29	28	breslow	breslow	ADJ
dpc-3517	29	29	thickness	thickness	NOUN
dpc-3517	29	30	at	at	ADP
dpc-3517	29	31	diagnosis	diagnosis	NOUN
dpc-3517	29	32	[	[	X
dpc-3517	29	33	3	3	NUM
dpc-3517	29	34	]	]	PUNCT
dpc-3517	29	35	.	.	PUNCT
dpc-3517	30	1	most	most	ADV
dpc-3517	30	2	published	publish	VERB
dpc-3517	30	3	data	datum	NOUN
dpc-3517	30	4	on	on	ADP
dpc-3517	30	5	pediatric	pediatric	ADJ
dpc-3517	30	6	melanoma	melanoma	NOUN
dpc-3517	30	7	have	have	AUX
dpc-3517	30	8	involved	involve	VERB
dpc-3517	30	9	retrospective	retrospective	ADJ
dpc-3517	30	10	,	,	PUNCT
dpc-3517	30	11	single	single	ADJ
dpc-3517	30	12	institution	institution	NOUN
dpc-3517	30	13	studies	study	NOUN
dpc-3517	30	14	with	with	ADP
dpc-3517	30	15	small	small	ADJ
dpc-3517	30	16	samples	sample	NOUN
dpc-3517	30	17	or	or	CCONJ
dpc-3517	30	18	case	case	NOUN
dpc-3517	30	19	reports	report	NOUN
dpc-3517	30	20	,	,	PUNCT
dpc-3517	30	21	and	and	CCONJ
dpc-3517	30	22	few	few	ADJ
dpc-3517	30	23	prospective	prospective	ADJ
dpc-3517	30	24	studies	study	NOUN
dpc-3517	30	25	have	have	AUX
dpc-3517	30	26	been	be	AUX
dpc-3517	30	27	conducted	conduct	VERB
dpc-3517	30	28	.	.	PUNCT
dpc-3517	31	1	although	although	SCONJ
dpc-3517	31	2	various	various	ADJ
dpc-3517	31	3	therapies	therapy	NOUN
dpc-3517	31	4	,	,	PUNCT
dpc-3517	31	5	including	include	VERB
dpc-3517	31	6	ipilimumab	ipilimumab	NOUN
dpc-3517	31	7	,	,	PUNCT
dpc-3517	31	8	pembrolizumab	pembrolizumab	NOUN
dpc-3517	31	9	,	,	PUNCT
dpc-3517	31	10	nivolumab	nivolumab	NOUN
dpc-3517	31	11	,	,	PUNCT
dpc-3517	31	12	and	and	CCONJ
dpc-3517	31	13	combination	combination	NOUN
dpc-3517	31	14	braf	braf	NOUN
dpc-3517	31	15	-	-	PUNCT
dpc-3517	31	16	mek	mek	NOUN
dpc-3517	31	17	inhibitors	inhibitor	NOUN
dpc-3517	31	18	,	,	PUNCT
dpc-3517	31	19	make	make	VERB
dpc-3517	31	20	a	a	DET
dpc-3517	31	21	huge	huge	ADJ
dpc-3517	31	22	difference	difference	NOUN
dpc-3517	31	23	in	in	ADP
dpc-3517	31	24	the	the	DET
dpc-3517	31	25	treatment	treatment	NOUN
dpc-3517	31	26	of	of	ADP
dpc-3517	31	27	melanoma	melanoma	NOUN
dpc-3517	31	28	in	in	ADP
dpc-3517	31	29	adults	adult	NOUN
dpc-3517	31	30	,	,	PUNCT
dpc-3517	31	31	scanty	scanty	ADJ
dpc-3517	31	32	information	information	NOUN
dpc-3517	31	33	on	on	ADP
dpc-3517	31	34	the	the	DET
dpc-3517	31	35	use	use	NOUN
dpc-3517	31	36	of	of	ADP
dpc-3517	31	37	these	these	DET
dpc-3517	31	38	therapies	therapy	NOUN
dpc-3517	31	39	in	in	ADP
dpc-3517	31	40	pediatric	pediatric	ADJ
dpc-3517	31	41	melanoma	melanoma	NOUN
dpc-3517	31	42	is	be	AUX
dpc-3517	31	43	available	available	ADJ
dpc-3517	31	44	.	.	PUNCT
dpc-3517	32	1	pembrolizumab	pembrolizumab	NOUN
dpc-3517	32	2	is	be	AUX
dpc-3517	32	3	a	a	DET
dpc-3517	32	4	highly	highly	ADV
dpc-3517	32	5	selective	selective	ADJ
dpc-3517	32	6	,	,	PUNCT
dpc-3517	32	7	humanized	humanize	VERB
dpc-3517	32	8	,	,	PUNCT
dpc-3517	32	9	igg4	igg4	NOUN
dpc-3517	32	10	monoclonal	monoclonal	NOUN
dpc-3517	32	11	antibody	antibody	NOUN
dpc-3517	32	12	with	with	ADP
dpc-3517	32	13	a	a	DET
dpc-3517	32	14	favorable	favorable	ADJ
dpc-3517	32	15	safety	safety	NOUN
dpc-3517	32	16	profile	profile	NOUN
dpc-3517	32	17	and	and	CCONJ
dpc-3517	32	18	good	good	ADJ
dpc-3517	32	19	efficacy	efficacy	NOUN
dpc-3517	32	20	and	and	CCONJ
dpc-3517	32	21	durability	durability	NOUN
dpc-3517	32	22	,	,	PUNCT
dpc-3517	32	23	which	which	PRON
dpc-3517	32	24	has	have	AUX
dpc-3517	32	25	been	be	AUX
dpc-3517	32	26	approved	approve	VERB
dpc-3517	32	27	by	by	ADP
dpc-3517	32	28	the	the	DET
dpc-3517	32	29	us	us	PROPN
dpc-3517	32	30	food	food	NOUN
dpc-3517	32	31	and	and	CCONJ
dpc-3517	32	32	drug	drug	PROPN
dpc-3517	32	33	administration	administration	PROPN
dpc-3517	32	34	(	(	PUNCT
dpc-3517	32	35	fda	fda	PROPN
dpc-3517	32	36	)	)	PUNCT
dpc-3517	32	37	for	for	ADP
dpc-3517	32	38	the	the	DET
dpc-3517	32	39	treatment	treatment	NOUN
dpc-3517	32	40	of	of	ADP
dpc-3517	32	41	several	several	ADJ
dpc-3517	32	42	tumor	tumor	NOUN
dpc-3517	32	43	types	type	NOUN
dpc-3517	32	44	,	,	PUNCT
dpc-3517	32	45	including	include	VERB
dpc-3517	32	46	melanoma	melanoma	NOUN
dpc-3517	32	47	,	,	PUNCT
dpc-3517	32	48	in	in	ADP
dpc-3517	32	49	both	both	DET
dpc-3517	32	50	adults	adult	NOUN
dpc-3517	32	51	and	and	CCONJ
dpc-3517	32	52	children	child	NOUN
dpc-3517	32	53	.	.	PUNCT
dpc-3517	33	1	an	an	DET
dpc-3517	33	2	interim	interim	ADJ
dpc-3517	33	3	analysis	analysis	NOUN
dpc-3517	33	4	of	of	ADP
dpc-3517	33	5	the	the	DET
dpc-3517	33	6	keynote-051	keynote-051	ADJ
dpc-3517	33	7	study	study	NOUN
dpc-3517	33	8	reported	report	VERB
dpc-3517	33	9	on	on	ADP
dpc-3517	33	10	the	the	DET
dpc-3517	33	11	use	use	NOUN
dpc-3517	33	12	of	of	ADP
dpc-3517	33	13	pembrolizumab	pembrolizumab	NOUN
dpc-3517	33	14	in	in	ADP
dpc-3517	33	15	children	child	NOUN
dpc-3517	33	16	with	with	ADP
dpc-3517	33	17	advanced	advanced	ADJ
dpc-3517	33	18	cancer	cancer	NOUN
dpc-3517	33	19	,	,	PUNCT
dpc-3517	33	20	including	include	VERB
dpc-3517	33	21	eight	eight	NUM
dpc-3517	33	22	cases	case	NOUN
dpc-3517	33	23	of	of	ADP
dpc-3517	33	24	pediatric	pediatric	ADJ
dpc-3517	33	25	melanoma	melanoma	NOUN
dpc-3517	33	26	.	.	PUNCT
dpc-3517	34	1	pembrolizumab	pembrolizumab	NOUN
dpc-3517	34	2	showed	show	VERB
dpc-3517	34	3	favorable	favorable	ADJ
dpc-3517	34	4	tolerance	tolerance	NOUN
dpc-3517	34	5	and	and	CCONJ
dpc-3517	34	6	encouraging	encourage	VERB
dpc-3517	34	7	antitumor	antitumor	NOUN
dpc-3517	34	8	activity	activity	NOUN
dpc-3517	34	9	in	in	ADP
dpc-3517	34	10	pediatric	pediatric	ADJ
dpc-3517	34	11	patients	patient	NOUN
dpc-3517	34	12	with	with	ADP
dpc-3517	34	13	relapsed	relapse	VERB
dpc-3517	34	14	or	or	CCONJ
dpc-3517	34	15	refractory	refractory	NOUN
dpc-3517	34	16	hodgkin	hodgkin	NOUN
dpc-3517	34	17	lymphoma	lymphoma	NOUN
dpc-3517	34	18	,	,	PUNCT
dpc-3517	34	19	but	but	CCONJ
dpc-3517	34	20	had	have	VERB
dpc-3517	34	21	low	low	ADJ
dpc-3517	34	22	antitumor	antitumor	NOUN
dpc-3517	34	23	activity	activity	NOUN
dpc-3517	34	24	in	in	ADP
dpc-3517	34	25	most	most	ADJ
dpc-3517	34	26	pediatric	pediatric	ADJ
dpc-3517	34	27	tumor	tumor	NOUN
dpc-3517	34	28	types	type	NOUN
dpc-3517	34	29	[	[	X
dpc-3517	34	30	4	4	NUM
dpc-3517	34	31	]	]	PUNCT
dpc-3517	34	32	.	.	PUNCT
dpc-3517	35	1	inhibitors	inhibitor	NOUN
dpc-3517	35	2	of	of	ADP
dpc-3517	35	3	programmed	programmed	ADJ
dpc-3517	35	4	cell	cell	NOUN
dpc-3517	35	5	death-1	death-1	NUM
dpc-3517	35	6	(	(	PUNCT
dpc-3517	35	7	pd-1	pd-1	ADV
dpc-3517	35	8	)	)	PUNCT
dpc-3517	35	9	have	have	AUX
dpc-3517	35	10	not	not	PART
dpc-3517	35	11	been	be	AUX
dpc-3517	35	12	explored	explore	VERB
dpc-3517	35	13	as	as	ADP
dpc-3517	35	14	adjuvant	adjuvant	ADJ
dpc-3517	35	15	therapies	therapy	NOUN
dpc-3517	35	16	for	for	ADP
dpc-3517	35	17	pediatric	pediatric	ADJ
dpc-3517	35	18	melanoma	melanoma	NOUN
dpc-3517	35	19	.	.	PUNCT
dpc-3517	36	1	previous	previous	ADJ
dpc-3517	36	2	clinical	clinical	ADJ
dpc-3517	36	3	trials	trial	NOUN
dpc-3517	36	4	demonstrated	demonstrate	VERB
dpc-3517	36	5	that	that	SCONJ
dpc-3517	36	6	adjuvant	adjuvant	ADJ
dpc-3517	36	7	high	high	ADV
dpc-3517	36	8	-	-	PUNCT
dpc-3517	36	9	dose	dose	NOUN
dpc-3517	36	10	interferon	interferon	NOUN
dpc-3517	36	11	(	(	PUNCT
dpc-3517	36	12	ifn)-α2b	ifn)-α2b	PROPN
dpc-3517	36	13	(	(	PUNCT
dpc-3517	36	14	hdi	hdi	PROPN
dpc-3517	36	15	)	)	PUNCT
dpc-3517	36	16	had	have	VERB
dpc-3517	36	17	similar	similar	ADJ
dpc-3517	36	18	safety	safety	NOUN
dpc-3517	36	19	profiles	profile	NOUN
dpc-3517	36	20	in	in	ADP
dpc-3517	36	21	pediatric	pediatric	ADJ
dpc-3517	36	22	and	and	CCONJ
dpc-3517	36	23	adult	adult	NOUN
dpc-3517	36	24	melanoma	melanoma	NOUN
dpc-3517	36	25	patients	patient	NOUN
dpc-3517	36	26	[	[	X
dpc-3517	36	27	5	5	NUM
dpc-3517	36	28	]	]	PUNCT
dpc-3517	36	29	.	.	PUNCT
dpc-3517	37	1	in	in	ADP
dpc-3517	37	2	this	this	DET
dpc-3517	37	3	study	study	NOUN
dpc-3517	37	4	,	,	PUNCT
dpc-3517	37	5	we	we	PRON
dpc-3517	37	6	retrospectively	retrospectively	ADV
dpc-3517	37	7	analyzed	analyze	VERB
dpc-3517	37	8	and	and	CCONJ
dpc-3517	37	9	compared	compare	VERB
dpc-3517	37	10	the	the	DET
dpc-3517	37	11	outcomes	outcome	NOUN
dpc-3517	37	12	of	of	ADP
dpc-3517	37	13	pediatric	pediatric	ADJ
dpc-3517	37	14	patients	patient	NOUN
dpc-3517	37	15	with	with	ADP
dpc-3517	37	16	completely	completely	ADV
dpc-3517	37	17	resected	resect	VERB
dpc-3517	37	18	melanoma	melanoma	NOUN
dpc-3517	37	19	treated	treat	VERB
dpc-3517	37	20	with	with	ADP
dpc-3517	37	21	adjuvant	adjuvant	ADJ
dpc-3517	37	22	pembrolizumab	pembrolizumab	NOUN
dpc-3517	37	23	or	or	CCONJ
dpc-3517	37	24	hdi	hdi	PROPN
dpc-3517	37	25	.	.	PUNCT
dpc-3517	38	1	methods	method	NOUN
dpc-3517	38	2	study	study	VERB
dpc-3517	38	3	design	design	NOUN
dpc-3517	38	4	and	and	CCONJ
dpc-3517	38	5	patients	patient	NOUN
dpc-3517	38	6	this	this	PRON
dpc-3517	38	7	was	be	AUX
dpc-3517	38	8	a	a	DET
dpc-3517	38	9	multicenter	multicenter	NOUN
dpc-3517	38	10	,	,	PUNCT
dpc-3517	38	11	retrospective	retrospective	ADJ
dpc-3517	38	12	study	study	NOUN
dpc-3517	38	13	of	of	ADP
dpc-3517	38	14	pembrolizumab	pembrolizumab	NOUN
dpc-3517	38	15	versus	versus	ADP
dpc-3517	38	16	hdi	hdi	PROPN
dpc-3517	38	17	as	as	ADP
dpc-3517	38	18	adjuvant	adjuvant	ADJ
dpc-3517	38	19	therapy	therapy	NOUN
dpc-3517	38	20	in	in	ADP
dpc-3517	38	21	pediatric	pediatric	ADJ
dpc-3517	38	22	patients	patient	NOUN
dpc-3517	38	23	with	with	ADP
dpc-3517	38	24	melanoma	melanoma	NOUN
dpc-3517	38	25	treated	treat	VERB
dpc-3517	38	26	at	at	ADP
dpc-3517	38	27	three	three	NUM
dpc-3517	38	28	tertiary	tertiary	ADJ
dpc-3517	38	29	hospitals	hospital	NOUN
dpc-3517	38	30	in	in	ADP
dpc-3517	38	31	china	china	PROPN
dpc-3517	38	32	.	.	PUNCT
dpc-3517	39	1	the	the	DET
dpc-3517	39	2	eligibility	eligibility	PROPN
dpc-3517	39	3	criteria	criterion	NOUN
dpc-3517	39	4	(	(	PUNCT
dpc-3517	39	5	figure	figure	NOUN
dpc-3517	39	6	1	1	NUM
dpc-3517	39	7	)	)	PUNCT
dpc-3517	39	8	were	be	AUX
dpc-3517	39	9	:	:	PUNCT
dpc-3517	39	10	1	1	X
dpc-3517	39	11	)	)	PUNCT
dpc-3517	39	12	<	<	X
dpc-3517	39	13	18	18	NUM
dpc-3517	39	14	-	-	PUNCT
dpc-3517	39	15	yearsold	yearsold	ADJ
dpc-3517	39	16	;	;	PUNCT
dpc-3517	39	17	2	2	X
dpc-3517	39	18	)	)	PUNCT
dpc-3517	39	19	diagnosis	diagnosis	NOUN
dpc-3517	39	20	of	of	ADP
dpc-3517	39	21	completely	completely	ADV
dpc-3517	39	22	resected	resect	VERB
dpc-3517	39	23	stage	stage	NOUN
dpc-3517	39	24	iib	iib	PROPN
dpc-3517	39	25	/	/	SYM
dpc-3517	39	26	iic	iic	PROPN
dpc-3517	39	27	/	/	SYM
dpc-3517	39	28	iii/	iii/	ADJ
dpc-3517	39	29	iv	iv	NUM
dpc-3517	39	30	melanoma	melanoma	NOUN
dpc-3517	39	31	;	;	PUNCT
dpc-3517	39	32	3	3	X
dpc-3517	39	33	)	)	PUNCT
dpc-3517	39	34	diagnosis	diagnosis	NOUN
dpc-3517	39	35	from	from	ADP
dpc-3517	39	36	january	january	PROPN
dpc-3517	39	37	1	1	NUM
dpc-3517	39	38	,	,	PUNCT
dpc-3517	39	39	2008	2008	NUM
dpc-3517	39	40	to	to	ADP
dpc-3517	39	41	april	april	PROPN
dpc-3517	39	42	30	30	NUM
dpc-3517	39	43	,	,	PUNCT
dpc-3517	39	44	2022	2022	NUM
dpc-3517	39	45	;	;	PUNCT
dpc-3517	39	46	4	4	X
dpc-3517	39	47	)	)	PUNCT
dpc-3517	39	48	pembrolizumab	pembrolizumab	NOUN
dpc-3517	39	49	adjuvant	adjuvant	NOUN
dpc-3517	39	50	therapy	therapy	NOUN
dpc-3517	39	51	(	(	PUNCT
dpc-3517	39	52	2	2	NUM
dpc-3517	39	53	mg	mg	PROPN
dpc-3517	39	54	/	/	SYM
dpc-3517	39	55	kg	kg	NOUN
dpc-3517	39	56	up	up	ADP
dpc-3517	39	57	to	to	ADP
dpc-3517	39	58	a	a	DET
dpc-3517	39	59	maximum	maximum	NOUN
dpc-3517	39	60	of	of	ADP
dpc-3517	39	61	200	200	NUM
dpc-3517	39	62	mg	mg	NOUN
dpc-3517	39	63	every	every	DET
dpc-3517	39	64	3	3	NUM
dpc-3517	39	65	weeks	week	NOUN
dpc-3517	39	66	via	via	ADP
dpc-3517	39	67	intravenous	intravenous	ADJ
dpc-3517	39	68	infusion	infusion	NOUN
dpc-3517	39	69	)	)	PUNCT
dpc-3517	39	70	or	or	CCONJ
dpc-3517	39	71	hdi	hdi	PROPN
dpc-3517	39	72	adjuvant	adjuvant	NOUN
dpc-3517	39	73	therapy	therapy	NOUN
dpc-3517	39	74	(	(	PUNCT
dpc-3517	39	75	18×106	18×106	NUM
dpc-3517	39	76	iu	iu	PROPN
dpc-3517	39	77	/	/	SYM
dpc-3517	39	78	m2	m2	PROPN
dpc-3517	39	79	per	per	ADP
dpc-3517	39	80	day	day	NOUN
dpc-3517	39	81	ifn	ifn	PROPN
dpc-3517	39	82	-	-	PUNCT
dpc-3517	39	83	α2b	α2b	NOUN
dpc-3517	39	84	subcutaneously	subcutaneously	ADV
dpc-3517	39	85	on	on	ADP
dpc-3517	39	86	days	day	NOUN
dpc-3517	39	87	1–5	1–5	NUM
dpc-3517	39	88	for	for	ADP
dpc-3517	39	89	4	4	NUM
dpc-3517	39	90	weeks	week	NOUN
dpc-3517	39	91	,	,	PUNCT
dpc-3517	39	92	followed	follow	VERB
dpc-3517	39	93	by	by	ADP
dpc-3517	39	94	9×106	9×106	NUM
dpc-3517	39	95	iu	iu	PROPN
dpc-3517	39	96	/	/	SYM
dpc-3517	39	97	m2	m2	PROPN
dpc-3517	39	98	per	per	ADP
dpc-3517	39	99	day	day	NOUN
dpc-3517	39	100	ifn	ifn	PROPN
dpc-3517	39	101	-	-	PUNCT
dpc-3517	39	102	α2b	α2b	NUM
dpc-3517	39	103	three	three	NUM
dpc-3517	39	104	times	time	NOUN
dpc-3517	39	105	a	a	DET
dpc-3517	39	106	week	week	NOUN
dpc-3517	39	107	subcutaneously	subcutaneously	ADV
dpc-3517	39	108	)	)	PUNCT
dpc-3517	39	109	within	within	ADP
dpc-3517	39	110	3	3	NUM
dpc-3517	39	111	months	month	NOUN
dpc-3517	39	112	after	after	ADP
dpc-3517	39	113	surgery	surgery	NOUN
dpc-3517	39	114	.	.	PUNCT
dpc-3517	40	1	clinical	clinical	ADJ
dpc-3517	40	2	data	datum	NOUN
dpc-3517	40	3	were	be	AUX
dpc-3517	40	4	extracted	extract	VERB
dpc-3517	40	5	from	from	ADP
dpc-3517	40	6	medical	medical	ADJ
dpc-3517	40	7	records	record	NOUN
dpc-3517	40	8	,	,	PUNCT
dpc-3517	40	9	including	include	VERB
dpc-3517	40	10	age	age	NOUN
dpc-3517	40	11	,	,	PUNCT
dpc-3517	40	12	sex	sex	NOUN
dpc-3517	40	13	,	,	PUNCT
dpc-3517	40	14	primary	primary	ADJ
dpc-3517	40	15	site	site	NOUN
dpc-3517	40	16	,	,	PUNCT
dpc-3517	40	17	histologic	histologic	ADJ
dpc-3517	40	18	subtype	subtype	NOUN
dpc-3517	40	19	,	,	PUNCT
dpc-3517	40	20	breslow	breslow	ADJ
dpc-3517	40	21	tumor	tumor	NOUN
dpc-3517	40	22	thickness	thickness	NOUN
dpc-3517	40	23	,	,	PUNCT
dpc-3517	40	24	ulceration	ulceration	NOUN
dpc-3517	40	25	,	,	PUNCT
dpc-3517	40	26	date	date	NOUN
dpc-3517	40	27	of	of	ADP
dpc-3517	40	28	surgery	surgery	NOUN
dpc-3517	40	29	,	,	PUNCT
dpc-3517	40	30	date	date	NOUN
dpc-3517	40	31	of	of	ADP
dpc-3517	40	32	recurrence	recurrence	NOUN
dpc-3517	40	33	,	,	PUNCT
dpc-3517	40	34	date	date	NOUN
dpc-3517	40	35	of	of	ADP
dpc-3517	40	36	death	death	NOUN
dpc-3517	40	37	,	,	PUNCT
dpc-3517	40	38	and	and	CCONJ
dpc-3517	40	39	side	side	NOUN
dpc-3517	40	40	effects	effect	NOUN
dpc-3517	40	41	graded	grade	VERB
dpc-3517	40	42	according	accord	VERB
dpc-3517	40	43	to	to	ADP
dpc-3517	40	44	the	the	DET
dpc-3517	40	45	national	national	PROPN
dpc-3517	40	46	cancer	cancer	PROPN
dpc-3517	40	47	institute	institute	PROPN
dpc-3517	40	48	common	common	ADJ
dpc-3517	40	49	toxicity	toxicity	NOUN
dpc-3517	40	50	criteria	criterion	NOUN
dpc-3517	40	51	version	version	NOUN
dpc-3517	40	52	4.03	4.03	NUM
dpc-3517	40	53	.	.	PUNCT
dpc-3517	41	1	relapse	relapse	NOUN
dpc-3517	41	2	-	-	PUNCT
dpc-3517	41	3	free	free	ADJ
dpc-3517	41	4	survival	survival	NOUN
dpc-3517	41	5	(	(	PUNCT
dpc-3517	41	6	rfs	rfs	PROPN
dpc-3517	41	7	)	)	PUNCT
dpc-3517	41	8	was	be	AUX
dpc-3517	41	9	defined	define	VERB
dpc-3517	41	10	as	as	ADP
dpc-3517	41	11	the	the	DET
dpc-3517	41	12	time	time	NOUN
dpc-3517	41	13	from	from	ADP
dpc-3517	41	14	the	the	DET
dpc-3517	41	15	start	start	NOUN
dpc-3517	41	16	of	of	ADP
dpc-3517	41	17	adjuvant	adjuvant	ADJ
dpc-3517	41	18	treatment	treatment	NOUN
dpc-3517	41	19	to	to	ADP
dpc-3517	41	20	the	the	DET
dpc-3517	41	21	date	date	NOUN
dpc-3517	41	22	of	of	ADP
dpc-3517	41	23	first	first	ADJ
dpc-3517	41	24	recurrence	recurrence	NOUN
dpc-3517	41	25	(	(	PUNCT
dpc-3517	41	26	local	local	ADJ
dpc-3517	41	27	,	,	PUNCT
dpc-3517	41	28	regional	regional	ADJ
dpc-3517	41	29	,	,	PUNCT
dpc-3517	41	30	or	or	CCONJ
dpc-3517	41	31	distant	distant	ADJ
dpc-3517	41	32	metastasis	metastasis	NOUN
dpc-3517	41	33	)	)	PUNCT
dpc-3517	41	34	or	or	CCONJ
dpc-3517	41	35	death	death	NOUN
dpc-3517	41	36	from	from	ADP
dpc-3517	41	37	any	any	DET
dpc-3517	41	38	cause	cause	NOUN
dpc-3517	41	39	.	.	PUNCT
dpc-3517	42	1	the	the	DET
dpc-3517	42	2	1	1	NUM
dpc-3517	42	3	-	-	PUNCT
dpc-3517	42	4	year	year	NOUN
dpc-3517	42	5	rfs	rfs	NOUN
dpc-3517	42	6	rate	rate	NOUN
dpc-3517	42	7	,	,	PUNCT
dpc-3517	42	8	overall	overall	ADJ
dpc-3517	42	9	survival	survival	NOUN
dpc-3517	42	10	(	(	PUNCT
dpc-3517	42	11	os	os	NOUN
dpc-3517	42	12	)	)	PUNCT
dpc-3517	42	13	,	,	PUNCT
dpc-3517	42	14	and	and	CCONJ
dpc-3517	42	15	safety	safety	NOUN
dpc-3517	42	16	were	be	AUX
dpc-3517	42	17	also	also	ADV
dpc-3517	42	18	assessed	assess	VERB
dpc-3517	42	19	.	.	PUNCT
dpc-3517	43	1	informed	inform	VERB
dpc-3517	43	2	written	write	VERB
dpc-3517	43	3	consent	consent	NOUN
dpc-3517	43	4	was	be	AUX
dpc-3517	43	5	obtained	obtain	VERB
dpc-3517	43	6	from	from	ADP
dpc-3517	43	7	all	all	DET
dpc-3517	43	8	patients	patient	NOUN
dpc-3517	43	9	.	.	PUNCT
dpc-3517	44	1	this	this	DET
dpc-3517	44	2	study	study	NOUN
dpc-3517	44	3	was	be	AUX
dpc-3517	44	4	approved	approve	VERB
dpc-3517	44	5	by	by	ADP
dpc-3517	44	6	the	the	DET
dpc-3517	44	7	institutional	institutional	ADJ
dpc-3517	44	8	review	review	PROPN
dpc-3517	44	9	board	board	NOUN
dpc-3517	44	10	of	of	ADP
dpc-3517	44	11	peking	peking	PROPN
dpc-3517	44	12	university	university	NOUN
dpc-3517	44	13	cancer	cancer	NOUN
dpc-3517	44	14	hospital	hospital	NOUN
dpc-3517	44	15	and	and	CCONJ
dpc-3517	44	16	was	be	AUX
dpc-3517	44	17	conducted	conduct	VERB
dpc-3517	44	18	according	accord	VERB
dpc-3517	44	19	to	to	ADP
dpc-3517	44	20	declaration	declaration	NOUN
dpc-3517	44	21	of	of	ADP
dpc-3517	44	22	helsinki	helsinki	PROPN
dpc-3517	44	23	principles	principle	NOUN
dpc-3517	44	24	.	.	PUNCT
dpc-3517	45	1	statistical	statistical	ADJ
dpc-3517	45	2	analysis	analysis	NOUN
dpc-3517	45	3	all	all	DET
dpc-3517	45	4	statistical	statistical	ADJ
dpc-3517	45	5	analyses	analysis	NOUN
dpc-3517	45	6	were	be	AUX
dpc-3517	45	7	performed	perform	VERB
dpc-3517	45	8	using	use	VERB
dpc-3517	45	9	r	r	NOUN
dpc-3517	45	10	version	version	NOUN
dpc-3517	45	11	4.2.1	4.2.1	NOUN
dpc-3517	45	12	.	.	PUNCT
dpc-3517	46	1	survival	survival	NOUN
dpc-3517	46	2	curves	curve	NOUN
dpc-3517	46	3	were	be	AUX
dpc-3517	46	4	plotted	plot	VERB
dpc-3517	46	5	using	use	VERB
dpc-3517	46	6	the	the	DET
dpc-3517	46	7	kaplan	kaplan	PROPN
dpc-3517	46	8	-	-	PUNCT
dpc-3517	46	9	meier	meier	PROPN
dpc-3517	46	10	method	method	NOUN
dpc-3517	46	11	conclusions	conclusion	NOUN
dpc-3517	46	12	:	:	PUNCT
dpc-3517	46	13	rfs	rfs	PROPN
dpc-3517	46	14	was	be	AUX
dpc-3517	46	15	similar	similar	ADJ
dpc-3517	46	16	in	in	ADP
dpc-3517	46	17	pediatric	pediatric	ADJ
dpc-3517	46	18	patients	patient	NOUN
dpc-3517	46	19	with	with	ADP
dpc-3517	46	20	melanoma	melanoma	NOUN
dpc-3517	46	21	receiving	receive	VERB
dpc-3517	46	22	adjuvant	adjuvant	ADJ
dpc-3517	46	23	pembrolizumab	pembrolizumab	NOUN
dpc-3517	46	24	or	or	CCONJ
dpc-3517	46	25	hdi	hdi	NOUN
dpc-3517	46	26	,	,	PUNCT
dpc-3517	46	27	but	but	CCONJ
dpc-3517	46	28	pembrolizumab	pembrolizumab	NOUN
dpc-3517	46	29	was	be	AUX
dpc-3517	46	30	associated	associate	VERB
dpc-3517	46	31	with	with	ADP
dpc-3517	46	32	a	a	DET
dpc-3517	46	33	reduced	reduced	ADJ
dpc-3517	46	34	risk	risk	NOUN
dpc-3517	46	35	of	of	ADP
dpc-3517	46	36	recurrence	recurrence	NOUN
dpc-3517	46	37	and	and	CCONJ
dpc-3517	46	38	a	a	DET
dpc-3517	46	39	more	more	ADV
dpc-3517	46	40	favorable	favorable	ADJ
dpc-3517	46	41	safety	safety	NOUN
dpc-3517	46	42	profile	profile	NOUN
dpc-3517	46	43	.	.	PUNCT
dpc-3517	47	1	however	however	ADV
dpc-3517	47	2	,	,	PUNCT
dpc-3517	47	3	due	due	ADP
dpc-3517	47	4	to	to	ADP
dpc-3517	47	5	the	the	DET
dpc-3517	47	6	small	small	ADJ
dpc-3517	47	7	sample	sample	NOUN
dpc-3517	47	8	size	size	NOUN
dpc-3517	47	9	and	and	CCONJ
dpc-3517	47	10	differences	difference	NOUN
dpc-3517	47	11	in	in	ADP
dpc-3517	47	12	follow	follow	NOUN
dpc-3517	47	13	-	-	PUNCT
dpc-3517	47	14	up	up	ADP
dpc-3517	47	15	time	time	NOUN
dpc-3517	47	16	,	,	PUNCT
dpc-3517	47	17	larger	large	ADJ
dpc-3517	47	18	and	and	CCONJ
dpc-3517	47	19	prospective	prospective	ADJ
dpc-3517	47	20	studies	study	NOUN
dpc-3517	47	21	are	be	AUX
dpc-3517	47	22	still	still	ADV
dpc-3517	47	23	warranted	warrant	VERB
dpc-3517	47	24	to	to	PART
dpc-3517	47	25	explore	explore	VERB
dpc-3517	47	26	better	well	ADV
dpc-3517	47	27	adjuvant	adjuvant	ADJ
dpc-3517	47	28	therapies	therapy	NOUN
dpc-3517	47	29	for	for	ADP
dpc-3517	47	30	pediatric	pediatric	ADJ
dpc-3517	47	31	melanoma	melanoma	NOUN
dpc-3517	47	32	.	.	PUNCT
dpc-3517	48	1	original	original	ADJ
dpc-3517	48	2	article	article	NOUN
dpc-3517	48	3	|	|	ADV
dpc-3517	48	4	dermatol	dermatol	ADJ
dpc-3517	48	5	pract	pract	NOUN
dpc-3517	48	6	concept	concept	NOUN
dpc-3517	48	7	.	.	PUNCT
dpc-3517	49	1	2024;14(1):e2024026	2024;14(1):e2024026	NUM
dpc-3517	49	2	3	3	NUM
dpc-3517	49	3	and	and	CCONJ
dpc-3517	49	4	compared	compare	VERB
dpc-3517	49	5	between	between	ADP
dpc-3517	49	6	groups	group	NOUN
dpc-3517	49	7	using	use	VERB
dpc-3517	49	8	log	log	NOUN
dpc-3517	49	9	-	-	PUNCT
dpc-3517	49	10	rank	rank	NOUN
dpc-3517	49	11	tests	test	NOUN
dpc-3517	49	12	.	.	PUNCT
dpc-3517	50	1	categorical	categorical	ADJ
dpc-3517	50	2	data	datum	NOUN
dpc-3517	50	3	were	be	AUX
dpc-3517	50	4	analyzed	analyze	VERB
dpc-3517	50	5	using	use	VERB
dpc-3517	50	6	χ2	χ2	PROPN
dpc-3517	50	7	or	or	CCONJ
dpc-3517	50	8	fisher	fisher	PROPN
dpc-3517	50	9	’s	’s	PART
dpc-3517	50	10	exact	exact	ADJ
dpc-3517	50	11	tests	test	NOUN
dpc-3517	50	12	.	.	PUNCT
dpc-3517	51	1	results	result	NOUN
dpc-3517	51	2	patient	patient	ADJ
dpc-3517	51	3	characteristics	characteristic	NOUN
dpc-3517	51	4	seventy	seventy	NUM
dpc-3517	51	5	-	-	PUNCT
dpc-3517	51	6	five	five	NUM
dpc-3517	51	7	pediatric	pediatric	ADJ
dpc-3517	51	8	patients	patient	NOUN
dpc-3517	51	9	with	with	ADP
dpc-3517	51	10	melanoma	melanoma	NOUN
dpc-3517	51	11	were	be	AUX
dpc-3517	51	12	screened	screen	VERB
dpc-3517	51	13	from	from	ADP
dpc-3517	51	14	a	a	DET
dpc-3517	51	15	database	database	NOUN
dpc-3517	51	16	of	of	ADP
dpc-3517	51	17	6013	6013	NUM
dpc-3517	51	18	patients	patient	NOUN
dpc-3517	51	19	at	at	ADP
dpc-3517	51	20	three	three	NUM
dpc-3517	51	21	hospitals	hospital	NOUN
dpc-3517	51	22	between	between	ADP
dpc-3517	51	23	january	january	PROPN
dpc-3517	51	24	1	1	NUM
dpc-3517	51	25	,	,	PUNCT
dpc-3517	51	26	2008	2008	NUM
dpc-3517	51	27	and	and	CCONJ
dpc-3517	51	28	april	april	PROPN
dpc-3517	51	29	30	30	NUM
dpc-3517	51	30	,	,	PUNCT
dpc-3517	51	31	2022	2022	NUM
dpc-3517	51	32	.	.	PUNCT
dpc-3517	52	1	twenty	twenty	NUM
dpc-3517	52	2	-	-	PUNCT
dpc-3517	52	3	eight	eight	NUM
dpc-3517	52	4	patients	patient	NOUN
dpc-3517	52	5	had	have	VERB
dpc-3517	52	6	completely	completely	ADV
dpc-3517	52	7	resected	resect	VERB
dpc-3517	52	8	stage	stage	NOUN
dpc-3517	52	9	iib	iib	PROPN
dpc-3517	52	10	/	/	SYM
dpc-3517	52	11	iic	iic	PROPN
dpc-3517	52	12	/	/	SYM
dpc-3517	52	13	iii	iii	PROPN
dpc-3517	52	14	/	/	SYM
dpc-3517	52	15	iv	iv	NUM
dpc-3517	52	16	melanoma	melanoma	NOUN
dpc-3517	52	17	,	,	PUNCT
dpc-3517	52	18	of	of	ADP
dpc-3517	52	19	whom	whom	PRON
dpc-3517	52	20	24	24	NUM
dpc-3517	52	21	patients	patient	NOUN
dpc-3517	52	22	were	be	AUX
dpc-3517	52	23	treated	treat	VERB
dpc-3517	52	24	with	with	ADP
dpc-3517	52	25	pembrolizumab	pembrolizumab	NOUN
dpc-3517	52	26	(	(	PUNCT
dpc-3517	52	27	n	n	NOUN
dpc-3517	52	28	=	=	SYM
dpc-3517	52	29	9	9	NUM
dpc-3517	52	30	;	;	PUNCT
dpc-3517	52	31	table	table	NOUN
dpc-3517	52	32	1	1	NUM
dpc-3517	52	33	)	)	PUNCT
dpc-3517	52	34	or	or	CCONJ
dpc-3517	52	35	hdi	hdi	PROPN
dpc-3517	52	36	(	(	PUNCT
dpc-3517	52	37	n	n	NOUN
dpc-3517	52	38	=	=	SYM
dpc-3517	52	39	15	15	NUM
dpc-3517	52	40	;	;	PUNCT
dpc-3517	52	41	table	table	NOUN
dpc-3517	52	42	2	2	NUM
dpc-3517	52	43	)	)	PUNCT
dpc-3517	52	44	as	as	ADP
dpc-3517	52	45	adjuvant	adjuvant	ADJ
dpc-3517	52	46	therapy	therapy	NOUN
dpc-3517	52	47	.	.	PUNCT
dpc-3517	53	1	there	there	PRON
dpc-3517	53	2	were	be	VERB
dpc-3517	53	3	12	12	NUM
dpc-3517	53	4	(	(	PUNCT
dpc-3517	53	5	50	50	NUM
dpc-3517	53	6	%	%	NOUN
dpc-3517	53	7	)	)	PUNCT
dpc-3517	53	8	male	male	NOUN
dpc-3517	53	9	and	and	CCONJ
dpc-3517	53	10	12	12	NUM
dpc-3517	53	11	(	(	PUNCT
dpc-3517	53	12	50	50	NUM
dpc-3517	53	13	%	%	NOUN
dpc-3517	53	14	)	)	PUNCT
dpc-3517	53	15	female	female	ADJ
dpc-3517	53	16	patients	patient	NOUN
dpc-3517	53	17	,	,	PUNCT
dpc-3517	53	18	and	and	CCONJ
dpc-3517	53	19	the	the	DET
dpc-3517	53	20	median	median	ADJ
dpc-3517	53	21	age	age	NOUN
dpc-3517	53	22	was	be	AUX
dpc-3517	53	23	13.5	13.5	NUM
dpc-3517	53	24	years	year	NOUN
dpc-3517	53	25	(	(	PUNCT
dpc-3517	53	26	interquartile	interquartile	NOUN
dpc-3517	53	27	range	range	PROPN
dpc-3517	53	28	9.5–14.5	9.5–14.5	NUM
dpc-3517	53	29	)	)	PUNCT
dpc-3517	53	30	.	.	PUNCT
dpc-3517	54	1	twenty	twenty	NUM
dpc-3517	54	2	-	-	PUNCT
dpc-3517	54	3	two	two	NUM
dpc-3517	54	4	(	(	PUNCT
dpc-3517	54	5	92	92	NUM
dpc-3517	54	6	%	%	NOUN
dpc-3517	54	7	)	)	PUNCT
dpc-3517	54	8	patients	patient	NOUN
dpc-3517	54	9	had	have	VERB
dpc-3517	54	10	stage	stage	NOUN
dpc-3517	54	11	ii	ii	PROPN
dpc-3517	54	12	/	/	SYM
dpc-3517	54	13	iii	iii	NUM
dpc-3517	54	14	melanoma	melanoma	NOUN
dpc-3517	54	15	and	and	CCONJ
dpc-3517	54	16	only	only	ADV
dpc-3517	54	17	two	two	NUM
dpc-3517	54	18	(	(	PUNCT
dpc-3517	54	19	8	8	NUM
dpc-3517	54	20	%	%	NOUN
dpc-3517	54	21	)	)	PUNCT
dpc-3517	54	22	patients	patient	NOUN
dpc-3517	54	23	had	have	VERB
dpc-3517	54	24	stage	stage	NOUN
dpc-3517	54	25	iv	iv	NUM
dpc-3517	54	26	melanoma	melanoma	NOUN
dpc-3517	54	27	.	.	PUNCT
dpc-3517	55	1	there	there	PRON
dpc-3517	55	2	were	be	VERB
dpc-3517	55	3	18	18	NUM
dpc-3517	55	4	cases	case	NOUN
dpc-3517	55	5	of	of	ADP
dpc-3517	55	6	cutaneous	cutaneous	ADJ
dpc-3517	55	7	,	,	PUNCT
dpc-3517	55	8	three	three	NUM
dpc-3517	55	9	acral	acral	ADJ
dpc-3517	55	10	,	,	PUNCT
dpc-3517	55	11	one	one	NUM
dpc-3517	55	12	mucosal	mucosal	NOUN
dpc-3517	55	13	,	,	PUNCT
dpc-3517	55	14	and	and	CCONJ
dpc-3517	55	15	two	two	NUM
dpc-3517	55	16	primary	primary	ADJ
dpc-3517	55	17	unknown	unknown	ADJ
dpc-3517	55	18	melanomas	melanomas	NOUN
dpc-3517	55	19	.	.	PUNCT
dpc-3517	56	1	most	most	ADJ
dpc-3517	56	2	patients	patient	NOUN
dpc-3517	56	3	had	have	VERB
dpc-3517	56	4	a	a	DET
dpc-3517	56	5	braf/	braf/	NUM
dpc-3517	56	6	ras	ras	NOUN
dpc-3517	56	7	/	/	SYM
dpc-3517	56	8	nf1	nf1	NOUN
dpc-3517	56	9	triple	triple	ADJ
dpc-3517	56	10	wild	wild	ADJ
dpc-3517	56	11	-	-	PUNCT
dpc-3517	56	12	type	type	NOUN
dpc-3517	56	13	genotype	genotype	NOUN
dpc-3517	56	14	,	,	PUNCT
dpc-3517	56	15	while	while	SCONJ
dpc-3517	56	16	one	one	NUM
dpc-3517	56	17	patient	patient	NOUN
dpc-3517	56	18	had	have	VERB
dpc-3517	56	19	a	a	DET
dpc-3517	56	20	braf	braf	NOUN
dpc-3517	56	21	v600e	v600e	NOUN
dpc-3517	56	22	mutation	mutation	NOUN
dpc-3517	56	23	and	and	CCONJ
dpc-3517	56	24	two	two	NUM
dpc-3517	56	25	patients	patient	NOUN
dpc-3517	56	26	had	have	VERB
dpc-3517	56	27	nras	nras	PROPN
dpc-3517	56	28	q61r	q61r	PROPN
dpc-3517	56	29	mutations	mutation	NOUN
dpc-3517	56	30	.	.	PUNCT
dpc-3517	57	1	there	there	PRON
dpc-3517	57	2	was	be	VERB
dpc-3517	57	3	no	no	DET
dpc-3517	57	4	significant	significant	ADJ
dpc-3517	57	5	difference	difference	NOUN
dpc-3517	57	6	in	in	ADP
dpc-3517	57	7	baseline	baseline	ADJ
dpc-3517	57	8	characteristics	characteristic	NOUN
dpc-3517	57	9	between	between	ADP
dpc-3517	57	10	the	the	DET
dpc-3517	57	11	two	two	NUM
dpc-3517	57	12	groups	group	NOUN
dpc-3517	57	13	(	(	PUNCT
dpc-3517	57	14	table	table	NOUN
dpc-3517	57	15	3	3	NUM
dpc-3517	57	16	)	)	PUNCT
dpc-3517	57	17	.	.	PUNCT
dpc-3517	58	1	figure	figure	NOUN
dpc-3517	58	2	1	1	NUM
dpc-3517	58	3	.	.	PUNCT
dpc-3517	59	1	flowchart	flowchart	NOUN
dpc-3517	59	2	of	of	ADP
dpc-3517	59	3	inclusion	inclusion	NOUN
dpc-3517	59	4	and	and	CCONJ
dpc-3517	59	5	exclusion	exclusion	NOUN
dpc-3517	59	6	criteria	criterion	NOUN
dpc-3517	59	7	for	for	ADP
dpc-3517	59	8	this	this	DET
dpc-3517	59	9	study	study	NOUN
dpc-3517	59	10	.	.	PUNCT
dpc-3517	60	1	table	table	NOUN
dpc-3517	60	2	1	1	NUM
dpc-3517	60	3	.	.	PUNCT
dpc-3517	61	1	clinical	clinical	ADJ
dpc-3517	61	2	characteristics	characteristic	NOUN
dpc-3517	61	3	of	of	ADP
dpc-3517	61	4	pediatric	pediatric	ADJ
dpc-3517	61	5	patients	patient	NOUN
dpc-3517	61	6	treated	treat	VERB
dpc-3517	61	7	with	with	ADP
dpc-3517	61	8	pembrolizumab	pembrolizumab	NOUN
dpc-3517	61	9	as	as	ADP
dpc-3517	61	10	adjuvant	adjuvant	ADJ
dpc-3517	61	11	therapy	therapy	NOUN
dpc-3517	61	12	.	.	PUNCT
dpc-3517	62	1	i	i	PRON
dpc-3517	62	2	d	d	PROPN
dpc-3517	62	3	age	age	NOUN
dpc-3517	62	4	sex	sex	NOUN
dpc-3517	62	5	location	location	NOUN
dpc-3517	62	6	stage	stage	NOUN
dpc-3517	62	7	mutation	mutation	NOUN
dpc-3517	62	8	ecog	ecog	VERB
dpc-3517	62	9	p1	p1	PROPN
dpc-3517	62	10	6	6	NUM
dpc-3517	62	11	m	m	NOUN
dpc-3517	62	12	right	right	ADJ
dpc-3517	62	13	heel	heel	NOUN
dpc-3517	63	1	t4bn0m0	t4bn0m0	PROPN
dpc-3517	63	2	/	/	SYM
dpc-3517	63	3	iic	iic	PROPN
dpc-3517	63	4	unknown	unknown	ADJ
dpc-3517	63	5	0	0	NUM
dpc-3517	63	6	p2	p2	PROPN
dpc-3517	63	7	14	14	NUM
dpc-3517	63	8	f	f	PROPN
dpc-3517	63	9	vulvar	vulvar	NOUN
dpc-3517	63	10	mucosa	mucosa	NOUN
dpc-3517	63	11	t4bn0m0	t4bn0m0	PROPN
dpc-3517	63	12	/	/	SYM
dpc-3517	63	13	iic	iic	PROPN
dpc-3517	63	14	wild	wild	ADJ
dpc-3517	63	15	1	1	NUM
dpc-3517	63	16	p3	p3	PROPN
dpc-3517	63	17	13	13	NUM
dpc-3517	63	18	f	f	PROPN
dpc-3517	63	19	vulvar	vulvar	NOUN
dpc-3517	63	20	skin	skin	NOUN
dpc-3517	63	21	t3bn1bm0	t3bn1bm0	PROPN
dpc-3517	63	22	/	/	SYM
dpc-3517	63	23	iiic	iiic	PROPN
dpc-3517	63	24	nras	nras	PROPN
dpc-3517	63	25	q61r	q61r	PROPN
dpc-3517	63	26	0	0	NUM
dpc-3517	63	27	p4	p4	ADJ
dpc-3517	63	28	15	15	NUM
dpc-3517	63	29	m	m	NOUN
dpc-3517	63	30	right	right	ADJ
dpc-3517	63	31	thigh	thigh	NOUN
dpc-3517	63	32	t4an3bm0	t4an3bm0	PROPN
dpc-3517	63	33	/	/	SYM
dpc-3517	63	34	iiic	iiic	PROPN
dpc-3517	63	35	wild	wild	PROPN
dpc-3517	63	36	0	0	NUM
dpc-3517	63	37	p5	p5	ADJ
dpc-3517	63	38	15	15	NUM
dpc-3517	63	39	f	f	NOUN
dpc-3517	63	40	right	right	ADJ
dpc-3517	63	41	buttock	buttock	NOUN
dpc-3517	63	42	t4bn0m0	t4bn0m0	PROPN
dpc-3517	63	43	/	/	SYM
dpc-3517	63	44	iic	iic	PROPN
dpc-3517	63	45	wild	wild	ADJ
dpc-3517	63	46	1	1	NUM
dpc-3517	63	47	p6	p6	ADJ
dpc-3517	63	48	11	11	NUM
dpc-3517	63	49	f	f	NOUN
dpc-3517	63	50	left	leave	VERB
dpc-3517	63	51	forearm	forearm	NOUN
dpc-3517	63	52	t4bn0m0	t4bn0m0	PROPN
dpc-3517	63	53	/	/	SYM
dpc-3517	63	54	iic	iic	PROPN
dpc-3517	63	55	wild	wild	ADJ
dpc-3517	63	56	0	0	NUM
dpc-3517	63	57	p7	p7	PROPN
dpc-3517	63	58	7	7	NUM
dpc-3517	63	59	f	f	NOUN
dpc-3517	63	60	face	face	NOUN
dpc-3517	63	61	t2an1bm0	t2an1bm0	NOUN
dpc-3517	63	62	/	/	SYM
dpc-3517	63	63	iiib	iiib	ADJ
dpc-3517	63	64	wild	wild	ADJ
dpc-3517	63	65	0	0	NUM
dpc-3517	63	66	p8	p8	PROPN
dpc-3517	63	67	14	14	NUM
dpc-3517	63	68	f	f	PROPN
dpc-3517	63	69	right	right	ADJ
dpc-3517	63	70	calf	calf	NOUN
dpc-3517	63	71	t3bn1cm0	t3bn1cm0	NUM
dpc-3517	63	72	/	/	SYM
dpc-3517	63	73	iiic	iiic	PROPN
dpc-3517	63	74	braf	braf	NOUN
dpc-3517	63	75	v600e	v600e	PROPN
dpc-3517	63	76	0	0	NUM
dpc-3517	63	77	p9	p9	PROPN
dpc-3517	63	78	7	7	NUM
dpc-3517	63	79	f	f	NOUN
dpc-3517	63	80	left	leave	VERB
dpc-3517	63	81	upper	upper	ADJ
dpc-3517	63	82	arm	arm	NOUN
dpc-3517	63	83	t4bn0m0	t4bn0m0	PROPN
dpc-3517	63	84	/	/	SYM
dpc-3517	63	85	iic	iic	PROPN
dpc-3517	63	86	wild	wild	ADJ
dpc-3517	63	87	0	0	NUM
dpc-3517	63	88	ecog	ecog	PROPN
dpc-3517	63	89	=	=	PUNCT
dpc-3517	63	90	eastern	eastern	ADJ
dpc-3517	63	91	cooperative	cooperative	ADJ
dpc-3517	63	92	oncology	oncology	NOUN
dpc-3517	63	93	group	group	NOUN
dpc-3517	63	94	performance	performance	NOUN
dpc-3517	63	95	status	status	NOUN
dpc-3517	63	96	score	score	NOUN
dpc-3517	63	97	.	.	PUNCT
dpc-3517	64	1	4	4	NUM
dpc-3517	64	2	original	original	ADJ
dpc-3517	64	3	article	article	NOUN
dpc-3517	64	4	|	|	ADV
dpc-3517	64	5	dermatol	dermatol	ADJ
dpc-3517	64	6	pract	pract	NOUN
dpc-3517	64	7	concept	concept	NOUN
dpc-3517	64	8	.	.	PUNCT
dpc-3517	65	1	2024;14(1):e2024026	2024;14(1):e2024026	NUM
dpc-3517	65	2	treatment	treatment	NOUN
dpc-3517	65	3	due	due	ADP
dpc-3517	65	4	to	to	ADP
dpc-3517	65	5	adverse	adverse	ADJ
dpc-3517	65	6	events	event	NOUN
dpc-3517	65	7	.	.	PUNCT
dpc-3517	66	1	one	one	NUM
dpc-3517	66	2	patient	patient	NOUN
dpc-3517	66	3	in	in	ADP
dpc-3517	66	4	the	the	DET
dpc-3517	66	5	pembrolizumab	pembrolizumab	NOUN
dpc-3517	66	6	group	group	NOUN
dpc-3517	66	7	discontinued	discontinue	VERB
dpc-3517	66	8	treatment	treatment	NOUN
dpc-3517	66	9	due	due	ADP
dpc-3517	66	10	to	to	ADP
dpc-3517	66	11	disease	disease	NOUN
dpc-3517	66	12	recurrence	recurrence	NOUN
dpc-3517	66	13	and	and	CCONJ
dpc-3517	66	14	one	one	NUM
dpc-3517	66	15	patient	patient	NOUN
dpc-3517	66	16	discontinued	discontinue	VERB
dpc-3517	66	17	treatment	treatment	NOUN
dpc-3517	66	18	due	due	ADP
dpc-3517	66	19	to	to	ADP
dpc-3517	66	20	an	an	DET
dpc-3517	66	21	adverse	adverse	ADJ
dpc-3517	66	22	event	event	NOUN
dpc-3517	66	23	.	.	PUNCT
dpc-3517	67	1	one	one	NUM
dpc-3517	67	2	patient	patient	NOUN
dpc-3517	67	3	treated	treat	VERB
dpc-3517	67	4	with	with	ADP
dpc-3517	67	5	pembrolizumab	pembrolizumab	NOUN
dpc-3517	67	6	was	be	AUX
dpc-3517	67	7	still	still	ADV
dpc-3517	67	8	receiving	receive	VERB
dpc-3517	67	9	treatment	treatment	NOUN
dpc-3517	67	10	by	by	ADP
dpc-3517	67	11	august	august	PROPN
dpc-3517	67	12	31	31	NUM
dpc-3517	67	13	,	,	PUNCT
dpc-3517	67	14	2022	2022	NUM
dpc-3517	67	15	.	.	PUNCT
dpc-3517	68	1	adverse	adverse	ADJ
dpc-3517	68	2	events	event	NOUN
dpc-3517	68	3	with	with	ADP
dpc-3517	68	4	any	any	DET
dpc-3517	68	5	cause	cause	NOUN
dpc-3517	68	6	occurred	occur	VERB
dpc-3517	68	7	in	in	ADP
dpc-3517	68	8	79	79	NUM
dpc-3517	68	9	%	%	NOUN
dpc-3517	68	10	(	(	PUNCT
dpc-3517	68	11	19/24	19/24	NUM
dpc-3517	68	12	)	)	PUNCT
dpc-3517	68	13	of	of	ADP
dpc-3517	68	14	patients	patient	NOUN
dpc-3517	68	15	overall	overall	ADV
dpc-3517	68	16	,	,	PUNCT
dpc-3517	68	17	44	44	NUM
dpc-3517	68	18	%	%	NOUN
dpc-3517	68	19	(	(	PUNCT
dpc-3517	68	20	4/9	4/9	NUM
dpc-3517	68	21	)	)	PUNCT
dpc-3517	68	22	of	of	ADP
dpc-3517	68	23	patients	patient	NOUN
dpc-3517	68	24	in	in	ADP
dpc-3517	68	25	the	the	DET
dpc-3517	68	26	pembrolizumab	pembrolizumab	NOUN
dpc-3517	68	27	group	group	NOUN
dpc-3517	68	28	,	,	PUNCT
dpc-3517	68	29	and	and	CCONJ
dpc-3517	68	30	100	100	NUM
dpc-3517	68	31	%	%	NOUN
dpc-3517	68	32	of	of	ADP
dpc-3517	68	33	patients	patient	NOUN
dpc-3517	68	34	in	in	ADP
dpc-3517	68	35	the	the	DET
dpc-3517	68	36	hdi	hdi	PROPN
dpc-3517	68	37	group	group	NOUN
dpc-3517	68	38	(	(	PUNCT
dpc-3517	68	39	15/15	15/15	NUM
dpc-3517	68	40	)	)	PUNCT
dpc-3517	68	41	(	(	PUNCT
dpc-3517	68	42	p	p	X
dpc-3517	68	43	=	=	NOUN
dpc-3517	68	44	0.003	0.003	NUM
dpc-3517	68	45	)	)	PUNCT
dpc-3517	68	46	.	.	PUNCT
dpc-3517	69	1	the	the	DET
dpc-3517	69	2	adverse	adverse	ADJ
dpc-3517	69	3	events	event	NOUN
dpc-3517	69	4	are	be	AUX
dpc-3517	69	5	summarized	summarize	VERB
dpc-3517	69	6	in	in	ADP
dpc-3517	69	7	table	table	NOUN
dpc-3517	69	8	4	4	NUM
dpc-3517	69	9	.	.	PUNCT
dpc-3517	70	1	most	most	ADJ
dpc-3517	70	2	adverse	adverse	ADJ
dpc-3517	70	3	events	event	NOUN
dpc-3517	70	4	were	be	AUX
dpc-3517	70	5	grade	grade	NOUN
dpc-3517	70	6	1	1	NUM
dpc-3517	70	7	or	or	CCONJ
dpc-3517	70	8	2	2	NUM
dpc-3517	70	9	,	,	PUNCT
dpc-3517	70	10	and	and	CCONJ
dpc-3517	70	11	grade	grade	NOUN
dpc-3517	70	12	3	3	NUM
dpc-3517	70	13	treatment	treatment	NOUN
dpc-3517	70	14	-	-	PUNCT
dpc-3517	70	15	related	relate	VERB
dpc-3517	70	16	adverse	adverse	ADJ
dpc-3517	70	17	events	event	NOUN
dpc-3517	70	18	(	(	PUNCT
dpc-3517	70	19	traes	traes	NOUN
dpc-3517	70	20	)	)	PUNCT
dpc-3517	70	21	,	,	PUNCT
dpc-3517	70	22	including	include	VERB
dpc-3517	70	23	neutropenia	neutropenia	NOUN
dpc-3517	70	24	,	,	PUNCT
dpc-3517	70	25	alanine	alanine	NOUN
dpc-3517	70	26	aminotransferase	aminotransferase	NOUN
dpc-3517	70	27	(	(	PUNCT
dpc-3517	70	28	alt	alt	ADJ
dpc-3517	70	29	)	)	PUNCT
dpc-3517	70	30	elevation	elevation	NOUN
dpc-3517	70	31	,	,	PUNCT
dpc-3517	70	32	and	and	CCONJ
dpc-3517	70	33	aspartate	aspartate	NOUN
dpc-3517	70	34	aminotransferase	aminotransferase	NOUN
dpc-3517	70	35	(	(	PUNCT
dpc-3517	70	36	ast	ast	NOUN
dpc-3517	70	37	)	)	PUNCT
dpc-3517	70	38	elevation	elevation	NOUN
dpc-3517	70	39	,	,	PUNCT
dpc-3517	70	40	only	only	ADV
dpc-3517	70	41	occurred	occur	VERB
dpc-3517	70	42	in	in	ADP
dpc-3517	70	43	two	two	NUM
dpc-3517	70	44	patients	patient	NOUN
dpc-3517	70	45	in	in	ADP
dpc-3517	70	46	the	the	DET
dpc-3517	70	47	hdi	hdi	PROPN
dpc-3517	70	48	group	group	NOUN
dpc-3517	70	49	.	.	PUNCT
dpc-3517	71	1	the	the	DET
dpc-3517	71	2	most	most	ADV
dpc-3517	71	3	common	common	ADJ
dpc-3517	71	4	adverse	adverse	ADJ
dpc-3517	71	5	events	event	NOUN
dpc-3517	71	6	in	in	ADP
dpc-3517	71	7	the	the	DET
dpc-3517	71	8	hdi	hdi	PROPN
dpc-3517	71	9	group	group	NOUN
dpc-3517	71	10	were	be	AUX
dpc-3517	71	11	myelosuppression	myelosuppression	NOUN
dpc-3517	71	12	,	,	PUNCT
dpc-3517	71	13	pyrexia	pyrexia	NOUN
dpc-3517	71	14	,	,	PUNCT
dpc-3517	71	15	and	and	CCONJ
dpc-3517	71	16	nausea	nausea	NOUN
dpc-3517	71	17	.	.	PUNCT
dpc-3517	72	1	adverse	adverse	ADJ
dpc-3517	72	2	events	event	NOUN
dpc-3517	72	3	did	do	AUX
dpc-3517	72	4	not	not	PART
dpc-3517	72	5	lead	lead	VERB
dpc-3517	72	6	to	to	ADP
dpc-3517	72	7	any	any	DET
dpc-3517	72	8	deaths	death	NOUN
dpc-3517	72	9	in	in	ADP
dpc-3517	72	10	either	either	DET
dpc-3517	72	11	group	group	NOUN
dpc-3517	72	12	.	.	PUNCT
dpc-3517	73	1	there	there	PRON
dpc-3517	73	2	were	be	VERB
dpc-3517	73	3	fewer	few	ADJ
dpc-3517	73	4	adverse	adverse	ADJ
dpc-3517	73	5	events	event	NOUN
dpc-3517	73	6	in	in	ADP
dpc-3517	73	7	the	the	DET
dpc-3517	73	8	pembrolizumab	pembrolizumab	NOUN
dpc-3517	73	9	group	group	NOUN
dpc-3517	73	10	compared	compare	VERB
dpc-3517	73	11	with	with	ADP
dpc-3517	73	12	the	the	DET
dpc-3517	73	13	hdi	hdi	PROPN
dpc-3517	73	14	group	group	NOUN
dpc-3517	73	15	,	,	PUNCT
dpc-3517	73	16	including	include	VERB
dpc-3517	73	17	hyperthyroidism	hyperthyroidism	NOUN
dpc-3517	73	18	(	(	PUNCT
dpc-3517	73	19	n	n	NOUN
dpc-3517	73	20	=	=	SYM
dpc-3517	73	21	2	2	NUM
dpc-3517	73	22	,	,	PUNCT
dpc-3517	73	23	grade	grade	NOUN
dpc-3517	73	24	1	1	NUM
dpc-3517	73	25	)	)	PUNCT
dpc-3517	73	26	,	,	PUNCT
dpc-3517	73	27	rash	rash	NOUN
dpc-3517	73	28	(	(	PUNCT
dpc-3517	73	29	n	n	NOUN
dpc-3517	73	30	=	=	SYM
dpc-3517	73	31	2	2	NUM
dpc-3517	73	32	,	,	PUNCT
dpc-3517	73	33	grade	grade	NOUN
dpc-3517	73	34	1	1	NUM
dpc-3517	73	35	)	)	PUNCT
dpc-3517	73	36	,	,	PUNCT
dpc-3517	73	37	alt	alt	VERB
dpc-3517	73	38	elevation	elevation	NOUN
dpc-3517	73	39	(	(	PUNCT
dpc-3517	73	40	n	n	NOUN
dpc-3517	73	41	=	=	SYM
dpc-3517	73	42	1	1	NUM
dpc-3517	73	43	,	,	PUNCT
dpc-3517	73	44	grade	grade	NOUN
dpc-3517	73	45	1	1	NUM
dpc-3517	73	46	)	)	PUNCT
dpc-3517	73	47	,	,	PUNCT
dpc-3517	73	48	ast	ast	NOUN
dpc-3517	73	49	elevation	elevation	NOUN
dpc-3517	73	50	(	(	PUNCT
dpc-3517	73	51	n	n	NOUN
dpc-3517	73	52	=	=	SYM
dpc-3517	73	53	1	1	NUM
dpc-3517	73	54	,	,	PUNCT
dpc-3517	73	55	grade	grade	NOUN
dpc-3517	73	56	1	1	NUM
dpc-3517	73	57	)	)	PUNCT
dpc-3517	73	58	,	,	PUNCT
dpc-3517	73	59	leucopenia	leucopenia	NOUN
dpc-3517	73	60	(	(	PUNCT
dpc-3517	73	61	n	n	NOUN
dpc-3517	73	62	=	=	SYM
dpc-3517	73	63	1	1	NUM
dpc-3517	73	64	,	,	PUNCT
dpc-3517	73	65	grade	grade	NOUN
dpc-3517	73	66	1	1	NUM
dpc-3517	73	67	)	)	PUNCT
dpc-3517	73	68	,	,	PUNCT
dpc-3517	73	69	neutropenia	neutropenia	NOUN
dpc-3517	73	70	(	(	PUNCT
dpc-3517	73	71	n	n	NOUN
dpc-3517	73	72	=	=	SYM
dpc-3517	73	73	1	1	NUM
dpc-3517	73	74	,	,	PUNCT
dpc-3517	73	75	grade	grade	NOUN
dpc-3517	73	76	1	1	NUM
dpc-3517	73	77	)	)	PUNCT
dpc-3517	73	78	,	,	PUNCT
dpc-3517	73	79	and	and	CCONJ
dpc-3517	73	80	alopecia	alopecia	NOUN
dpc-3517	73	81	(	(	PUNCT
dpc-3517	73	82	n	n	NOUN
dpc-3517	73	83	=	=	SYM
dpc-3517	73	84	1	1	NUM
dpc-3517	73	85	,	,	PUNCT
dpc-3517	73	86	grade	grade	NOUN
dpc-3517	73	87	2	2	NUM
dpc-3517	73	88	)	)	PUNCT
dpc-3517	73	89	.	.	PUNCT
dpc-3517	74	1	conclusions	conclusion	NOUN
dpc-3517	74	2	pediatric	pediatric	ADJ
dpc-3517	74	3	melanoma	melanoma	NOUN
dpc-3517	74	4	is	be	AUX
dpc-3517	74	5	a	a	DET
dpc-3517	74	6	rare	rare	ADJ
dpc-3517	74	7	type	type	NOUN
dpc-3517	74	8	of	of	ADP
dpc-3517	74	9	tumor	tumor	NOUN
dpc-3517	74	10	in	in	ADP
dpc-3517	74	11	the	the	DET
dpc-3517	74	12	pediatric	pediatric	ADJ
dpc-3517	74	13	population	population	NOUN
dpc-3517	74	14	,	,	PUNCT
dpc-3517	74	15	qualifying	qualify	VERB
dpc-3517	74	16	as	as	ADP
dpc-3517	74	17	an	an	DET
dpc-3517	74	18	“	"	PUNCT
dpc-3517	74	19	orphan	orphan	NOUN
dpc-3517	74	20	”	"	PUNCT
dpc-3517	74	21	disease	disease	NOUN
dpc-3517	74	22	according	accord	VERB
dpc-3517	74	23	to	to	ADP
dpc-3517	74	24	the	the	DET
dpc-3517	74	25	definition	definition	NOUN
dpc-3517	74	26	adopted	adopt	VERB
dpc-3517	74	27	by	by	ADP
dpc-3517	74	28	pediatric	pediatric	ADJ
dpc-3517	74	29	cooperative	cooperative	ADJ
dpc-3517	74	30	groups	group	NOUN
dpc-3517	74	31	for	for	ADP
dpc-3517	74	32	rare	rare	ADJ
dpc-3517	74	33	childhood	childhood	NOUN
dpc-3517	74	34	tumors	tumor	NOUN
dpc-3517	74	35	in	in	ADP
dpc-3517	74	36	europe	europe	PROPN
dpc-3517	74	37	[	[	X
dpc-3517	74	38	6	6	NUM
dpc-3517	74	39	]	]	PUNCT
dpc-3517	74	40	.	.	PUNCT
dpc-3517	75	1	given	give	VERB
dpc-3517	75	2	its	its	PRON
dpc-3517	75	3	rarity	rarity	NOUN
dpc-3517	75	4	,	,	PUNCT
dpc-3517	75	5	efficacy	efficacy	NOUN
dpc-3517	75	6	by	by	ADP
dpc-3517	75	7	the	the	DET
dpc-3517	75	8	cut	cut	VERB
dpc-3517	75	9	-	-	PUNCT
dpc-3517	75	10	off	off	ADP
dpc-3517	75	11	date	date	NOUN
dpc-3517	75	12	of	of	ADP
dpc-3517	75	13	august	august	PROPN
dpc-3517	75	14	31	31	NUM
dpc-3517	75	15	,	,	PUNCT
dpc-3517	75	16	2022	2022	NUM
dpc-3517	75	17	,	,	PUNCT
dpc-3517	75	18	the	the	DET
dpc-3517	75	19	median	median	ADJ
dpc-3517	75	20	follow	follow	VERB
dpc-3517	75	21	-	-	PUNCT
dpc-3517	75	22	up	up	NOUN
dpc-3517	75	23	times	time	NOUN
dpc-3517	75	24	were	be	AUX
dpc-3517	75	25	23.6	23.6	NUM
dpc-3517	75	26	months	month	NOUN
dpc-3517	75	27	(	(	PUNCT
dpc-3517	75	28	95	95	NUM
dpc-3517	75	29	%	%	NOUN
dpc-3517	75	30	ci	ci	NOUN
dpc-3517	75	31	:	:	PUNCT
dpc-3517	75	32	8.9	8.9	NUM
dpc-3517	75	33	–	–	PUNCT
dpc-3517	75	34	not	not	PART
dpc-3517	75	35	reached	reach	VERB
dpc-3517	75	36	[	[	X
dpc-3517	75	37	nr	nr	X
dpc-3517	75	38	]	]	X
dpc-3517	75	39	)	)	PUNCT
dpc-3517	75	40	for	for	ADP
dpc-3517	75	41	the	the	DET
dpc-3517	75	42	pembrolizumab	pembrolizumab	NOUN
dpc-3517	75	43	group	group	NOUN
dpc-3517	75	44	and	and	CCONJ
dpc-3517	75	45	98.7	98.7	NUM
dpc-3517	75	46	months	month	NOUN
dpc-3517	75	47	(	(	PUNCT
dpc-3517	75	48	95	95	NUM
dpc-3517	75	49	%	%	NOUN
dpc-3517	75	50	ci	ci	NOUN
dpc-3517	75	51	:	:	PUNCT
dpc-3517	75	52	63.9	63.9	NUM
dpc-3517	75	53	–	–	PUNCT
dpc-3517	75	54	nr	nr	X
dpc-3517	75	55	)	)	PUNCT
dpc-3517	75	56	for	for	ADP
dpc-3517	75	57	the	the	DET
dpc-3517	75	58	hdi	hdi	PROPN
dpc-3517	75	59	group	group	NOUN
dpc-3517	75	60	.	.	PUNCT
dpc-3517	76	1	six	six	NUM
dpc-3517	76	2	(	(	PUNCT
dpc-3517	76	3	6/9	6/9	NUM
dpc-3517	76	4	,	,	PUNCT
dpc-3517	76	5	67	67	NUM
dpc-3517	76	6	%	%	NOUN
dpc-3517	76	7	)	)	PUNCT
dpc-3517	76	8	patients	patient	NOUN
dpc-3517	76	9	in	in	ADP
dpc-3517	76	10	the	the	DET
dpc-3517	76	11	pembrolizumab	pembrolizumab	NOUN
dpc-3517	76	12	group	group	NOUN
dpc-3517	76	13	and	and	CCONJ
dpc-3517	76	14	10	10	NUM
dpc-3517	76	15	(	(	PUNCT
dpc-3517	76	16	10/15	10/15	NUM
dpc-3517	76	17	,	,	PUNCT
dpc-3517	76	18	67	67	NUM
dpc-3517	76	19	%	%	NOUN
dpc-3517	76	20	)	)	PUNCT
dpc-3517	76	21	patients	patient	NOUN
dpc-3517	76	22	in	in	ADP
dpc-3517	76	23	the	the	DET
dpc-3517	76	24	hdi	hdi	PROPN
dpc-3517	76	25	group	group	NOUN
dpc-3517	76	26	completed	complete	VERB
dpc-3517	76	27	1	1	NUM
dpc-3517	76	28	year	year	NOUN
dpc-3517	76	29	of	of	ADP
dpc-3517	76	30	treatment	treatment	NOUN
dpc-3517	76	31	.	.	PUNCT
dpc-3517	77	1	eleven	eleven	NUM
dpc-3517	77	2	(	(	PUNCT
dpc-3517	77	3	46	46	NUM
dpc-3517	77	4	%	%	NOUN
dpc-3517	77	5	)	)	PUNCT
dpc-3517	77	6	patients	patient	NOUN
dpc-3517	77	7	had	have	VERB
dpc-3517	77	8	disease	disease	NOUN
dpc-3517	77	9	recurrence	recurrence	NOUN
dpc-3517	77	10	,	,	PUNCT
dpc-3517	77	11	including	include	VERB
dpc-3517	77	12	one	one	NUM
dpc-3517	77	13	(	(	PUNCT
dpc-3517	77	14	1/9	1/9	NUM
dpc-3517	77	15	,	,	PUNCT
dpc-3517	77	16	11	11	NUM
dpc-3517	77	17	%	%	NOUN
dpc-3517	77	18	)	)	PUNCT
dpc-3517	77	19	in	in	ADP
dpc-3517	77	20	the	the	DET
dpc-3517	77	21	pembrolizumab	pembrolizumab	NOUN
dpc-3517	77	22	group	group	NOUN
dpc-3517	77	23	and	and	CCONJ
dpc-3517	77	24	10	10	NUM
dpc-3517	77	25	(	(	PUNCT
dpc-3517	77	26	10/15	10/15	NUM
dpc-3517	77	27	,	,	PUNCT
dpc-3517	77	28	67	67	NUM
dpc-3517	77	29	%	%	NOUN
dpc-3517	77	30	)	)	PUNCT
dpc-3517	77	31	in	in	ADP
dpc-3517	77	32	the	the	DET
dpc-3517	77	33	hdi	hdi	PROPN
dpc-3517	77	34	group	group	NOUN
dpc-3517	77	35	.	.	PUNCT
dpc-3517	78	1	the	the	DET
dpc-3517	78	2	patient	patient	NOUN
dpc-3517	78	3	in	in	ADP
dpc-3517	78	4	the	the	DET
dpc-3517	78	5	pembrolizumab	pembrolizumab	NOUN
dpc-3517	78	6	group	group	NOUN
dpc-3517	78	7	who	who	PRON
dpc-3517	78	8	relapsed	relapse	VERB
dpc-3517	78	9	had	have	VERB
dpc-3517	78	10	a	a	DET
dpc-3517	78	11	nras	nras	PROPN
dpc-3517	78	12	q61r	q61r	PROPN
dpc-3517	78	13	mutation	mutation	NOUN
dpc-3517	78	14	.	.	PUNCT
dpc-3517	79	1	one	one	NUM
dpc-3517	79	2	(	(	PUNCT
dpc-3517	79	3	1/9	1/9	NUM
dpc-3517	79	4	,	,	PUNCT
dpc-3517	79	5	11	11	NUM
dpc-3517	79	6	%	%	NOUN
dpc-3517	79	7	)	)	PUNCT
dpc-3517	79	8	patient	patient	NOUN
dpc-3517	79	9	in	in	ADP
dpc-3517	79	10	the	the	DET
dpc-3517	79	11	pembrolizumab	pembrolizumab	NOUN
dpc-3517	79	12	group	group	NOUN
dpc-3517	79	13	and	and	CCONJ
dpc-3517	79	14	five	five	NUM
dpc-3517	79	15	patients	patient	NOUN
dpc-3517	79	16	(	(	PUNCT
dpc-3517	79	17	5/15	5/15	NUM
dpc-3517	79	18	,	,	PUNCT
dpc-3517	79	19	33	33	NUM
dpc-3517	79	20	%	%	NOUN
dpc-3517	79	21	)	)	PUNCT
dpc-3517	79	22	in	in	ADP
dpc-3517	79	23	the	the	DET
dpc-3517	79	24	hdi	hdi	PROPN
dpc-3517	79	25	group	group	NOUN
dpc-3517	79	26	relapsed	relapse	VERB
dpc-3517	79	27	with	with	ADP
dpc-3517	79	28	distant	distant	ADJ
dpc-3517	79	29	metastases	metastasis	NOUN
dpc-3517	79	30	.	.	PUNCT
dpc-3517	80	1	no	no	DET
dpc-3517	80	2	 	 	SPACE
dpc-3517	80	3	patients	patient	NOUN
dpc-3517	80	4	in	in	ADP
dpc-3517	80	5	the	the	DET
dpc-3517	80	6	pembrolizumab	pembrolizumab	NOUN
dpc-3517	80	7	group	group	NOUN
dpc-3517	80	8	and	and	CCONJ
dpc-3517	80	9	six	six	NUM
dpc-3517	80	10	(	(	PUNCT
dpc-3517	80	11	6/15	6/15	NUM
dpc-3517	80	12	,	,	PUNCT
dpc-3517	80	13	40	40	NUM
dpc-3517	80	14	%	%	NOUN
dpc-3517	80	15	)	)	PUNCT
dpc-3517	80	16	patients	patient	NOUN
dpc-3517	80	17	in	in	ADP
dpc-3517	80	18	the	the	DET
dpc-3517	80	19	hdi	hdi	PROPN
dpc-3517	80	20	group	group	NOUN
dpc-3517	80	21	died	die	VERB
dpc-3517	80	22	.	.	PUNCT
dpc-3517	81	1	the	the	DET
dpc-3517	81	2	median	median	ADJ
dpc-3517	81	3	rfs	rfs	PROPN
dpc-3517	81	4	was	be	AUX
dpc-3517	81	5	not	not	PART
dpc-3517	81	6	reached	reach	VERB
dpc-3517	81	7	in	in	ADP
dpc-3517	81	8	the	the	DET
dpc-3517	81	9	pembrolizumab	pembrolizumab	NOUN
dpc-3517	81	10	group	group	NOUN
dpc-3517	81	11	and	and	CCONJ
dpc-3517	81	12	the	the	DET
dpc-3517	81	13	median	median	ADJ
dpc-3517	81	14	rfs	rfs	NOUN
dpc-3517	81	15	in	in	ADP
dpc-3517	81	16	the	the	DET
dpc-3517	81	17	hdi	hdi	PROPN
dpc-3517	81	18	group	group	NOUN
dpc-3517	81	19	was	be	AUX
dpc-3517	81	20	38.7	38.7	NUM
dpc-3517	81	21	months	month	NOUN
dpc-3517	81	22	(	(	PUNCT
dpc-3517	81	23	95	95	NUM
dpc-3517	81	24	%	%	NOUN
dpc-3517	81	25	ci	ci	NOUN
dpc-3517	81	26	:	:	PUNCT
dpc-3517	81	27	10.8	10.8	NUM
dpc-3517	81	28	–	–	PUNCT
dpc-3517	81	29	nr	nr	NUM
dpc-3517	81	30	;	;	PUNCT
dpc-3517	81	31	hazard	hazard	NOUN
dpc-3517	81	32	ratio	ratio	NOUN
dpc-3517	81	33	0.23	0.23	NUM
dpc-3517	81	34	;	;	PUNCT
dpc-3517	81	35	95	95	NUM
dpc-3517	81	36	%	%	NOUN
dpc-3517	81	37	ci	ci	NOUN
dpc-3517	81	38	:	:	PUNCT
dpc-3517	81	39	0.06–0.82	0.06–0.82	NUM
dpc-3517	81	40	;	;	PUNCT
dpc-3517	81	41	p	p	X
dpc-3517	81	42	=	=	NOUN
dpc-3517	81	43	0.11	0.11	NUM
dpc-3517	81	44	)	)	PUNCT
dpc-3517	81	45	(	(	PUNCT
dpc-3517	81	46	figure	figure	NOUN
dpc-3517	81	47	2	2	NUM
dpc-3517	81	48	)	)	PUNCT
dpc-3517	81	49	.	.	PUNCT
dpc-3517	82	1	the	the	DET
dpc-3517	82	2	median	median	PROPN
dpc-3517	82	3	os	os	NOUN
dpc-3517	82	4	was	be	AUX
dpc-3517	82	5	not	not	PART
dpc-3517	82	6	reached	reach	VERB
dpc-3517	82	7	in	in	ADP
dpc-3517	82	8	either	either	DET
dpc-3517	82	9	group	group	NOUN
dpc-3517	82	10	.	.	PUNCT
dpc-3517	83	1	the	the	DET
dpc-3517	83	2	1	1	NUM
dpc-3517	83	3	-	-	PUNCT
dpc-3517	83	4	year	year	NOUN
dpc-3517	83	5	rfs	rfs	NOUN
dpc-3517	83	6	rates	rate	NOUN
dpc-3517	83	7	were	be	AUX
dpc-3517	83	8	88.9	88.9	NUM
dpc-3517	83	9	%	%	NOUN
dpc-3517	83	10	(	(	PUNCT
dpc-3517	83	11	95	95	NUM
dpc-3517	83	12	%	%	NOUN
dpc-3517	83	13	ci	ci	NOUN
dpc-3517	83	14	:	:	PUNCT
dpc-3517	83	15	70.6–100	70.6–100	NUM
dpc-3517	83	16	)	)	PUNCT
dpc-3517	83	17	and	and	CCONJ
dpc-3517	83	18	66.7	66.7	NUM
dpc-3517	83	19	%	%	NOUN
dpc-3517	83	20	(	(	PUNCT
dpc-3517	83	21	95	95	NUM
dpc-3517	83	22	%	%	NOUN
dpc-3517	83	23	ci	ci	NOUN
dpc-3517	83	24	:	:	PUNCT
dpc-3517	83	25	46.6–95.3	46.6–95.3	NUM
dpc-3517	83	26	)	)	PUNCT
dpc-3517	83	27	and	and	CCONJ
dpc-3517	83	28	the	the	DET
dpc-3517	83	29	2	2	NUM
dpc-3517	83	30	-	-	PUNCT
dpc-3517	83	31	year	year	NOUN
dpc-3517	83	32	rfs	rfs	NOUN
dpc-3517	83	33	rates	rate	NOUN
dpc-3517	83	34	were	be	AUX
dpc-3517	83	35	88.9	88.9	NUM
dpc-3517	83	36	%	%	NOUN
dpc-3517	83	37	(	(	PUNCT
dpc-3517	83	38	95	95	NUM
dpc-3517	83	39	%	%	NOUN
dpc-3517	83	40	ci	ci	NOUN
dpc-3517	83	41	:	:	PUNCT
dpc-3517	83	42	70.6–100	70.6–100	NUM
dpc-3517	83	43	)	)	PUNCT
dpc-3517	83	44	and	and	CCONJ
dpc-3517	83	45	60.0	60.0	NUM
dpc-3517	83	46	%	%	NOUN
dpc-3517	83	47	(	(	PUNCT
dpc-3517	83	48	95	95	NUM
dpc-3517	83	49	%	%	NOUN
dpc-3517	83	50	ci	ci	NOUN
dpc-3517	83	51	:	:	PUNCT
dpc-3517	83	52	39.7–90.7	39.7–90.7	NUM
dpc-3517	83	53	)	)	PUNCT
dpc-3517	83	54	in	in	ADP
dpc-3517	83	55	the	the	DET
dpc-3517	83	56	pembrolizumab	pembrolizumab	NOUN
dpc-3517	83	57	and	and	CCONJ
dpc-3517	83	58	hdi	hdi	PROPN
dpc-3517	83	59	groups	group	NOUN
dpc-3517	83	60	,	,	PUNCT
dpc-3517	83	61	respectively	respectively	ADV
dpc-3517	83	62	.	.	PUNCT
dpc-3517	84	1	safety	safety	NOUN
dpc-3517	84	2	five	five	NUM
dpc-3517	84	3	(	(	PUNCT
dpc-3517	84	4	33	33	NUM
dpc-3517	84	5	%	%	NOUN
dpc-3517	84	6	)	)	PUNCT
dpc-3517	84	7	patients	patient	NOUN
dpc-3517	84	8	in	in	ADP
dpc-3517	84	9	the	the	DET
dpc-3517	84	10	hdi	hdi	PROPN
dpc-3517	84	11	group	group	NOUN
dpc-3517	84	12	discontinued	discontinue	VERB
dpc-3517	84	13	treatment	treatment	NOUN
dpc-3517	84	14	due	due	ADP
dpc-3517	84	15	to	to	ADP
dpc-3517	84	16	disease	disease	NOUN
dpc-3517	84	17	recurrence	recurrence	NOUN
dpc-3517	84	18	but	but	CCONJ
dpc-3517	84	19	no	no	DET
dpc-3517	84	20	patient	patient	NOUN
dpc-3517	84	21	discontinued	discontinue	VERB
dpc-3517	84	22	table	table	NOUN
dpc-3517	84	23	2	2	NUM
dpc-3517	84	24	.	.	PUNCT
dpc-3517	85	1	clinical	clinical	ADJ
dpc-3517	85	2	characteristics	characteristic	NOUN
dpc-3517	85	3	of	of	ADP
dpc-3517	85	4	pediatric	pediatric	ADJ
dpc-3517	85	5	patients	patient	NOUN
dpc-3517	85	6	treated	treat	VERB
dpc-3517	85	7	with	with	ADP
dpc-3517	85	8	high	high	ADJ
dpc-3517	85	9	-	-	PUNCT
dpc-3517	85	10	dose	dose	NOUN
dpc-3517	85	11	interferon	interferon	NOUN
dpc-3517	85	12	-	-	PUNCT
dpc-3517	85	13	α2b	α2b	NOUN
dpc-3517	85	14	as	as	ADP
dpc-3517	85	15	adjuvant	adjuvant	ADJ
dpc-3517	85	16	therapy	therapy	NOUN
dpc-3517	85	17	.	.	PUNCT
dpc-3517	86	1	i	i	PRON
dpc-3517	86	2	d	d	PROPN
dpc-3517	86	3	age	age	NOUN
dpc-3517	86	4	sex	sex	NOUN
dpc-3517	86	5	location	location	NOUN
dpc-3517	86	6	stage	stage	NOUN
dpc-3517	86	7	mutation	mutation	NOUN
dpc-3517	86	8	ecog	ecog	VERB
dpc-3517	86	9	h1	h1	PROPN
dpc-3517	86	10	13	13	NUM
dpc-3517	86	11	m	m	NOUN
dpc-3517	86	12	left	leave	VERB
dpc-3517	86	13	upper	upper	ADJ
dpc-3517	86	14	arm	arm	NOUN
dpc-3517	86	15	t4bn0m0	t4bn0m0	PROPN
dpc-3517	86	16	/	/	SYM
dpc-3517	86	17	iic	iic	PROPN
dpc-3517	86	18	unknown	unknown	ADJ
dpc-3517	86	19	0	0	NUM
dpc-3517	86	20	h2	h2	NOUN
dpc-3517	86	21	15	15	NUM
dpc-3517	86	22	m	m	VERB
dpc-3517	86	23	left	leave	VERB
dpc-3517	86	24	upper	upper	ADJ
dpc-3517	86	25	arm	arm	NOUN
dpc-3517	86	26	txn1bm0	txn1bm0	PROPN
dpc-3517	86	27	/	/	SYM
dpc-3517	86	28	iii	iii	NUM
dpc-3517	86	29	wild	wild	ADJ
dpc-3517	86	30	0	0	NUM
dpc-3517	86	31	h3	h3	NOUN
dpc-3517	86	32	14	14	NUM
dpc-3517	86	33	f	f	NOUN
dpc-3517	86	34	left	leave	VERB
dpc-3517	86	35	middle	middle	ADJ
dpc-3517	86	36	finger	finger	NOUN
dpc-3517	86	37	t4bn2bm0	t4bn2bm0	PROPN
dpc-3517	86	38	/	/	SYM
dpc-3517	86	39	iiic	iiic	PROPN
dpc-3517	86	40	wild	wild	ADJ
dpc-3517	86	41	1	1	NUM
dpc-3517	86	42	h4	h4	PROPN
dpc-3517	86	43	14	14	NUM
dpc-3517	86	44	m	m	NOUN
dpc-3517	86	45	right	right	ADJ
dpc-3517	86	46	groin	groin	NOUN
dpc-3517	86	47	txn3bm0	txn3bm0	PROPN
dpc-3517	86	48	/	/	SYM
dpc-3517	86	49	iii	iii	PROPN
dpc-3517	86	50	unknown	unknown	ADJ
dpc-3517	86	51	1	1	NUM
dpc-3517	86	52	h5	h5	NOUN
dpc-3517	86	53	13	13	NUM
dpc-3517	86	54	m	m	AUX
dpc-3517	86	55	not	not	PART
dpc-3517	86	56	known	know	VERB
dpc-3517	86	57	txnxm0	txnxm0	PROPN
dpc-3517	86	58	/	/	SYM
dpc-3517	86	59	iii	iii	PROPN
dpc-3517	86	60	wild	wild	ADJ
dpc-3517	86	61	1	1	NUM
dpc-3517	86	62	h6	h6	PROPN
dpc-3517	86	63	12	12	NUM
dpc-3517	86	64	m	m	NOUN
dpc-3517	86	65	scalp	scalp	NOUN
dpc-3517	86	66	t4an0m0	t4an0m0	PROPN
dpc-3517	86	67	/	/	SYM
dpc-3517	86	68	iib	iib	NOUN
dpc-3517	86	69	wild	wild	PROPN
dpc-3517	86	70	0	0	NUM
dpc-3517	86	71	h7	h7	PROPN
dpc-3517	86	72	16	16	NUM
dpc-3517	86	73	m	m	VERB
dpc-3517	86	74	left	leave	VERB
dpc-3517	86	75	upper	upper	ADJ
dpc-3517	86	76	arm	arm	NOUN
dpc-3517	86	77	t4bn0m0	t4bn0m0	PROPN
dpc-3517	86	78	/	/	SYM
dpc-3517	86	79	iic	iic	PROPN
dpc-3517	86	80	unknown	unknown	ADJ
dpc-3517	86	81	0	0	NUM
dpc-3517	86	82	h8	h8	PROPN
dpc-3517	86	83	15	15	NUM
dpc-3517	86	84	m	m	AUX
dpc-3517	86	85	not	not	PART
dpc-3517	86	86	known	know	VERB
dpc-3517	86	87	txnxm1c	txnxm1c	NOUN
dpc-3517	86	88	/	/	SYM
dpc-3517	86	89	iv	iv	NOUN
dpc-3517	86	90	unknown	unknown	ADJ
dpc-3517	86	91	1	1	NUM
dpc-3517	86	92	h9	h9	NOUN
dpc-3517	86	93	8	8	NUM
dpc-3517	86	94	m	m	NOUN
dpc-3517	86	95	right	right	ADJ
dpc-3517	86	96	knee	knee	NOUN
dpc-3517	86	97	txn0m1a	txn0m1a	NOUN
dpc-3517	86	98	/	/	SYM
dpc-3517	86	99	iv	iv	NUM
dpc-3517	86	100	wild	wild	ADJ
dpc-3517	86	101	1	1	NUM
dpc-3517	86	102	h10	h10	NOUN
dpc-3517	86	103	17	17	NUM
dpc-3517	86	104	f	f	PROPN
dpc-3517	86	105	vulvar	vulvar	NOUN
dpc-3517	86	106	skin	skin	NOUN
dpc-3517	86	107	t4bn0m0	t4bn0m0	PROPN
dpc-3517	86	108	/	/	SYM
dpc-3517	86	109	iic	iic	PROPN
dpc-3517	86	110	nras	nras	PROPN
dpc-3517	86	111	q61r	q61r	PROPN
dpc-3517	86	112	0	0	NUM
dpc-3517	86	113	h11	h11	NOUN
dpc-3517	86	114	8	8	NUM
dpc-3517	86	115	f	f	PROPN
dpc-3517	86	116	dorsum	dorsum	NOUN
dpc-3517	86	117	of	of	ADP
dpc-3517	86	118	right	right	ADJ
dpc-3517	86	119	foot	foot	NOUN
dpc-3517	86	120	txn3am0	txn3am0	PROPN
dpc-3517	86	121	/	/	SYM
dpc-3517	86	122	iii	iii	NUM
dpc-3517	86	123	wild	wild	ADJ
dpc-3517	86	124	0	0	NUM
dpc-3517	86	125	h12	h12	NOUN
dpc-3517	86	126	14	14	NUM
dpc-3517	86	127	m	m	NOUN
dpc-3517	86	128	right	right	ADJ
dpc-3517	86	129	shoulder	shoulder	NOUN
dpc-3517	86	130	t3an1am0	t3an1am0	NOUN
dpc-3517	86	131	/	/	SYM
dpc-3517	86	132	iiib	iiib	NOUN
dpc-3517	86	133	unknown	unknown	ADJ
dpc-3517	86	134	0	0	NUM
dpc-3517	86	135	h13	h13	NOUN
dpc-3517	86	136	11	11	NUM
dpc-3517	86	137	f	f	NOUN
dpc-3517	86	138	left	leave	VERB
dpc-3517	86	139	heel	heel	NOUN
dpc-3517	86	140	t3bn0m0	t3bn0m0	PROPN
dpc-3517	86	141	/	/	SYM
dpc-3517	86	142	iib	iib	PROPN
dpc-3517	86	143	unknown	unknown	ADJ
dpc-3517	86	144	0	0	NUM
dpc-3517	86	145	h14	h14	NOUN
dpc-3517	86	146	8	8	NUM
dpc-3517	86	147	f	f	NOUN
dpc-3517	86	148	scalp	scalp	NOUN
dpc-3517	86	149	t4an2cm0	t4an2cm0	NUM
dpc-3517	86	150	/	/	SYM
dpc-3517	86	151	iiic	iiic	PROPN
dpc-3517	86	152	unknown	unknown	ADJ
dpc-3517	86	153	0	0	NUM
dpc-3517	86	154	h15	h15	NUM
dpc-3517	86	155	14	14	NUM
dpc-3517	86	156	m	m	NOUN
dpc-3517	86	157	scalp	scalp	NOUN
dpc-3517	86	158	t4an0m0	t4an0m0	PROPN
dpc-3517	86	159	/	/	SYM
dpc-3517	86	160	iib	iib	NOUN
dpc-3517	86	161	wild	wild	ADJ
dpc-3517	86	162	0	0	NUM
dpc-3517	86	163	ecog	ecog	PROPN
dpc-3517	86	164	=	=	PUNCT
dpc-3517	86	165	eastern	eastern	ADJ
dpc-3517	86	166	cooperative	cooperative	ADJ
dpc-3517	86	167	oncology	oncology	NOUN
dpc-3517	86	168	group	group	NOUN
dpc-3517	86	169	performance	performance	NOUN
dpc-3517	86	170	status	status	NOUN
dpc-3517	86	171	score	score	NOUN
dpc-3517	86	172	.	.	PUNCT
dpc-3517	87	1	original	original	ADJ
dpc-3517	87	2	article	article	NOUN
dpc-3517	87	3	|	|	ADV
dpc-3517	87	4	dermatol	dermatol	ADJ
dpc-3517	87	5	pract	pract	NOUN
dpc-3517	87	6	concept	concept	NOUN
dpc-3517	87	7	.	.	PUNCT
dpc-3517	88	1	2024;14(1):e2024026	2024;14(1):e2024026	NUM
dpc-3517	88	2	5	5	NUM
dpc-3517	88	3	the	the	DET
dpc-3517	88	4	use	use	NOUN
dpc-3517	88	5	of	of	ADP
dpc-3517	88	6	different	different	ADJ
dpc-3517	88	7	therapies	therapy	NOUN
dpc-3517	88	8	for	for	ADP
dpc-3517	88	9	melanomas	melanoma	NOUN
dpc-3517	88	10	in	in	ADP
dpc-3517	88	11	children	child	NOUN
dpc-3517	88	12	and	and	CCONJ
dpc-3517	88	13	adolescents	adolescent	NOUN
dpc-3517	88	14	.	.	PUNCT
dpc-3517	89	1	current	current	ADJ
dpc-3517	89	2	management	management	NOUN
dpc-3517	89	3	guidelines	guideline	NOUN
dpc-3517	89	4	for	for	ADP
dpc-3517	89	5	pediatric	pediatric	ADJ
dpc-3517	89	6	melanoma	melanoma	NOUN
dpc-3517	89	7	are	be	AUX
dpc-3517	89	8	mainly	mainly	ADV
dpc-3517	89	9	based	base	VERB
dpc-3517	89	10	on	on	ADP
dpc-3517	89	11	experience	experience	NOUN
dpc-3517	89	12	of	of	ADP
dpc-3517	89	13	therapies	therapy	NOUN
dpc-3517	89	14	in	in	ADP
dpc-3517	89	15	adults	adult	NOUN
dpc-3517	89	16	,	,	PUNCT
dpc-3517	89	17	and	and	CCONJ
dpc-3517	89	18	the	the	DET
dpc-3517	89	19	efficacy	efficacy	NOUN
dpc-3517	89	20	and	and	CCONJ
dpc-3517	89	21	safety	safety	NOUN
dpc-3517	89	22	of	of	ADP
dpc-3517	89	23	these	these	DET
dpc-3517	89	24	therapies	therapy	NOUN
dpc-3517	89	25	in	in	ADP
dpc-3517	89	26	pediatric	pediatric	ADJ
dpc-3517	89	27	patients	patient	NOUN
dpc-3517	89	28	remains	remain	VERB
dpc-3517	89	29	unclear	unclear	ADJ
dpc-3517	89	30	.	.	PUNCT
dpc-3517	90	1	considering	consider	VERB
dpc-3517	90	2	the	the	DET
dpc-3517	90	3	differences	difference	NOUN
dpc-3517	90	4	between	between	ADP
dpc-3517	90	5	pediatric	pediatric	ADJ
dpc-3517	90	6	and	and	CCONJ
dpc-3517	90	7	adult	adult	NOUN
dpc-3517	90	8	melanoma	melanoma	NOUN
dpc-3517	90	9	,	,	PUNCT
dpc-3517	90	10	there	there	PRON
dpc-3517	90	11	is	be	VERB
dpc-3517	90	12	thus	thus	ADV
dpc-3517	90	13	a	a	DET
dpc-3517	90	14	need	need	NOUN
dpc-3517	90	15	to	to	PART
dpc-3517	90	16	identify	identify	VERB
dpc-3517	90	17	effective	effective	ADJ
dpc-3517	90	18	systemic	systemic	ADJ
dpc-3517	90	19	adjuvant	adjuvant	ADJ
dpc-3517	90	20	therapies	therapy	NOUN
dpc-3517	90	21	to	to	PART
dpc-3517	90	22	reduce	reduce	VERB
dpc-3517	90	23	the	the	DET
dpc-3517	90	24	risk	risk	NOUN
dpc-3517	90	25	of	of	ADP
dpc-3517	90	26	recurrence	recurrence	NOUN
dpc-3517	90	27	and	and	CCONJ
dpc-3517	90	28	improve	improve	VERB
dpc-3517	90	29	survival	survival	NOUN
dpc-3517	90	30	in	in	ADP
dpc-3517	90	31	pediatric	pediatric	ADJ
dpc-3517	90	32	patients	patient	NOUN
dpc-3517	90	33	with	with	ADP
dpc-3517	90	34	melanoma	melanoma	NOUN
dpc-3517	90	35	.	.	PUNCT
dpc-3517	91	1	adjuvant	adjuvant	ADJ
dpc-3517	91	2	therapy	therapy	NOUN
dpc-3517	91	3	with	with	ADP
dpc-3517	91	4	pd-1	pd-1	VERB
dpc-3517	91	5	inhibitors	inhibitor	NOUN
dpc-3517	91	6	reduced	reduce	VERB
dpc-3517	91	7	the	the	DET
dpc-3517	91	8	risk	risk	NOUN
dpc-3517	91	9	of	of	ADP
dpc-3517	91	10	recurrence	recurrence	NOUN
dpc-3517	91	11	or	or	CCONJ
dpc-3517	91	12	death	death	NOUN
dpc-3517	91	13	by	by	ADP
dpc-3517	91	14	40%–50	40%–50	NUM
dpc-3517	91	15	%	%	NOUN
dpc-3517	91	16	and	and	CCONJ
dpc-3517	91	17	significantly	significantly	ADV
dpc-3517	91	18	increased	increase	VERB
dpc-3517	91	19	rfs	rfs	NOUN
dpc-3517	91	20	in	in	ADP
dpc-3517	91	21	patients	patient	NOUN
dpc-3517	91	22	with	with	ADP
dpc-3517	91	23	resected	resect	VERB
dpc-3517	91	24	stage	stage	NOUN
dpc-3517	91	25	iii	iii	SYM
dpc-3517	91	26	/	/	SYM
dpc-3517	91	27	iv	iv	NUM
dpc-3517	91	28	melanoma	melanoma	NOUN
dpc-3517	92	1	[	[	X
dpc-3517	92	2	8	8	NUM
dpc-3517	92	3	-	-	SYM
dpc-3517	92	4	10	10	NUM
dpc-3517	92	5	]	]	PUNCT
dpc-3517	92	6	.	.	PUNCT
dpc-3517	93	1	adjuvant	adjuvant	ADJ
dpc-3517	93	2	immunotherapy	immunotherapy	NOUN
dpc-3517	93	3	is	be	AUX
dpc-3517	93	4	currently	currently	ADV
dpc-3517	93	5	a	a	DET
dpc-3517	93	6	standard	standard	ADJ
dpc-3517	93	7	treatment	treatment	NOUN
dpc-3517	93	8	for	for	ADP
dpc-3517	93	9	stage	stage	NOUN
dpc-3517	93	10	iii	iii	SYM
dpc-3517	93	11	/	/	SYM
dpc-3517	93	12	iv	iv	NUM
dpc-3517	93	13	cutaneous	cutaneous	ADJ
dpc-3517	93	14	melanoma	melanoma	NOUN
dpc-3517	93	15	,	,	PUNCT
dpc-3517	93	16	but	but	CCONJ
dpc-3517	93	17	there	there	PRON
dpc-3517	93	18	is	be	VERB
dpc-3517	93	19	no	no	DET
dpc-3517	93	20	standard	standard	ADJ
dpc-3517	93	21	adjuvant	adjuvant	ADJ
dpc-3517	93	22	therapy	therapy	NOUN
dpc-3517	93	23	for	for	ADP
dpc-3517	93	24	stage	stage	NOUN
dpc-3517	93	25	iib	iib	PROPN
dpc-3517	93	26	and	and	CCONJ
dpc-3517	93	27	iic	iic	PROPN
dpc-3517	93	28	melanomas	melanomas	PROPN
dpc-3517	93	29	.	.	PUNCT
dpc-3517	94	1	in	in	ADP
dpc-3517	94	2	the	the	DET
dpc-3517	94	3	phase	phase	NOUN
dpc-3517	94	4	3	3	NUM
dpc-3517	94	5	keynote-716	keynote-716	NOUN
dpc-3517	94	6	study	study	NOUN
dpc-3517	94	7	,	,	PUNCT
dpc-3517	94	8	adjuvant	adjuvant	ADJ
dpc-3517	94	9	epidemiological	epidemiological	ADJ
dpc-3517	94	10	and	and	CCONJ
dpc-3517	94	11	natural	natural	ADJ
dpc-3517	94	12	history	history	NOUN
dpc-3517	94	13	studies	study	NOUN
dpc-3517	94	14	of	of	ADP
dpc-3517	94	15	pediatric	pediatric	ADJ
dpc-3517	94	16	melanoma	melanoma	NOUN
dpc-3517	94	17	are	be	AUX
dpc-3517	94	18	not	not	PART
dpc-3517	94	19	well	well	ADV
dpc-3517	94	20	-	-	PUNCT
dpc-3517	94	21	understood	understand	VERB
dpc-3517	94	22	.	.	PUNCT
dpc-3517	95	1	distinct	distinct	ADJ
dpc-3517	95	2	from	from	ADP
dpc-3517	95	3	melanoma	melanoma	NOUN
dpc-3517	95	4	in	in	ADP
dpc-3517	95	5	adults	adult	NOUN
dpc-3517	95	6	,	,	PUNCT
dpc-3517	95	7	spitzoid	spitzoid	ADJ
dpc-3517	95	8	melanoma	melanoma	NOUN
dpc-3517	95	9	is	be	AUX
dpc-3517	95	10	one	one	NUM
dpc-3517	95	11	of	of	ADP
dpc-3517	95	12	the	the	DET
dpc-3517	95	13	most	most	ADV
dpc-3517	95	14	common	common	ADJ
dpc-3517	95	15	histologic	histologic	ADJ
dpc-3517	95	16	subtypes	subtype	NOUN
dpc-3517	95	17	in	in	ADP
dpc-3517	95	18	pediatric	pediatric	ADJ
dpc-3517	95	19	patients	patient	NOUN
dpc-3517	95	20	with	with	ADP
dpc-3517	95	21	melanoma	melanoma	NOUN
dpc-3517	95	22	.	.	PUNCT
dpc-3517	96	1	interestingly	interestingly	ADV
dpc-3517	96	2	,	,	PUNCT
dpc-3517	96	3	a	a	DET
dpc-3517	96	4	recent	recent	ADJ
dpc-3517	96	5	meta	meta	ADJ
dpc-3517	96	6	-	-	PUNCT
dpc-3517	96	7	analysis	analysis	NOUN
dpc-3517	96	8	including	include	VERB
dpc-3517	96	9	1002	1002	NUM
dpc-3517	96	10	patients	patient	NOUN
dpc-3517	96	11	with	with	ADP
dpc-3517	96	12	melanoma	melanoma	NOUN
dpc-3517	96	13	have	have	AUX
dpc-3517	96	14	demonstrated	demonstrate	VERB
dpc-3517	96	15	that	that	SCONJ
dpc-3517	96	16	spitzoid	spitzoid	ADJ
dpc-3517	96	17	melanoma	melanoma	NOUN
dpc-3517	96	18	with	with	ADP
dpc-3517	96	19	higher	high	ADJ
dpc-3517	96	20	occurrence	occurrence	NOUN
dpc-3517	96	21	in	in	ADP
dpc-3517	96	22	children	child	NOUN
dpc-3517	96	23	younger	young	ADJ
dpc-3517	96	24	than	than	ADP
dpc-3517	96	25	10	10	NUM
dpc-3517	96	26	years	year	NOUN
dpc-3517	96	27	harbors	harbor	VERB
dpc-3517	96	28	higher	high	ADJ
dpc-3517	96	29	breslow	breslow	ADJ
dpc-3517	96	30	thickness	thickness	NOUN
dpc-3517	96	31	and	and	CCONJ
dpc-3517	96	32	more	more	ADJ
dpc-3517	96	33	propensity	propensity	NOUN
dpc-3517	96	34	to	to	PART
dpc-3517	96	35	nodal	nodal	VERB
dpc-3517	96	36	metastasis	metastasis	NOUN
dpc-3517	96	37	than	than	ADP
dpc-3517	96	38	non	non	ADJ
dpc-3517	96	39	-	-	ADJ
dpc-3517	96	40	spitzoid	spitzoid	ADJ
dpc-3517	96	41	melanomas	melanoma	NOUN
dpc-3517	96	42	,	,	PUNCT
dpc-3517	96	43	but	but	CCONJ
dpc-3517	96	44	shows	show	VERB
dpc-3517	96	45	a	a	DET
dpc-3517	96	46	more	more	ADV
dpc-3517	96	47	indolent	indolent	ADJ
dpc-3517	96	48	biological	biological	ADJ
dpc-3517	96	49	behavior	behavior	NOUN
dpc-3517	96	50	and	and	CCONJ
dpc-3517	96	51	a	a	DET
dpc-3517	96	52	better	well	ADJ
dpc-3517	96	53	prognosis	prognosis	NOUN
dpc-3517	96	54	[	[	X
dpc-3517	96	55	7	7	NUM
dpc-3517	96	56	]	]	PUNCT
dpc-3517	96	57	.	.	PUNCT
dpc-3517	97	1	additionally	additionally	ADV
dpc-3517	97	2	,	,	PUNCT
dpc-3517	97	3	nevus	nevus	ADJ
dpc-3517	97	4	-	-	PUNCT
dpc-3517	97	5	associated	associate	VERB
dpc-3517	97	6	melanoma	melanoma	NOUN
dpc-3517	97	7	is	be	AUX
dpc-3517	97	8	more	more	ADV
dpc-3517	97	9	frequently	frequently	ADV
dpc-3517	97	10	observed	observe	VERB
dpc-3517	97	11	in	in	ADP
dpc-3517	97	12	children	child	NOUN
dpc-3517	97	13	than	than	ADP
dpc-3517	97	14	in	in	ADP
dpc-3517	97	15	adults	adult	NOUN
dpc-3517	97	16	,	,	PUNCT
dpc-3517	97	17	as	as	SCONJ
dpc-3517	97	18	a	a	DET
dpc-3517	97	19	higher	high	ADJ
dpc-3517	97	20	number	number	NOUN
dpc-3517	97	21	of	of	ADP
dpc-3517	97	22	pediatric	pediatric	ADJ
dpc-3517	97	23	melanomas	melanoma	NOUN
dpc-3517	97	24	are	be	AUX
dpc-3517	97	25	associated	associate	VERB
dpc-3517	97	26	with	with	ADP
dpc-3517	97	27	congenital	congenital	ADJ
dpc-3517	97	28	nevi	nevi	NOUN
dpc-3517	97	29	in	in	ADP
dpc-3517	97	30	younger	young	ADJ
dpc-3517	97	31	patients	patient	NOUN
dpc-3517	97	32	.	.	PUNCT
dpc-3517	98	1	all	all	DET
dpc-3517	98	2	these	these	DET
dpc-3517	98	3	results	result	NOUN
dpc-3517	98	4	suggest	suggest	VERB
dpc-3517	98	5	a	a	DET
dpc-3517	98	6	different	different	ADJ
dpc-3517	98	7	biological	biological	ADJ
dpc-3517	98	8	behavior	behavior	NOUN
dpc-3517	98	9	of	of	ADP
dpc-3517	98	10	pediatric	pediatric	ADJ
dpc-3517	98	11	melanoma	melanoma	NOUN
dpc-3517	98	12	from	from	ADP
dpc-3517	98	13	the	the	DET
dpc-3517	98	14	adult	adult	NOUN
dpc-3517	98	15	melanoma	melanoma	NOUN
dpc-3517	98	16	.	.	PUNCT
dpc-3517	99	1	compared	compare	VERB
dpc-3517	99	2	with	with	ADP
dpc-3517	99	3	melanoma	melanoma	NOUN
dpc-3517	99	4	in	in	ADP
dpc-3517	99	5	adults	adult	NOUN
dpc-3517	99	6	,	,	PUNCT
dpc-3517	99	7	there	there	PRON
dpc-3517	99	8	is	be	VERB
dpc-3517	99	9	limited	limited	ADJ
dpc-3517	99	10	evidence	evidence	NOUN
dpc-3517	99	11	to	to	PART
dpc-3517	99	12	support	support	VERB
dpc-3517	99	13	table	table	NOUN
dpc-3517	99	14	3	3	NUM
dpc-3517	99	15	.	.	PUNCT
dpc-3517	99	16	baseline	baseline	PROPN
dpc-3517	99	17	characteristics	characteristic	NOUN
dpc-3517	99	18	of	of	ADP
dpc-3517	99	19	patients	patient	NOUN
dpc-3517	99	20	.	.	PUNCT
dpc-3517	100	1	pembrolizumab	pembrolizumab	NOUN
dpc-3517	100	2	(	(	PUNCT
dpc-3517	100	3	n=9	n=9	NOUN
dpc-3517	100	4	)	)	PUNCT
dpc-3517	100	5	hdi	hdi	NOUN
dpc-3517	100	6	(	(	PUNCT
dpc-3517	100	7	n=15	n=15	PROPN
dpc-3517	100	8	)	)	PUNCT
dpc-3517	100	9	p	p	NOUN
dpc-3517	100	10	age	age	NOUN
dpc-3517	100	11	mean	mean	NOUN
dpc-3517	100	12	(	(	PUNCT
dpc-3517	100	13	sd	sd	NOUN
dpc-3517	100	14	)	)	PUNCT
dpc-3517	100	15	11.3(3.7	11.3(3.7	NUM
dpc-3517	100	16	)	)	PUNCT
dpc-3517	100	17	12.8(2.9	12.8(2.9	NUM
dpc-3517	100	18	)	)	PUNCT
dpc-3517	100	19	0.290	0.290	NUM
dpc-3517	100	20	≤	≤	NUM
dpc-3517	100	21	10	10	NUM
dpc-3517	100	22	3(33	3(33	NUM
dpc-3517	100	23	)	)	PUNCT
dpc-3517	100	24	3(20	3(20	NUM
dpc-3517	100	25	)	)	PUNCT
dpc-3517	100	26	0.635	0.635	NUM
dpc-3517	100	27	>	>	SYM
dpc-3517	100	28	10	10	NUM
dpc-3517	100	29	6(67	6(67	NOUN
dpc-3517	100	30	)	)	PUNCT
dpc-3517	100	31	12(80	12(80	PROPN
dpc-3517	100	32	)	)	PUNCT
dpc-3517	100	33	sex	sex	NOUN
dpc-3517	100	34	0.089	0.089	NUM
dpc-3517	100	35	male	male	NOUN
dpc-3517	100	36	2(22	2(22	NUM
dpc-3517	100	37	)	)	PUNCT
dpc-3517	100	38	10(67	10(67	NOUN
dpc-3517	100	39	)	)	PUNCT
dpc-3517	100	40	female	female	ADJ
dpc-3517	100	41	7(78	7(78	NOUN
dpc-3517	100	42	)	)	PUNCT
dpc-3517	100	43	5(33	5(33	NUM
dpc-3517	100	44	)	)	PUNCT
dpc-3517	100	45	subtype	subtype	NOUN
dpc-3517	100	46	0.583	0.583	NUM
dpc-3517	100	47	cutaneous	cutaneous	ADJ
dpc-3517	100	48	7(78	7(78	NOUN
dpc-3517	100	49	)	)	PUNCT
dpc-3517	100	50	11(73	11(73	NUM
dpc-3517	100	51	)	)	PUNCT
dpc-3517	100	52	acral	acral	ADJ
dpc-3517	100	53	1(11	1(11	NUM
dpc-3517	100	54	)	)	PUNCT
dpc-3517	100	55	2(13	2(13	NUM
dpc-3517	100	56	)	)	PUNCT
dpc-3517	100	57	mucosal	mucosal	NOUN
dpc-3517	100	58	1(11	1(11	NUM
dpc-3517	100	59	)	)	PUNCT
dpc-3517	100	60	0	0	NUM
dpc-3517	100	61	primary	primary	ADJ
dpc-3517	100	62	unknown	unknown	ADJ
dpc-3517	100	63	0	0	NUM
dpc-3517	100	64	2(13	2(13	NUM
dpc-3517	100	65	)	)	PUNCT
dpc-3517	100	66	stage	stage	NOUN
dpc-3517	100	67	0.833	0.833	NUM
dpc-3517	100	68	ii	ii	NOUN
dpc-3517	100	69	5(56	5(56	NUM
dpc-3517	100	70	)	)	PUNCT
dpc-3517	100	71	6(40	6(40	NUM
dpc-3517	100	72	)	)	PUNCT
dpc-3517	100	73	iii	iii	NOUN
dpc-3517	100	74	4(44	4(44	NUM
dpc-3517	100	75	)	)	PUNCT
dpc-3517	100	76	7(47	7(47	NUM
dpc-3517	100	77	)	)	PUNCT
dpc-3517	100	78	iv	iv	NUM
dpc-3517	100	79	0	0	NUM
dpc-3517	100	80	2(13	2(13	NUM
dpc-3517	100	81	)	)	PUNCT
dpc-3517	100	82	mutation	mutation	NOUN
dpc-3517	100	83	status	status	NOUN
dpc-3517	100	84	0.170	0.170	NUM
dpc-3517	100	85	braf	braf	NOUN
dpc-3517	100	86	1(11	1(11	NUM
dpc-3517	100	87	)	)	PUNCT
dpc-3517	100	88	0(0	0(0	NUM
dpc-3517	100	89	)	)	PUNCT
dpc-3517	101	1	ras	ras	PROPN
dpc-3517	101	2	1(11	1(11	NUM
dpc-3517	101	3	)	)	PUNCT
dpc-3517	101	4	1(7	1(7	NUM
dpc-3517	101	5	)	)	PUNCT
dpc-3517	101	6	nf1	nf1	NOUN
dpc-3517	101	7	0(0.0	0(0.0	NOUN
dpc-3517	101	8	)	)	PUNCT
dpc-3517	101	9	0(0	0(0	NUM
dpc-3517	101	10	)	)	PUNCT
dpc-3517	101	11	braf	braf	NOUN
dpc-3517	101	12	/	/	SYM
dpc-3517	101	13	ras	ras	NOUN
dpc-3517	101	14	/	/	SYM
dpc-3517	101	15	nf1	nf1	NOUN
dpc-3517	101	16	triple	triple	ADJ
dpc-3517	101	17	wild	wild	ADJ
dpc-3517	101	18	type	type	NOUN
dpc-3517	101	19	6(67	6(67	NOUN
dpc-3517	101	20	)	)	PUNCT
dpc-3517	101	21	7(47	7(47	NUM
dpc-3517	101	22	)	)	PUNCT
dpc-3517	101	23	unknown	unknown	ADJ
dpc-3517	101	24	1(11	1(11	NUM
dpc-3517	101	25	)	)	PUNCT
dpc-3517	101	26	7(47	7(47	NUM
dpc-3517	101	27	)	)	PUNCT
dpc-3517	101	28	ecog	ecog	VERB
dpc-3517	101	29	ps	ps	PROPN
dpc-3517	101	30	0.669	0.669	NUM
dpc-3517	101	31	0	0	NUM
dpc-3517	101	32	7(78	7(78	NUM
dpc-3517	101	33	)	)	PUNCT
dpc-3517	101	34	10(67	10(67	NOUN
dpc-3517	101	35	)	)	PUNCT
dpc-3517	101	36	1	1	NUM
dpc-3517	101	37	2(22	2(22	NUM
dpc-3517	101	38	)	)	PUNCT
dpc-3517	101	39	5(33	5(33	NUM
dpc-3517	101	40	)	)	PUNCT
dpc-3517	101	41	ecog	ecog	VERB
dpc-3517	101	42	ps	ps	PROPN
dpc-3517	101	43	=	=	SYM
dpc-3517	101	44	eastern	eastern	ADJ
dpc-3517	101	45	cooperative	cooperative	ADJ
dpc-3517	101	46	oncology	oncology	NOUN
dpc-3517	101	47	group	group	NOUN
dpc-3517	101	48	performance	performance	NOUN
dpc-3517	101	49	status	status	NOUN
dpc-3517	101	50	score	score	NOUN
dpc-3517	101	51	.	.	PUNCT
dpc-3517	102	1	hdi	hdi	PROPN
dpc-3517	102	2	=	=	SYM
dpc-3517	102	3	high	high	ADV
dpc-3517	102	4	-	-	PUNCT
dpc-3517	102	5	dose	dose	NOUN
dpc-3517	102	6	interferon	interferon	NOUN
dpc-3517	102	7	-	-	PUNCT
dpc-3517	102	8	α2b	α2b	NUM
dpc-3517	102	9	;	;	PUNCT
dpc-3517	102	10	sd	sd	NOUN
dpc-3517	102	11	=	=	SYM
dpc-3517	102	12	standard	standard	ADJ
dpc-3517	102	13	deviation	deviation	NOUN
dpc-3517	102	14	.	.	PUNCT
dpc-3517	103	1	6	6	NUM
dpc-3517	103	2	original	original	ADJ
dpc-3517	103	3	article	article	NOUN
dpc-3517	103	4	|	|	ADV
dpc-3517	103	5	dermatol	dermatol	ADJ
dpc-3517	103	6	pract	pract	NOUN
dpc-3517	103	7	concept	concept	NOUN
dpc-3517	103	8	.	.	PUNCT
dpc-3517	104	1	2024;14(1):e2024026	2024;14(1):e2024026	NUM
dpc-3517	104	2	pembrolizumab	pembrolizumab	NOUN
dpc-3517	104	3	and	and	CCONJ
dpc-3517	104	4	placebo	placebo	NOUN
dpc-3517	104	5	groups	group	NOUN
dpc-3517	104	6	,	,	PUNCT
dpc-3517	104	7	respectively	respectively	ADV
dpc-3517	104	8	[	[	X
dpc-3517	104	9	11	11	NUM
dpc-3517	104	10	]	]	PUNCT
dpc-3517	104	11	.	.	PUNCT
dpc-3517	105	1	in	in	ADP
dpc-3517	105	2	addition	addition	NOUN
dpc-3517	105	3	,	,	PUNCT
dpc-3517	105	4	each	each	DET
dpc-3517	105	5	group	group	NOUN
dpc-3517	105	6	included	include	VERB
dpc-3517	105	7	one	one	NUM
dpc-3517	105	8	pediatric	pediatric	ADJ
dpc-3517	105	9	patient	patient	NOUN
dpc-3517	105	10	,	,	PUNCT
dpc-3517	105	11	and	and	CCONJ
dpc-3517	105	12	on	on	ADP
dpc-3517	105	13	the	the	DET
dpc-3517	105	14	basis	basis	NOUN
dpc-3517	105	15	of	of	ADP
dpc-3517	105	16	these	these	DET
dpc-3517	105	17	data	datum	NOUN
dpc-3517	105	18	,	,	PUNCT
dpc-3517	105	19	the	the	DET
dpc-3517	105	20	fda	fda	PROPN
dpc-3517	105	21	approved	approve	VERB
dpc-3517	105	22	pembrolizumab	pembrolizumab	NOUN
dpc-3517	105	23	as	as	ADP
dpc-3517	105	24	adjuvant	adjuvant	ADJ
dpc-3517	105	25	therapy	therapy	NOUN
dpc-3517	105	26	for	for	ADP
dpc-3517	105	27	adult	adult	NOUN
dpc-3517	105	28	and	and	CCONJ
dpc-3517	105	29	pediatric	pediatric	ADJ
dpc-3517	105	30	patients	patient	NOUN
dpc-3517	105	31	with	with	ADP
dpc-3517	105	32	high	high	ADJ
dpc-3517	105	33	-	-	PUNCT
dpc-3517	105	34	risk	risk	NOUN
dpc-3517	105	35	pembrolizumab	pembrolizumab	NOUN
dpc-3517	105	36	significantly	significantly	ADV
dpc-3517	105	37	reduced	reduce	VERB
dpc-3517	105	38	the	the	DET
dpc-3517	105	39	risk	risk	NOUN
dpc-3517	105	40	of	of	ADP
dpc-3517	105	41	recurrence	recurrence	NOUN
dpc-3517	105	42	or	or	CCONJ
dpc-3517	105	43	death	death	NOUN
dpc-3517	105	44	in	in	ADP
dpc-3517	105	45	patients	patient	NOUN
dpc-3517	105	46	with	with	ADP
dpc-3517	105	47	resected	resected	ADJ
dpc-3517	105	48	stage	stage	NOUN
dpc-3517	105	49	iib	iib	NOUN
dpc-3517	105	50	or	or	CCONJ
dpc-3517	105	51	iic	iic	PROPN
dpc-3517	105	52	melanoma	melanoma	PROPN
dpc-3517	105	53	,	,	PUNCT
dpc-3517	105	54	compared	compare	VERB
dpc-3517	105	55	with	with	ADP
dpc-3517	105	56	placebo	placebo	NOUN
dpc-3517	105	57	,	,	PUNCT
dpc-3517	105	58	with	with	ADP
dpc-3517	105	59	12	12	NUM
dpc-3517	105	60	-	-	PUNCT
dpc-3517	105	61	month	month	NOUN
dpc-3517	105	62	rfs	rfs	NOUN
dpc-3517	105	63	rates	rate	NOUN
dpc-3517	105	64	of	of	ADP
dpc-3517	105	65	90	90	NUM
dpc-3517	105	66	%	%	NOUN
dpc-3517	105	67	and	and	CCONJ
dpc-3517	105	68	83	83	NUM
dpc-3517	105	69	%	%	NOUN
dpc-3517	105	70	and	and	CCONJ
dpc-3517	105	71	18	18	NUM
dpc-3517	105	72	-	-	PUNCT
dpc-3517	105	73	month	month	NOUN
dpc-3517	105	74	rfs	rfs	NOUN
dpc-3517	105	75	rates	rate	NOUN
dpc-3517	105	76	of	of	ADP
dpc-3517	105	77	86	86	NUM
dpc-3517	105	78	%	%	NOUN
dpc-3517	105	79	and	and	CCONJ
dpc-3517	105	80	77	77	NUM
dpc-3517	105	81	%	%	NOUN
dpc-3517	105	82	in	in	ADP
dpc-3517	105	83	the	the	DET
dpc-3517	105	84	figure	figure	NOUN
dpc-3517	105	85	2	2	NUM
dpc-3517	105	86	.	.	PUNCT
dpc-3517	106	1	kaplan	kaplan	PROPN
dpc-3517	106	2	-	-	PUNCT
dpc-3517	106	3	meier	meier	PROPN
dpc-3517	106	4	estimates	estimate	NOUN
dpc-3517	106	5	of	of	ADP
dpc-3517	106	6	recurrence	recurrence	NOUN
dpc-3517	106	7	-	-	PUNCT
dpc-3517	106	8	free	free	ADJ
dpc-3517	106	9	survival	survival	NOUN
dpc-3517	106	10	in	in	ADP
dpc-3517	106	11	pediatric	pediatric	ADJ
dpc-3517	106	12	patients	patient	NOUN
dpc-3517	106	13	with	with	ADP
dpc-3517	106	14	melanoma	melanoma	NOUN
dpc-3517	106	15	treated	treat	VERB
dpc-3517	106	16	with	with	ADP
dpc-3517	106	17	pembrolizumab	pembrolizumab	NOUN
dpc-3517	106	18	or	or	CCONJ
dpc-3517	106	19	highdose	highdose	VERB
dpc-3517	106	20	interferon	interferon	ADJ
dpc-3517	106	21	-	-	PUNCT
dpc-3517	106	22	α2b	α2b	NOUN
dpc-3517	106	23	.	.	PUNCT
dpc-3517	107	1	ci	ci	NOUN
dpc-3517	107	2	=	=	NOUN
dpc-3517	107	3	confidence	confidence	NOUN
dpc-3517	107	4	interval	interval	NOUN
dpc-3517	107	5	;	;	PUNCT
dpc-3517	107	6	hr	hr	NOUN
dpc-3517	107	7	=	=	PUNCT
dpc-3517	107	8	hazard	hazard	NOUN
dpc-3517	107	9	ratio	ratio	NOUN
dpc-3517	107	10	.	.	PUNCT
dpc-3517	108	1	table	table	NOUN
dpc-3517	108	2	4	4	NUM
dpc-3517	108	3	.	.	PUNCT
dpc-3517	108	4	adverse	adverse	ADJ
dpc-3517	108	5	events	event	NOUN
dpc-3517	108	6	in	in	ADP
dpc-3517	108	7	pediatric	pediatric	ADJ
dpc-3517	108	8	patients	patient	NOUN
dpc-3517	108	9	with	with	ADP
dpc-3517	108	10	melanoma	melanoma	NOUN
dpc-3517	108	11	treated	treat	VERB
dpc-3517	108	12	with	with	ADP
dpc-3517	108	13	pembrolizumab	pembrolizumab	NOUN
dpc-3517	108	14	or	or	CCONJ
dpc-3517	108	15	high	high	ADV
dpc-3517	108	16	-	-	PUNCT
dpc-3517	108	17	dose	dose	NOUN
dpc-3517	108	18	interferon	interferon	NOUN
dpc-3517	108	19	-	-	PUNCT
dpc-3517	108	20	α2b	α2b	NOUN
dpc-3517	108	21	.	.	PUNCT
dpc-3517	109	1	adverse	adverse	ADJ
dpc-3517	109	2	event	event	NOUN
dpc-3517	109	3	,	,	PUNCT
dpc-3517	109	4	n	n	PROPN
dpc-3517	109	5	(	(	PUNCT
dpc-3517	109	6	%	%	INTJ
dpc-3517	109	7	)	)	PUNCT
dpc-3517	109	8	pembrolizumab	pembrolizumab	NOUN
dpc-3517	109	9	(	(	PUNCT
dpc-3517	109	10	n	n	NOUN
dpc-3517	109	11	=	=	SYM
dpc-3517	109	12	9	9	X
dpc-3517	109	13	)	)	PUNCT
dpc-3517	109	14	hdi	hdi	NOUN
dpc-3517	109	15	(	(	PUNCT
dpc-3517	109	16	n	n	NOUN
dpc-3517	109	17	=	=	SYM
dpc-3517	109	18	15	15	NUM
dpc-3517	109	19	)	)	PUNCT
dpc-3517	109	20	any	any	DET
dpc-3517	109	21	grade	grade	NOUN
dpc-3517	109	22	≥3	≥3	PROPN
dpc-3517	109	23	any	any	DET
dpc-3517	109	24	grade	grade	NOUN
dpc-3517	109	25	≥3	≥3	NOUN
dpc-3517	109	26	any	any	DET
dpc-3517	109	27	cause	cause	NOUN
dpc-3517	109	28	adverse	adverse	ADJ
dpc-3517	109	29	event	event	NOUN
dpc-3517	109	30	4(44	4(44	NUM
dpc-3517	109	31	)	)	PUNCT
dpc-3517	109	32	0	0	NUM
dpc-3517	109	33	15(100	15(100	NOUN
dpc-3517	109	34	)	)	PUNCT
dpc-3517	109	35	2(13	2(13	NUM
dpc-3517	109	36	)	)	PUNCT
dpc-3517	109	37	treatment	treatment	NOUN
dpc-3517	109	38	-	-	PUNCT
dpc-3517	109	39	related	relate	VERB
dpc-3517	109	40	adverse	adverse	ADJ
dpc-3517	109	41	event	event	NOUN
dpc-3517	109	42	4(44	4(44	NUM
dpc-3517	109	43	)	)	PUNCT
dpc-3517	109	44	0	0	NUM
dpc-3517	109	45	15(100	15(100	NOUN
dpc-3517	109	46	)	)	PUNCT
dpc-3517	109	47	2(13	2(13	NUM
dpc-3517	109	48	)	)	PUNCT
dpc-3517	109	49	leucopenia	leucopenia	NOUN
dpc-3517	109	50	1(11	1(11	NUM
dpc-3517	109	51	)	)	PUNCT
dpc-3517	109	52	0	0	NUM
dpc-3517	110	1	14(93	14(93	NUM
dpc-3517	110	2	)	)	PUNCT
dpc-3517	110	3	0	0	NUM
dpc-3517	111	1	neutropenia	neutropenia	NOUN
dpc-3517	111	2	1(11	1(11	NUM
dpc-3517	111	3	)	)	PUNCT
dpc-3517	111	4	0	0	NUM
dpc-3517	112	1	13(87	13(87	NUM
dpc-3517	112	2	)	)	PUNCT
dpc-3517	112	3	1(7	1(7	NUM
dpc-3517	112	4	)	)	PUNCT
dpc-3517	112	5	pyrexia	pyrexia	NOUN
dpc-3517	112	6	0	0	NUM
dpc-3517	112	7	0	0	NUM
dpc-3517	112	8	13(87	13(87	NUM
dpc-3517	112	9	)	)	PUNCT
dpc-3517	112	10	0	0	NUM
dpc-3517	113	1	nausea	nausea	NOUN
dpc-3517	113	2	0	0	NUM
dpc-3517	113	3	0	0	NUM
dpc-3517	113	4	7(47	7(47	NUM
dpc-3517	113	5	)	)	PUNCT
dpc-3517	113	6	0	0	NUM
dpc-3517	113	7	hyperthyroidism	hyperthyroidism	NOUN
dpc-3517	113	8	2(22	2(22	NUM
dpc-3517	113	9	)	)	PUNCT
dpc-3517	113	10	0	0	NUM
dpc-3517	113	11	0	0	NUM
dpc-3517	113	12	0	0	NUM
dpc-3517	113	13	alt	alt	NOUN
dpc-3517	113	14	elevation	elevation	NOUN
dpc-3517	113	15	1(11	1(11	NUM
dpc-3517	113	16	)	)	PUNCT
dpc-3517	113	17	0	0	NUM
dpc-3517	113	18	3(20	3(20	NUM
dpc-3517	113	19	)	)	PUNCT
dpc-3517	113	20	1(7	1(7	NUM
dpc-3517	113	21	)	)	PUNCT
dpc-3517	113	22	ast	ast	NOUN
dpc-3517	113	23	elevation	elevation	NOUN
dpc-3517	113	24	1(11	1(11	NUM
dpc-3517	113	25	)	)	PUNCT
dpc-3517	113	26	0	0	NUM
dpc-3517	113	27	3(20	3(20	NUM
dpc-3517	113	28	)	)	PUNCT
dpc-3517	113	29	1(7	1(7	NUM
dpc-3517	113	30	)	)	PUNCT
dpc-3517	113	31	rash	rash	NOUN
dpc-3517	113	32	2(22	2(22	NUM
dpc-3517	113	33	)	)	PUNCT
dpc-3517	113	34	0	0	NUM
dpc-3517	113	35	2(13	2(13	NUM
dpc-3517	113	36	)	)	PUNCT
dpc-3517	113	37	0	0	NUM
dpc-3517	114	1	fatigue	fatigue	NOUN
dpc-3517	114	2	0	0	NUM
dpc-3517	114	3	0	0	NUM
dpc-3517	114	4	4(27	4(27	NUM
dpc-3517	114	5	)	)	PUNCT
dpc-3517	114	6	0	0	NUM
dpc-3517	115	1	myalgia	myalgia	NOUN
dpc-3517	115	2	0	0	NUM
dpc-3517	115	3	0	0	NUM
dpc-3517	115	4	2(13	2(13	NUM
dpc-3517	115	5	)	)	PUNCT
dpc-3517	115	6	0	0	NUM
dpc-3517	115	7	alopecia	alopecia	NOUN
dpc-3517	115	8	1(11	1(11	NUM
dpc-3517	115	9	)	)	PUNCT
dpc-3517	115	10	0	0	NUM
dpc-3517	115	11	0	0	NUM
dpc-3517	115	12	0	0	NUM
dpc-3517	116	1	thrombocytopenia	thrombocytopenia	NOUN
dpc-3517	116	2	0	0	NUM
dpc-3517	116	3	0	0	NUM
dpc-3517	116	4	1(7	1(7	NUM
dpc-3517	116	5	)	)	PUNCT
dpc-3517	116	6	0	0	NUM
dpc-3517	116	7	wenckebach	wenckebach	NOUN
dpc-3517	116	8	block	block	NOUN
dpc-3517	116	9	0	0	NUM
dpc-3517	116	10	0	0	NUM
dpc-3517	116	11	1(7	1(7	NUM
dpc-3517	116	12	)	)	PUNCT
dpc-3517	116	13	0	0	NUM
dpc-3517	116	14	original	original	ADJ
dpc-3517	116	15	article	article	NOUN
dpc-3517	116	16	|	|	ADV
dpc-3517	116	17	dermatol	dermatol	ADJ
dpc-3517	116	18	pract	pract	NOUN
dpc-3517	116	19	concept	concept	NOUN
dpc-3517	116	20	.	.	PUNCT
dpc-3517	117	1	2024;14(1):e2024026	2024;14(1):e2024026	NUM
dpc-3517	117	2	7	7	NUM
dpc-3517	117	3	most	most	ADV
dpc-3517	117	4	frequent	frequent	ADJ
dpc-3517	117	5	grade	grade	NOUN
dpc-3517	118	1	3–5	3–5	NUM
dpc-3517	118	2	traes	traes	NOUN
dpc-3517	118	3	were	be	AUX
dpc-3517	118	4	decreased	decrease	VERB
dpc-3517	118	5	lymphocyte	lymphocyte	ADJ
dpc-3517	118	6	count	count	NOUN
dpc-3517	118	7	and	and	CCONJ
dpc-3517	118	8	anemia	anemia	NOUN
dpc-3517	118	9	.	.	PUNCT
dpc-3517	119	1	two	two	NUM
dpc-3517	119	2	patients	patient	NOUN
dpc-3517	119	3	had	have	VERB
dpc-3517	119	4	grade	grade	NOUN
dpc-3517	119	5	5	5	NUM
dpc-3517	119	6	toxicities	toxicity	NOUN
dpc-3517	119	7	including	include	VERB
dpc-3517	119	8	treatment	treatment	NOUN
dpc-3517	119	9	-	-	PUNCT
dpc-3517	119	10	related	relate	VERB
dpc-3517	119	11	pneumonitis	pneumonitis	NOUN
dpc-3517	119	12	,	,	PUNCT
dpc-3517	119	13	pleural	pleural	ADJ
dpc-3517	119	14	effusion	effusion	NOUN
dpc-3517	119	15	,	,	PUNCT
dpc-3517	119	16	and	and	CCONJ
dpc-3517	119	17	pulmonary	pulmonary	ADJ
dpc-3517	119	18	edema	edema	NOUN
dpc-3517	119	19	[	[	X
dpc-3517	119	20	4	4	NUM
dpc-3517	119	21	]	]	PUNCT
dpc-3517	119	22	.	.	PUNCT
dpc-3517	120	1	in	in	ADP
dpc-3517	120	2	the	the	DET
dpc-3517	120	3	current	current	ADJ
dpc-3517	120	4	study	study	NOUN
dpc-3517	120	5	,	,	PUNCT
dpc-3517	120	6	pembrolizumab	pembrolizumab	NOUN
dpc-3517	120	7	had	have	VERB
dpc-3517	120	8	a	a	DET
dpc-3517	120	9	much	much	ADV
dpc-3517	120	10	lower	low	ADJ
dpc-3517	120	11	incidence	incidence	NOUN
dpc-3517	120	12	of	of	ADP
dpc-3517	120	13	traes	traes	PROPN
dpc-3517	120	14	than	than	ADP
dpc-3517	120	15	hdi	hdi	PROPN
dpc-3517	120	16	.	.	PUNCT
dpc-3517	121	1	the	the	DET
dpc-3517	121	2	most	most	ADV
dpc-3517	121	3	common	common	ADJ
dpc-3517	121	4	adverse	adverse	ADJ
dpc-3517	121	5	events	event	NOUN
dpc-3517	121	6	were	be	AUX
dpc-3517	121	7	hyperthyroidism	hyperthyroidism	NOUN
dpc-3517	121	8	and	and	CCONJ
dpc-3517	121	9	rash	rash	NOUN
dpc-3517	121	10	,	,	PUNCT
dpc-3517	121	11	and	and	CCONJ
dpc-3517	121	12	there	there	PRON
dpc-3517	121	13	were	be	VERB
dpc-3517	121	14	no	no	DET
dpc-3517	121	15	grade	grade	NOUN
dpc-3517	121	16	3–5	3–5	NUM
dpc-3517	121	17	traes	traes	NOUN
dpc-3517	121	18	in	in	ADP
dpc-3517	121	19	the	the	DET
dpc-3517	121	20	pembrolizumab	pembrolizumab	NOUN
dpc-3517	121	21	group	group	NOUN
dpc-3517	121	22	.	.	PUNCT
dpc-3517	122	1	in	in	ADP
dpc-3517	122	2	contrast	contrast	NOUN
dpc-3517	122	3	,	,	PUNCT
dpc-3517	122	4	the	the	DET
dpc-3517	122	5	incidences	incidence	NOUN
dpc-3517	122	6	of	of	ADP
dpc-3517	122	7	myelosuppression	myelosuppression	NOUN
dpc-3517	122	8	(	(	PUNCT
dpc-3517	122	9	any	any	DET
dpc-3517	122	10	grade	grade	NOUN
dpc-3517	122	11	:	:	PUNCT
dpc-3517	122	12	93	93	NUM
dpc-3517	122	13	%	%	NOUN
dpc-3517	122	14	versus	versus	ADP
dpc-3517	122	15	11	11	NUM
dpc-3517	122	16	%	%	NOUN
dpc-3517	122	17	;	;	PUNCT
dpc-3517	122	18	grade	grade	NOUN
dpc-3517	122	19	≥3	≥3	PROPN
dpc-3517	122	20	:	:	PUNCT
dpc-3517	122	21	7	7	NUM
dpc-3517	122	22	%	%	NOUN
dpc-3517	122	23	versus	versus	ADP
dpc-3517	122	24	0	0	NUM
dpc-3517	122	25	)	)	PUNCT
dpc-3517	122	26	,	,	PUNCT
dpc-3517	122	27	pyrexia	pyrexia	NOUN
dpc-3517	122	28	(	(	PUNCT
dpc-3517	122	29	87	87	NUM
dpc-3517	122	30	%	%	NOUN
dpc-3517	122	31	versus	versus	ADP
dpc-3517	122	32	0	0	NUM
dpc-3517	122	33	)	)	PUNCT
dpc-3517	122	34	,	,	PUNCT
dpc-3517	122	35	nausea	nausea	NOUN
dpc-3517	122	36	(	(	PUNCT
dpc-3517	122	37	47	47	NUM
dpc-3517	122	38	%	%	NOUN
dpc-3517	122	39	versus	versus	ADP
dpc-3517	122	40	0	0	NUM
dpc-3517	122	41	)	)	PUNCT
dpc-3517	122	42	,	,	PUNCT
dpc-3517	122	43	elevated	elevated	ADJ
dpc-3517	122	44	transaminase	transaminase	NOUN
dpc-3517	122	45	level	level	NOUN
dpc-3517	122	46	(	(	PUNCT
dpc-3517	122	47	ast	ast	NOUN
dpc-3517	122	48	elevation	elevation	NOUN
dpc-3517	122	49	:	:	PUNCT
dpc-3517	122	50	27	27	NUM
dpc-3517	122	51	%	%	NOUN
dpc-3517	122	52	versus	versus	ADP
dpc-3517	122	53	11	11	NUM
dpc-3517	122	54	%	%	NOUN
dpc-3517	122	55	,	,	PUNCT
dpc-3517	122	56	alt	alt	VERB
dpc-3517	122	57	elevation	elevation	NOUN
dpc-3517	122	58	:	:	PUNCT
dpc-3517	122	59	27	27	NUM
dpc-3517	122	60	%	%	NOUN
dpc-3517	122	61	versus	versus	ADP
dpc-3517	122	62	11	11	NUM
dpc-3517	122	63	%	%	NOUN
dpc-3517	122	64	)	)	PUNCT
dpc-3517	122	65	,	,	PUNCT
dpc-3517	122	66	and	and	CCONJ
dpc-3517	122	67	fatigue	fatigue	NOUN
dpc-3517	122	68	(	(	PUNCT
dpc-3517	122	69	27	27	NUM
dpc-3517	122	70	%	%	NOUN
dpc-3517	122	71	versus	versus	ADP
dpc-3517	122	72	0	0	NUM
dpc-3517	122	73	)	)	PUNCT
dpc-3517	122	74	were	be	AUX
dpc-3517	122	75	higher	high	ADJ
dpc-3517	122	76	in	in	ADP
dpc-3517	122	77	the	the	DET
dpc-3517	122	78	hdi	hdi	PROPN
dpc-3517	122	79	group	group	NOUN
dpc-3517	122	80	than	than	ADP
dpc-3517	122	81	in	in	ADP
dpc-3517	122	82	the	the	DET
dpc-3517	122	83	pembrolizumab	pembrolizumab	NOUN
dpc-3517	122	84	group	group	NOUN
dpc-3517	122	85	.	.	PUNCT
dpc-3517	123	1	pembrolizumab	pembrolizumab	NOUN
dpc-3517	123	2	might	might	AUX
dpc-3517	123	3	thus	thus	ADV
dpc-3517	123	4	be	be	AUX
dpc-3517	123	5	a	a	DET
dpc-3517	123	6	better	well	ADV
dpc-3517	123	7	adjuvant	adjuvant	ADJ
dpc-3517	123	8	treatment	treatment	NOUN
dpc-3517	123	9	choice	choice	NOUN
dpc-3517	123	10	than	than	ADP
dpc-3517	123	11	hdi	hdi	PROPN
dpc-3517	123	12	because	because	SCONJ
dpc-3517	123	13	of	of	ADP
dpc-3517	123	14	its	its	PRON
dpc-3517	123	15	more	more	ADV
dpc-3517	123	16	favorable	favorable	ADJ
dpc-3517	123	17	safety	safety	NOUN
dpc-3517	123	18	and	and	CCONJ
dpc-3517	123	19	tolerability	tolerability	NOUN
dpc-3517	123	20	profile	profile	NOUN
dpc-3517	123	21	.	.	PUNCT
dpc-3517	124	1	this	this	DET
dpc-3517	124	2	study	study	NOUN
dpc-3517	124	3	had	have	VERB
dpc-3517	124	4	some	some	DET
dpc-3517	124	5	limitations	limitation	NOUN
dpc-3517	124	6	.	.	PUNCT
dpc-3517	125	1	it	it	PRON
dpc-3517	125	2	was	be	AUX
dpc-3517	125	3	a	a	DET
dpc-3517	125	4	retrospective	retrospective	ADJ
dpc-3517	125	5	study	study	NOUN
dpc-3517	125	6	and	and	CCONJ
dpc-3517	125	7	thus	thus	ADV
dpc-3517	125	8	had	have	VERB
dpc-3517	125	9	some	some	DET
dpc-3517	125	10	information	information	NOUN
dpc-3517	125	11	bias	bias	NOUN
dpc-3517	125	12	.	.	PUNCT
dpc-3517	126	1	in	in	ADP
dpc-3517	126	2	addition	addition	NOUN
dpc-3517	126	3	,	,	PUNCT
dpc-3517	126	4	the	the	DET
dpc-3517	126	5	follow	follow	VERB
dpc-3517	126	6	-	-	PUNCT
dpc-3517	126	7	up	up	ADP
dpc-3517	126	8	time	time	NOUN
dpc-3517	126	9	was	be	AUX
dpc-3517	126	10	shorter	short	ADJ
dpc-3517	126	11	in	in	ADP
dpc-3517	126	12	the	the	DET
dpc-3517	126	13	pembrolizumab	pembrolizumab	NOUN
dpc-3517	126	14	group	group	NOUN
dpc-3517	126	15	compared	compare	VERB
dpc-3517	126	16	with	with	ADP
dpc-3517	126	17	the	the	DET
dpc-3517	126	18	hdi	hdi	PROPN
dpc-3517	126	19	group	group	NOUN
dpc-3517	126	20	.	.	PUNCT
dpc-3517	127	1	the	the	DET
dpc-3517	127	2	study	study	NOUN
dpc-3517	127	3	was	be	AUX
dpc-3517	127	4	also	also	ADV
dpc-3517	127	5	limited	limit	VERB
dpc-3517	127	6	by	by	ADP
dpc-3517	127	7	the	the	DET
dpc-3517	127	8	small	small	ADJ
dpc-3517	127	9	numbers	number	NOUN
dpc-3517	127	10	of	of	ADP
dpc-3517	127	11	patients	patient	NOUN
dpc-3517	127	12	in	in	ADP
dpc-3517	127	13	both	both	DET
dpc-3517	127	14	groups	group	NOUN
dpc-3517	127	15	;	;	PUNCT
dpc-3517	127	16	however	however	ADV
dpc-3517	127	17	,	,	PUNCT
dpc-3517	127	18	the	the	DET
dpc-3517	127	19	rarity	rarity	NOUN
dpc-3517	127	20	of	of	ADP
dpc-3517	127	21	pediatric	pediatric	ADJ
dpc-3517	127	22	melanoma	melanoma	NOUN
dpc-3517	127	23	means	mean	VERB
dpc-3517	127	24	that	that	SCONJ
dpc-3517	127	25	it	it	PRON
dpc-3517	127	26	is	be	AUX
dpc-3517	127	27	difficult	difficult	ADJ
dpc-3517	127	28	to	to	PART
dpc-3517	127	29	conduct	conduct	VERB
dpc-3517	127	30	large	large	ADJ
dpc-3517	127	31	or	or	CCONJ
dpc-3517	127	32	prospective	prospective	ADJ
dpc-3517	127	33	studies	study	NOUN
dpc-3517	127	34	in	in	ADP
dpc-3517	127	35	these	these	DET
dpc-3517	127	36	patients	patient	NOUN
dpc-3517	127	37	.	.	PUNCT
dpc-3517	128	1	furthermore	furthermore	ADV
dpc-3517	128	2	,	,	PUNCT
dpc-3517	128	3	hdi	hdi	PROPN
dpc-3517	128	4	might	might	AUX
dpc-3517	128	5	not	not	PART
dpc-3517	128	6	be	be	AUX
dpc-3517	128	7	the	the	DET
dpc-3517	128	8	best	good	ADJ
dpc-3517	128	9	control	control	NOUN
dpc-3517	128	10	treatment	treatment	NOUN
dpc-3517	128	11	,	,	PUNCT
dpc-3517	128	12	given	give	VERB
dpc-3517	128	13	that	that	SCONJ
dpc-3517	128	14	it	it	PRON
dpc-3517	128	15	is	be	AUX
dpc-3517	128	16	no	no	ADV
dpc-3517	128	17	longer	long	ADV
dpc-3517	128	18	the	the	DET
dpc-3517	128	19	standard	standard	ADJ
dpc-3517	128	20	adjuvant	adjuvant	ADJ
dpc-3517	128	21	therapy	therapy	NOUN
dpc-3517	128	22	for	for	ADP
dpc-3517	128	23	cutaneous	cutaneous	ADJ
dpc-3517	128	24	melanoma	melanoma	NOUN
dpc-3517	128	25	.	.	PUNCT
dpc-3517	129	1	the	the	DET
dpc-3517	129	2	study	study	NOUN
dpc-3517	129	3	was	be	AUX
dpc-3517	129	4	further	far	ADV
dpc-3517	129	5	limited	limit	VERB
dpc-3517	129	6	by	by	ADP
dpc-3517	129	7	the	the	DET
dpc-3517	129	8	lack	lack	NOUN
dpc-3517	129	9	of	of	ADP
dpc-3517	129	10	racial	racial	ADJ
dpc-3517	129	11	diversity	diversity	NOUN
dpc-3517	129	12	,	,	PUNCT
dpc-3517	129	13	given	give	VERB
dpc-3517	129	14	that	that	SCONJ
dpc-3517	129	15	it	it	PRON
dpc-3517	129	16	only	only	ADV
dpc-3517	129	17	included	include	VERB
dpc-3517	129	18	asian	asian	ADJ
dpc-3517	129	19	pediatric	pediatric	ADJ
dpc-3517	129	20	patients	patient	NOUN
dpc-3517	129	21	.	.	PUNCT
dpc-3517	130	1	in	in	ADP
dpc-3517	130	2	summary	summary	NOUN
dpc-3517	130	3	,	,	PUNCT
dpc-3517	130	4	pembrolizumab	pembrolizumab	NOUN
dpc-3517	130	5	was	be	AUX
dpc-3517	130	6	associated	associate	VERB
dpc-3517	130	7	with	with	ADP
dpc-3517	130	8	a	a	DET
dpc-3517	130	9	lower	low	ADJ
dpc-3517	130	10	risk	risk	NOUN
dpc-3517	130	11	of	of	ADP
dpc-3517	130	12	recurrence	recurrence	NOUN
dpc-3517	130	13	in	in	ADP
dpc-3517	130	14	pediatric	pediatric	ADJ
dpc-3517	130	15	patients	patient	NOUN
dpc-3517	130	16	with	with	ADP
dpc-3517	130	17	melanoma	melanoma	NOUN
dpc-3517	130	18	,	,	PUNCT
dpc-3517	130	19	compared	compare	VERB
dpc-3517	130	20	with	with	ADP
dpc-3517	130	21	hdi	hdi	PROPN
dpc-3517	130	22	,	,	PUNCT
dpc-3517	130	23	but	but	CCONJ
dpc-3517	130	24	there	there	PRON
dpc-3517	130	25	was	be	VERB
dpc-3517	130	26	no	no	DET
dpc-3517	130	27	significant	significant	ADJ
dpc-3517	130	28	difference	difference	NOUN
dpc-3517	130	29	in	in	ADP
dpc-3517	130	30	rfs	rfs	PROPN
dpc-3517	130	31	between	between	ADP
dpc-3517	130	32	the	the	DET
dpc-3517	130	33	two	two	NUM
dpc-3517	130	34	treatments	treatment	NOUN
dpc-3517	130	35	.	.	PUNCT
dpc-3517	131	1	pembrolizumab	pembrolizumab	NOUN
dpc-3517	131	2	also	also	ADV
dpc-3517	131	3	had	have	VERB
dpc-3517	131	4	a	a	DET
dpc-3517	131	5	more	more	ADV
dpc-3517	131	6	favorable	favorable	ADJ
dpc-3517	131	7	safety	safety	NOUN
dpc-3517	131	8	profile	profile	NOUN
dpc-3517	131	9	,	,	PUNCT
dpc-3517	131	10	consistent	consistent	ADJ
dpc-3517	131	11	with	with	ADP
dpc-3517	131	12	its	its	PRON
dpc-3517	131	13	toxicity	toxicity	NOUN
dpc-3517	131	14	spectrum	spectrum	NOUN
dpc-3517	131	15	in	in	ADP
dpc-3517	131	16	previous	previous	ADJ
dpc-3517	131	17	studies	study	NOUN
dpc-3517	131	18	.	.	PUNCT
dpc-3517	132	1	these	these	DET
dpc-3517	132	2	data	datum	NOUN
dpc-3517	132	3	suggested	suggest	VERB
dpc-3517	132	4	that	that	SCONJ
dpc-3517	132	5	pembrolizumab	pembrolizumab	NOUN
dpc-3517	132	6	might	might	AUX
dpc-3517	132	7	be	be	AUX
dpc-3517	132	8	better	well	ADJ
dpc-3517	132	9	than	than	ADP
dpc-3517	132	10	hdi	hdi	PROPN
dpc-3517	132	11	as	as	ADP
dpc-3517	132	12	an	an	DET
dpc-3517	132	13	adjuvant	adjuvant	ADJ
dpc-3517	132	14	therapy	therapy	NOUN
dpc-3517	132	15	for	for	ADP
dpc-3517	132	16	pediatric	pediatric	ADJ
dpc-3517	132	17	patients	patient	NOUN
dpc-3517	132	18	with	with	ADP
dpc-3517	132	19	melanoma	melanoma	NOUN
dpc-3517	132	20	.	.	PUNCT
dpc-3517	133	1	these	these	DET
dpc-3517	133	2	findings	finding	NOUN
dpc-3517	133	3	warrant	warrant	VERB
dpc-3517	133	4	further	far	ADV
dpc-3517	133	5	large	large	ADJ
dpc-3517	133	6	,	,	PUNCT
dpc-3517	133	7	prospective	prospective	ADJ
dpc-3517	133	8	and	and	CCONJ
dpc-3517	133	9	dedicated	dedicated	ADJ
dpc-3517	133	10	trials	trial	NOUN
dpc-3517	133	11	to	to	PART
dpc-3517	133	12	evaluate	evaluate	VERB
dpc-3517	133	13	the	the	DET
dpc-3517	133	14	efficacy	efficacy	NOUN
dpc-3517	133	15	and	and	CCONJ
dpc-3517	133	16	safety	safety	NOUN
dpc-3517	133	17	of	of	ADP
dpc-3517	133	18	adjuvant	adjuvant	ADJ
dpc-3517	133	19	pembrolizumab	pembrolizumab	NOUN
dpc-3517	133	20	therapy	therapy	NOUN
dpc-3517	133	21	for	for	ADP
dpc-3517	133	22	pediatric	pediatric	ADJ
dpc-3517	133	23	melanoma	melanoma	NOUN
dpc-3517	133	24	.	.	PUNCT
dpc-3517	134	1	references	reference	NOUN
dpc-3517	134	2	1	1	NUM
dpc-3517	134	3	.	.	PUNCT
dpc-3517	134	4	wong	wong	PROPN
dpc-3517	134	5	jr	jr	PROPN
dpc-3517	134	6	,	,	PUNCT
dpc-3517	134	7	harris	harris	PROPN
dpc-3517	134	8	jk	jk	PROPN
dpc-3517	134	9	,	,	PUNCT
dpc-3517	134	10	rodriguez	rodriguez	PROPN
dpc-3517	134	11	-	-	PUNCT
dpc-3517	134	12	galindo	galindo	PROPN
dpc-3517	134	13	c	c	PROPN
dpc-3517	134	14	,	,	PUNCT
dpc-3517	134	15	johnson	johnson	PROPN
dpc-3517	134	16	kj	kj	PROPN
dpc-3517	134	17	.	.	PUNCT
dpc-3517	135	1	incidence	incidence	NOUN
dpc-3517	135	2	of	of	ADP
dpc-3517	135	3	childhood	childhood	NOUN
dpc-3517	135	4	and	and	CCONJ
dpc-3517	135	5	adolescent	adolescent	ADJ
dpc-3517	135	6	melanoma	melanoma	NOUN
dpc-3517	135	7	in	in	ADP
dpc-3517	135	8	the	the	DET
dpc-3517	135	9	united	united	PROPN
dpc-3517	135	10	states	states	PROPN
dpc-3517	135	11	:	:	PUNCT
dpc-3517	135	12	1973	1973	NUM
dpc-3517	135	13	-	-	SYM
dpc-3517	135	14	2009	2009	NUM
dpc-3517	135	15	.	.	PUNCT
dpc-3517	136	1	pediatrics	pediatric	NOUN
dpc-3517	136	2	.	.	PUNCT
dpc-3517	137	1	2013;131(5):846	2013;131(5):846	NUM
dpc-3517	137	2	-	-	SYM
dpc-3517	137	3	854	854	NUM
dpc-3517	137	4	.	.	PUNCT
dpc-3517	137	5	doi:10.1542	doi:10.1542	PROPN
dpc-3517	137	6	/peds.2012	/peds.2012	PUNCT
dpc-3517	137	7	-	-	PUNCT
dpc-3517	137	8	2520	2520	NUM
dpc-3517	137	9	.	.	PUNCT
dpc-3517	138	1	pmid	pmid	NOUN
dpc-3517	138	2	:	:	PUNCT
dpc-3517	138	3	23589817	23589817	NUM
dpc-3517	138	4	.	.	PUNCT
dpc-3517	139	1	pmcid	pmcid	NOUN
dpc-3517	139	2	:	:	PUNCT
dpc-3517	139	3	pmc3639457	pmc3639457	NOUN
dpc-3517	139	4	.	.	PUNCT
dpc-3517	140	1	2	2	X
dpc-3517	140	2	.	.	X
dpc-3517	140	3	merkel	merkel	PROPN
dpc-3517	140	4	ea	ea	PROPN
dpc-3517	140	5	,	,	PUNCT
dpc-3517	140	6	mohan	mohan	PROPN
dpc-3517	140	7	ls	ls	PROPN
dpc-3517	140	8	,	,	PUNCT
dpc-3517	140	9	shi	shi	PROPN
dpc-3517	140	10	k	k	PROPN
dpc-3517	140	11	,	,	PUNCT
dpc-3517	140	12	panah	panah	PROPN
dpc-3517	140	13	e	e	PROPN
dpc-3517	140	14	,	,	PUNCT
dpc-3517	140	15	zhang	zhang	PROPN
dpc-3517	140	16	b	b	PROPN
dpc-3517	140	17	,	,	PUNCT
dpc-3517	140	18	gerami	gerami	ADJ
dpc-3517	140	19	p.	p.	NOUN
dpc-3517	140	20	paediatric	paediatric	ADJ
dpc-3517	140	21	melanoma	melanoma	NOUN
dpc-3517	140	22	:	:	PUNCT
dpc-3517	140	23	clinical	clinical	ADJ
dpc-3517	140	24	update	update	NOUN
dpc-3517	140	25	,	,	PUNCT
dpc-3517	140	26	genetic	genetic	ADJ
dpc-3517	140	27	basis	basis	NOUN
dpc-3517	140	28	,	,	PUNCT
dpc-3517	140	29	and	and	CCONJ
dpc-3517	140	30	advances	advance	NOUN
dpc-3517	140	31	in	in	ADP
dpc-3517	140	32	diagnosis	diagnosis	NOUN
dpc-3517	140	33	.	.	PUNCT
dpc-3517	141	1	lancet	lancet	PROPN
dpc-3517	141	2	child	child	PROPN
dpc-3517	141	3	adolesc	adolesc	PROPN
dpc-3517	141	4	.	.	PUNCT
dpc-3517	142	1	2019;3(9):646	2019;3(9):646	X
dpc-3517	142	2	-	-	SYM
dpc-3517	142	3	654	654	NUM
dpc-3517	142	4	.	.	PUNCT
dpc-3517	143	1	doi:10.1016	doi:10.1016	PROPN
dpc-3517	143	2	/	/	SYM
dpc-3517	143	3	s2352	s2352	PROPN
dpc-3517	143	4	-	-	PUNCT
dpc-3517	143	5	4642(19)30116	4642(19)30116	NOUN
dpc-3517	143	6	-	-	PUNCT
dpc-3517	143	7	6	6	NUM
dpc-3517	143	8	.	.	PUNCT
dpc-3517	144	1	pmid	pmid	NOUN
dpc-3517	144	2	:	:	PUNCT
dpc-3517	144	3	31204309	31204309	NUM
dpc-3517	144	4	.	.	PUNCT
dpc-3517	145	1	3	3	X
dpc-3517	145	2	.	.	X
dpc-3517	145	3	averbook	averbook	NOUN
dpc-3517	145	4	bj	bj	PROPN
dpc-3517	145	5	,	,	PUNCT
dpc-3517	145	6	lee	lee	PROPN
dpc-3517	145	7	sj	sj	PROPN
dpc-3517	145	8	,	,	PUNCT
dpc-3517	145	9	delman	delman	PROPN
dpc-3517	145	10	ka	ka	PROPN
dpc-3517	145	11	,	,	PUNCT
dpc-3517	145	12	et	et	PROPN
dpc-3517	145	13	al	al	PROPN
dpc-3517	145	14	.	.	PUNCT
dpc-3517	146	1	pediatric	pediatric	ADJ
dpc-3517	146	2	melanoma	melanoma	NOUN
dpc-3517	146	3	:	:	PUNCT
dpc-3517	146	4	analysis	analysis	NOUN
dpc-3517	146	5	of	of	ADP
dpc-3517	146	6	an	an	DET
dpc-3517	146	7	international	international	ADJ
dpc-3517	146	8	registry	registry	NOUN
dpc-3517	146	9	.	.	PUNCT
dpc-3517	147	1	cancer	cancer	NOUN
dpc-3517	147	2	.	.	PUNCT
dpc-3517	148	1	2013;119(22):40124019	2013;119(22):40124019	X
dpc-3517	148	2	.	.	PUNCT
dpc-3517	149	1	doi:10.1002	doi:10.1002	NOUN
dpc-3517	149	2	/	/	SYM
dpc-3517	149	3	cncr.28289	cncr.28289	PROPN
dpc-3517	149	4	.	.	PUNCT
dpc-3517	149	5	pmid	pmid	NOUN
dpc-3517	149	6	:	:	PUNCT
dpc-3517	149	7	24022819	24022819	NUM
dpc-3517	149	8	.	.	PUNCT
dpc-3517	150	1	pmcid	pmcid	NOUN
dpc-3517	150	2	:	:	PUNCT
dpc-3517	150	3	pmc4096292	pmc4096292	NOUN
dpc-3517	150	4	.	.	PUNCT
dpc-3517	151	1	stage	stage	PROPN
dpc-3517	151	2	ii	ii	PROPN
dpc-3517	151	3	and	and	CCONJ
dpc-3517	151	4	stage	stage	NOUN
dpc-3517	151	5	iii	iii	NUM
dpc-3517	151	6	melanomas	melanomas	NOUN
dpc-3517	151	7	.	.	PUNCT
dpc-3517	152	1	however	however	ADV
dpc-3517	152	2	,	,	PUNCT
dpc-3517	152	3	information	information	NOUN
dpc-3517	152	4	on	on	ADP
dpc-3517	152	5	the	the	DET
dpc-3517	152	6	use	use	NOUN
dpc-3517	152	7	of	of	ADP
dpc-3517	152	8	immunotherapy	immunotherapy	NOUN
dpc-3517	152	9	as	as	ADP
dpc-3517	152	10	adjuvant	adjuvant	ADJ
dpc-3517	152	11	therapy	therapy	NOUN
dpc-3517	152	12	for	for	ADP
dpc-3517	152	13	pediatric	pediatric	ADJ
dpc-3517	152	14	patients	patient	NOUN
dpc-3517	152	15	is	be	AUX
dpc-3517	152	16	limited	limited	ADJ
dpc-3517	152	17	.	.	PUNCT
dpc-3517	153	1	most	most	ADJ
dpc-3517	153	2	studies	study	NOUN
dpc-3517	153	3	have	have	AUX
dpc-3517	153	4	investigated	investigate	VERB
dpc-3517	153	5	immunotherapy	immunotherapy	NOUN
dpc-3517	153	6	in	in	ADP
dpc-3517	153	7	pediatric	pediatric	ADJ
dpc-3517	153	8	patients	patient	NOUN
dpc-3517	153	9	with	with	ADP
dpc-3517	153	10	advanced	advanced	ADJ
dpc-3517	153	11	tumors	tumor	NOUN
dpc-3517	153	12	.	.	PUNCT
dpc-3517	154	1	to	to	ADP
dpc-3517	154	2	date	date	NOUN
dpc-3517	154	3	,	,	PUNCT
dpc-3517	154	4	nivolumab	nivolumab	X
dpc-3517	154	5	(	(	PUNCT
dpc-3517	154	6	nct0230445848	nct0230445848	NOUN
dpc-3517	154	7	[	[	X
dpc-3517	154	8	12	12	NUM
dpc-3517	154	9	]	]	PUNCT
dpc-3517	154	10	)	)	PUNCT
dpc-3517	154	11	,	,	PUNCT
dpc-3517	154	12	pembrolizumab	pembrolizumab	NOUN
dpc-3517	154	13	(	(	PUNCT
dpc-3517	154	14	nct0233266849	nct0233266849	NOUN
dpc-3517	154	15	[	[	X
dpc-3517	154	16	4	4	NUM
dpc-3517	154	17	]	]	NUM
dpc-3517	154	18	)	)	PUNCT
dpc-3517	154	19	,	,	PUNCT
dpc-3517	154	20	atezolizumab	atezolizumab	NOUN
dpc-3517	154	21	(	(	PUNCT
dpc-3517	154	22	nct0254160450	nct0254160450	X
dpc-3517	154	23	[	[	X
dpc-3517	154	24	13	13	NUM
dpc-3517	154	25	]	]	NUM
dpc-3517	154	26	)	)	PUNCT
dpc-3517	154	27	,	,	PUNCT
dpc-3517	154	28	and	and	CCONJ
dpc-3517	154	29	avelumab	avelumab	PRON
dpc-3517	154	30	(	(	PUNCT
dpc-3517	154	31	nct0345182551	nct0345182551	X
dpc-3517	155	1	[	[	X
dpc-3517	155	2	14	14	NUM
dpc-3517	155	3	]	]	PUNCT
dpc-3517	155	4	)	)	PUNCT
dpc-3517	155	5	have	have	AUX
dpc-3517	155	6	been	be	AUX
dpc-3517	155	7	investigated	investigate	VERB
dpc-3517	155	8	as	as	ADP
dpc-3517	155	9	monotherapies	monotherapie	NOUN
dpc-3517	155	10	for	for	ADP
dpc-3517	155	11	recurrent	recurrent	ADJ
dpc-3517	155	12	and	and	CCONJ
dpc-3517	155	13	refractory	refractory	NOUN
dpc-3517	155	14	pediatric	pediatric	ADJ
dpc-3517	155	15	tumors	tumor	NOUN
dpc-3517	155	16	,	,	PUNCT
dpc-3517	155	17	but	but	CCONJ
dpc-3517	155	18	only	only	ADV
dpc-3517	155	19	3	3	NUM
dpc-3517	155	20	%	%	NOUN
dpc-3517	155	21	of	of	ADP
dpc-3517	155	22	patients	patient	NOUN
dpc-3517	155	23	with	with	ADP
dpc-3517	155	24	solid	solid	ADJ
dpc-3517	155	25	tumors	tumor	NOUN
dpc-3517	155	26	experienced	experience	VERB
dpc-3517	155	27	an	an	DET
dpc-3517	155	28	objective	objective	ADJ
dpc-3517	155	29	response	response	NOUN
dpc-3517	155	30	across	across	ADP
dpc-3517	155	31	all	all	DET
dpc-3517	155	32	four	four	NUM
dpc-3517	155	33	trials	trial	NOUN
dpc-3517	155	34	.	.	PUNCT
dpc-3517	156	1	compared	compare	VERB
dpc-3517	156	2	with	with	ADP
dpc-3517	156	3	adult	adult	NOUN
dpc-3517	156	4	cancers	cancer	NOUN
dpc-3517	156	5	,	,	PUNCT
dpc-3517	156	6	most	most	ADJ
dpc-3517	156	7	pediatric	pediatric	ADJ
dpc-3517	156	8	cancers	cancer	NOUN
dpc-3517	156	9	have	have	VERB
dpc-3517	156	10	lower	low	ADJ
dpc-3517	156	11	mutational	mutational	ADJ
dpc-3517	156	12	burdens	burden	NOUN
dpc-3517	156	13	and	and	CCONJ
dpc-3517	156	14	fewer	few	ADJ
dpc-3517	156	15	infiltrating	infiltrating	ADJ
dpc-3517	156	16	t	t	NOUN
dpc-3517	156	17	cells	cell	NOUN
dpc-3517	156	18	,	,	PUNCT
dpc-3517	156	19	which	which	PRON
dpc-3517	156	20	may	may	AUX
dpc-3517	156	21	account	account	VERB
dpc-3517	156	22	for	for	ADP
dpc-3517	156	23	this	this	DET
dpc-3517	156	24	lack	lack	NOUN
dpc-3517	156	25	of	of	ADP
dpc-3517	156	26	efficacy	efficacy	NOUN
dpc-3517	156	27	[	[	X
dpc-3517	156	28	15	15	NUM
dpc-3517	156	29	]	]	PUNCT
dpc-3517	156	30	.	.	PUNCT
dpc-3517	157	1	the	the	DET
dpc-3517	157	2	keynote-051	keynote-051	ADJ
dpc-3517	157	3	study	study	NOUN
dpc-3517	157	4	found	find	VERB
dpc-3517	157	5	no	no	DET
dpc-3517	157	6	objective	objective	ADJ
dpc-3517	157	7	responses	response	NOUN
dpc-3517	157	8	in	in	ADP
dpc-3517	157	9	the	the	DET
dpc-3517	157	10	eight	eight	NUM
dpc-3517	157	11	enrolled	enrol	VERB
dpc-3517	157	12	pediatric	pediatric	ADJ
dpc-3517	157	13	patients	patient	NOUN
dpc-3517	157	14	with	with	ADP
dpc-3517	157	15	cutaneous	cutaneous	ADJ
dpc-3517	157	16	melanoma	melanoma	NOUN
dpc-3517	157	17	who	who	PRON
dpc-3517	157	18	received	receive	VERB
dpc-3517	157	19	pembrolizumab	pembrolizumab	NOUN
dpc-3517	157	20	treatment	treatment	NOUN
dpc-3517	157	21	[	[	X
dpc-3517	157	22	4	4	NUM
dpc-3517	157	23	]	]	PUNCT
dpc-3517	157	24	.	.	PUNCT
dpc-3517	158	1	the	the	DET
dpc-3517	158	2	combination	combination	NOUN
dpc-3517	158	3	of	of	ADP
dpc-3517	158	4	pd-1	pd-1	ADJ
dpc-3517	158	5	and	and	CCONJ
dpc-3517	158	6	cytotoxic	cytotoxic	ADJ
dpc-3517	158	7	t	t	PROPN
dpc-3517	158	8	lymphocyte	lymphocyte	NOUN
dpc-3517	158	9	-	-	PUNCT
dpc-3517	158	10	associated	associate	VERB
dpc-3517	158	11	antigen-4	antigen-4	NUM
dpc-3517	158	12	blockade	blockade	NOUN
dpc-3517	158	13	have	have	AUX
dpc-3517	158	14	added	add	VERB
dpc-3517	158	15	benefit	benefit	NOUN
dpc-3517	158	16	compared	compare	VERB
dpc-3517	158	17	with	with	ADP
dpc-3517	158	18	monotherapy	monotherapy	NOUN
dpc-3517	158	19	in	in	ADP
dpc-3517	158	20	adult	adult	NOUN
dpc-3517	158	21	patients	patient	NOUN
dpc-3517	158	22	;	;	PUNCT
dpc-3517	158	23	however	however	ADV
dpc-3517	158	24	,	,	PUNCT
dpc-3517	158	25	the	the	DET
dpc-3517	158	26	combination	combination	NOUN
dpc-3517	158	27	of	of	ADP
dpc-3517	158	28	ipilimumab	ipilimumab	NOUN
dpc-3517	158	29	/	/	SYM
dpc-3517	158	30	nivolumab	nivolumab	NOUN
dpc-3517	158	31	does	do	AUX
dpc-3517	158	32	not	not	PART
dpc-3517	158	33	seem	seem	VERB
dpc-3517	158	34	to	to	PART
dpc-3517	158	35	exert	exert	VERB
dpc-3517	158	36	synergistic	synergistic	ADJ
dpc-3517	158	37	effects	effect	NOUN
dpc-3517	158	38	in	in	ADP
dpc-3517	158	39	pediatric	pediatric	ADJ
dpc-3517	158	40	patients	patient	NOUN
dpc-3517	158	41	.	.	PUNCT
dpc-3517	159	1	in	in	ADP
dpc-3517	159	2	advl1412	advl1412	PROPN
dpc-3517	159	3	,	,	PUNCT
dpc-3517	159	4	only	only	ADV
dpc-3517	159	5	two	two	NUM
dpc-3517	159	6	pediatric	pediatric	ADJ
dpc-3517	159	7	patients	patient	NOUN
dpc-3517	159	8	achieved	achieve	VERB
dpc-3517	159	9	partial	partial	ADJ
dpc-3517	159	10	responses	response	NOUN
dpc-3517	159	11	among	among	ADP
dpc-3517	159	12	55	55	NUM
dpc-3517	159	13	evaluable	evaluable	ADJ
dpc-3517	159	14	patients	patient	NOUN
dpc-3517	159	15	receiving	receive	VERB
dpc-3517	159	16	combination	combination	NOUN
dpc-3517	159	17	ipilimumab	ipilimumab	NOUN
dpc-3517	159	18	/	/	SYM
dpc-3517	159	19	nivolumab	nivolumab	NOUN
dpc-3517	160	1	[	[	X
dpc-3517	160	2	16	16	NUM
dpc-3517	160	3	]	]	PUNCT
dpc-3517	160	4	.	.	PUNCT
dpc-3517	161	1	overall	overall	ADJ
dpc-3517	161	2	,	,	PUNCT
dpc-3517	161	3	in	in	ADP
dpc-3517	161	4	contrast	contrast	NOUN
dpc-3517	161	5	to	to	ADP
dpc-3517	161	6	the	the	DET
dpc-3517	161	7	impressive	impressive	ADJ
dpc-3517	161	8	responses	response	NOUN
dpc-3517	161	9	seen	see	VERB
dpc-3517	161	10	with	with	ADP
dpc-3517	161	11	adult	adult	NOUN
dpc-3517	161	12	cancers	cancer	NOUN
dpc-3517	161	13	,	,	PUNCT
dpc-3517	161	14	most	most	ADJ
dpc-3517	161	15	pediatric	pediatric	ADJ
dpc-3517	161	16	cancers	cancer	NOUN
dpc-3517	161	17	seem	seem	VERB
dpc-3517	161	18	to	to	PART
dpc-3517	161	19	have	have	VERB
dpc-3517	161	20	a	a	DET
dpc-3517	161	21	poor	poor	ADJ
dpc-3517	161	22	response	response	NOUN
dpc-3517	161	23	to	to	ADP
dpc-3517	161	24	immunotherapies	immunotherapy	NOUN
dpc-3517	161	25	.	.	PUNCT
dpc-3517	162	1	whether	whether	SCONJ
dpc-3517	162	2	the	the	DET
dpc-3517	162	3	efficacy	efficacy	NOUN
dpc-3517	162	4	and	and	CCONJ
dpc-3517	162	5	safety	safety	NOUN
dpc-3517	162	6	profile	profile	NOUN
dpc-3517	162	7	of	of	ADP
dpc-3517	162	8	adjuvant	adjuvant	ADJ
dpc-3517	162	9	pembrolizumab	pembrolizumab	NOUN
dpc-3517	162	10	treatment	treatment	NOUN
dpc-3517	162	11	are	be	AUX
dpc-3517	162	12	the	the	DET
dpc-3517	162	13	same	same	ADJ
dpc-3517	162	14	in	in	ADP
dpc-3517	162	15	pediatric	pediatric	ADJ
dpc-3517	162	16	patients	patient	NOUN
dpc-3517	162	17	as	as	SCONJ
dpc-3517	162	18	in	in	ADP
dpc-3517	162	19	adult	adult	NOUN
dpc-3517	162	20	patients	patient	NOUN
dpc-3517	162	21	remains	remain	VERB
dpc-3517	162	22	unclear	unclear	ADJ
dpc-3517	162	23	.	.	PUNCT
dpc-3517	163	1	a	a	DET
dpc-3517	163	2	case	case	NOUN
dpc-3517	163	3	report	report	NOUN
dpc-3517	163	4	described	describe	VERB
dpc-3517	163	5	a	a	DET
dpc-3517	163	6	7	7	NUM
dpc-3517	163	7	-	-	PUNCT
dpc-3517	163	8	year	year	NOUN
dpc-3517	163	9	-	-	PUNCT
dpc-3517	163	10	old	old	ADJ
dpc-3517	163	11	patient	patient	NOUN
dpc-3517	163	12	with	with	ADP
dpc-3517	163	13	recurrent	recurrent	ADJ
dpc-3517	163	14	metastatic	metastatic	ADJ
dpc-3517	163	15	melanoma	melanoma	NOUN
dpc-3517	163	16	who	who	PRON
dpc-3517	163	17	underwent	undergo	VERB
dpc-3517	163	18	complete	complete	ADJ
dpc-3517	163	19	resection	resection	NOUN
dpc-3517	163	20	of	of	ADP
dpc-3517	163	21	metastases	metastasis	NOUN
dpc-3517	163	22	and	and	CCONJ
dpc-3517	163	23	received	receive	VERB
dpc-3517	163	24	adjuvant	adjuvant	ADJ
dpc-3517	163	25	pembrolizumab	pembrolizumab	NOUN
dpc-3517	163	26	.	.	PUNCT
dpc-3517	164	1	although	although	SCONJ
dpc-3517	164	2	pembrolizumab	pembrolizumab	NOUN
dpc-3517	164	3	treatment	treatment	NOUN
dpc-3517	164	4	only	only	ADV
dpc-3517	164	5	lasted	last	VERB
dpc-3517	164	6	for	for	ADP
dpc-3517	164	7	5	5	NUM
dpc-3517	164	8	months	month	NOUN
dpc-3517	164	9	because	because	SCONJ
dpc-3517	164	10	of	of	ADP
dpc-3517	164	11	adverse	adverse	ADJ
dpc-3517	164	12	events	event	NOUN
dpc-3517	164	13	(	(	PUNCT
dpc-3517	164	14	arthritis	arthritis	NOUN
dpc-3517	164	15	and	and	CCONJ
dpc-3517	164	16	uveitis	uveitis	NOUN
dpc-3517	164	17	)	)	PUNCT
dpc-3517	164	18	,	,	PUNCT
dpc-3517	164	19	the	the	DET
dpc-3517	164	20	patient	patient	NOUN
dpc-3517	164	21	had	have	VERB
dpc-3517	164	22	no	no	DET
dpc-3517	164	23	relapse	relapse	NOUN
dpc-3517	164	24	within	within	ADP
dpc-3517	164	25	1	1	NUM
dpc-3517	164	26	year	year	NOUN
dpc-3517	164	27	of	of	ADP
dpc-3517	164	28	follow	follow	NOUN
dpc-3517	164	29	-	-	PUNCT
dpc-3517	164	30	up	up	NOUN
dpc-3517	164	31	[	[	X
dpc-3517	164	32	17	17	NUM
dpc-3517	164	33	]	]	PUNCT
dpc-3517	164	34	.	.	PUNCT
dpc-3517	165	1	only	only	ADV
dpc-3517	165	2	one	one	NUM
dpc-3517	165	3	patient	patient	NOUN
dpc-3517	165	4	in	in	ADP
dpc-3517	165	5	the	the	DET
dpc-3517	165	6	pembrolizumab	pembrolizumab	NOUN
dpc-3517	165	7	group	group	NOUN
dpc-3517	165	8	in	in	ADP
dpc-3517	165	9	the	the	DET
dpc-3517	165	10	current	current	ADJ
dpc-3517	165	11	study	study	NOUN
dpc-3517	165	12	had	have	VERB
dpc-3517	165	13	a	a	DET
dpc-3517	165	14	recurrence	recurrence	NOUN
dpc-3517	165	15	and	and	CCONJ
dpc-3517	165	16	the	the	DET
dpc-3517	165	17	1	1	NUM
dpc-3517	165	18	-	-	PUNCT
dpc-3517	165	19	year	year	NOUN
dpc-3517	165	20	rfs	rfs	NOUN
dpc-3517	165	21	rate	rate	NOUN
dpc-3517	165	22	was	be	AUX
dpc-3517	165	23	88.9	88.9	NUM
dpc-3517	165	24	%	%	NOUN
dpc-3517	165	25	.	.	PUNCT
dpc-3517	166	1	in	in	ADP
dpc-3517	166	2	addition	addition	NOUN
dpc-3517	166	3	,	,	PUNCT
dpc-3517	166	4	the	the	DET
dpc-3517	166	5	median	median	ADJ
dpc-3517	166	6	rfs	rfs	NOUN
dpc-3517	166	7	was	be	AUX
dpc-3517	166	8	not	not	PART
dpc-3517	166	9	reached	reach	VERB
dpc-3517	166	10	in	in	ADP
dpc-3517	166	11	pembrolizumab	pembrolizumab	NOUN
dpc-3517	166	12	group	group	NOUN
dpc-3517	166	13	.	.	PUNCT
dpc-3517	167	1	thus	thus	ADV
dpc-3517	167	2	,	,	PUNCT
dpc-3517	167	3	although	although	SCONJ
dpc-3517	167	4	there	there	PRON
dpc-3517	167	5	was	be	VERB
dpc-3517	167	6	no	no	DET
dpc-3517	167	7	significant	significant	ADJ
dpc-3517	167	8	difference	difference	NOUN
dpc-3517	167	9	between	between	ADP
dpc-3517	167	10	the	the	DET
dpc-3517	167	11	pembrolizumab	pembrolizumab	NOUN
dpc-3517	167	12	and	and	CCONJ
dpc-3517	167	13	hdi	hdi	PROPN
dpc-3517	167	14	groups	group	NOUN
dpc-3517	167	15	,	,	PUNCT
dpc-3517	167	16	pembrolizumab	pembrolizumab	NOUN
dpc-3517	167	17	seemed	seem	VERB
dpc-3517	167	18	to	to	PART
dpc-3517	167	19	be	be	AUX
dpc-3517	167	20	associated	associate	VERB
dpc-3517	167	21	with	with	ADP
dpc-3517	167	22	a	a	DET
dpc-3517	167	23	lower	low	ADJ
dpc-3517	167	24	risk	risk	NOUN
dpc-3517	167	25	of	of	ADP
dpc-3517	167	26	recurrence	recurrence	NOUN
dpc-3517	167	27	.	.	PUNCT
dpc-3517	168	1	the	the	DET
dpc-3517	168	2	safety	safety	NOUN
dpc-3517	168	3	of	of	ADP
dpc-3517	168	4	adjuvant	adjuvant	ADJ
dpc-3517	168	5	immunotherapies	immunotherapy	NOUN
dpc-3517	168	6	in	in	ADP
dpc-3517	168	7	pediatric	pediatric	ADJ
dpc-3517	168	8	patients	patient	NOUN
dpc-3517	168	9	with	with	ADP
dpc-3517	168	10	cancer	cancer	NOUN
dpc-3517	168	11	is	be	AUX
dpc-3517	168	12	unclear	unclear	ADJ
dpc-3517	168	13	.	.	PUNCT
dpc-3517	169	1	although	although	SCONJ
dpc-3517	169	2	immune	immune	ADJ
dpc-3517	169	3	checkpoint	checkpoint	NOUN
dpc-3517	169	4	inhibitors	inhibitor	NOUN
dpc-3517	169	5	have	have	VERB
dpc-3517	169	6	similar	similar	ADJ
dpc-3517	169	7	adverse	adverse	ADJ
dpc-3517	169	8	effects	effect	NOUN
dpc-3517	169	9	in	in	ADP
dpc-3517	169	10	children	child	NOUN
dpc-3517	169	11	and	and	CCONJ
dpc-3517	169	12	adults	adult	NOUN
dpc-3517	169	13	,	,	PUNCT
dpc-3517	169	14	the	the	DET
dpc-3517	169	15	most	most	ADV
dpc-3517	169	16	common	common	ADJ
dpc-3517	169	17	adverse	adverse	ADJ
dpc-3517	169	18	events	event	NOUN
dpc-3517	169	19	in	in	ADP
dpc-3517	169	20	pediatric	pediatric	ADJ
dpc-3517	169	21	patients	patient	NOUN
dpc-3517	169	22	,	,	PUNCT
dpc-3517	169	23	unlike	unlike	ADP
dpc-3517	169	24	adult	adult	NOUN
dpc-3517	169	25	patients	patient	NOUN
dpc-3517	169	26	,	,	PUNCT
dpc-3517	169	27	were	be	AUX
dpc-3517	169	28	fatigue	fatigue	NOUN
dpc-3517	169	29	and	and	CCONJ
dpc-3517	169	30	fever	fever	NOUN
dpc-3517	169	31	.	.	PUNCT
dpc-3517	170	1	elevated	elevated	ADJ
dpc-3517	170	2	transaminase	transaminase	NOUN
dpc-3517	170	3	was	be	AUX
dpc-3517	170	4	the	the	DET
dpc-3517	170	5	most	most	ADV
dpc-3517	170	6	common	common	ADJ
dpc-3517	170	7	immune	immune	NOUN
dpc-3517	170	8	-	-	PUNCT
dpc-3517	170	9	related	relate	VERB
dpc-3517	170	10	adverse	adverse	ADJ
dpc-3517	170	11	event	event	NOUN
dpc-3517	170	12	,	,	PUNCT
dpc-3517	170	13	while	while	SCONJ
dpc-3517	170	14	immune	immune	NOUN
dpc-3517	170	15	-	-	PUNCT
dpc-3517	170	16	related	relate	VERB
dpc-3517	170	17	adverse	adverse	ADJ
dpc-3517	170	18	events	event	NOUN
dpc-3517	170	19	such	such	ADJ
dpc-3517	170	20	as	as	ADP
dpc-3517	170	21	elevated	elevated	ADJ
dpc-3517	170	22	lipase	lipase	NOUN
dpc-3517	170	23	,	,	PUNCT
dpc-3517	170	24	thyroiditis	thyroiditis	NOUN
dpc-3517	170	25	,	,	PUNCT
dpc-3517	170	26	pleural	pleural	ADJ
dpc-3517	170	27	and	and	CCONJ
dpc-3517	170	28	pericardial	pericardial	ADJ
dpc-3517	170	29	effusions	effusion	NOUN
dpc-3517	170	30	,	,	PUNCT
dpc-3517	170	31	and	and	CCONJ
dpc-3517	170	32	colitis	colitis	NOUN
dpc-3517	170	33	were	be	AUX
dpc-3517	170	34	less	less	ADV
dpc-3517	170	35	common	common	ADJ
dpc-3517	170	36	in	in	ADP
dpc-3517	170	37	pediatric	pediatric	NOUN
dpc-3517	170	38	than	than	ADP
dpc-3517	170	39	in	in	ADP
dpc-3517	170	40	adult	adult	NOUN
dpc-3517	170	41	patients	patient	NOUN
dpc-3517	170	42	.	.	PUNCT
dpc-3517	171	1	in	in	ADP
dpc-3517	171	2	keynote-051	keynote-051	ADJ
dpc-3517	171	3	,	,	PUNCT
dpc-3517	171	4	pembrolizumab	pembrolizumab	NOUN
dpc-3517	171	5	was	be	AUX
dpc-3517	171	6	well	well	ADV
dpc-3517	171	7	tolerated	tolerate	VERB
dpc-3517	171	8	in	in	ADP
dpc-3517	171	9	pediatric	pediatric	ADJ
dpc-3517	171	10	patients	patient	NOUN
dpc-3517	171	11	,	,	PUNCT
dpc-3517	171	12	with	with	ADP
dpc-3517	171	13	adverse	adverse	ADJ
dpc-3517	171	14	events	event	NOUN
dpc-3517	171	15	of	of	ADP
dpc-3517	171	16	any	any	DET
dpc-3517	171	17	grade	grade	NOUN
dpc-3517	171	18	,	,	PUNCT
dpc-3517	171	19	mostly	mostly	ADV
dpc-3517	171	20	grade	grade	NOUN
dpc-3517	171	21	1	1	NUM
dpc-3517	171	22	and	and	CCONJ
dpc-3517	171	23	2	2	NUM
dpc-3517	171	24	,	,	PUNCT
dpc-3517	171	25	occurring	occur	VERB
dpc-3517	171	26	in	in	ADP
dpc-3517	171	27	149	149	NUM
dpc-3517	171	28	(	(	PUNCT
dpc-3517	171	29	97	97	NUM
dpc-3517	171	30	%	%	NOUN
dpc-3517	171	31	)	)	PUNCT
dpc-3517	171	32	patients	patient	NOUN
dpc-3517	171	33	.	.	PUNCT
dpc-3517	172	1	the	the	DET
dpc-3517	172	2	8	8	NUM
dpc-3517	172	3	original	original	ADJ
dpc-3517	172	4	article	article	NOUN
dpc-3517	172	5	|	|	ADV
dpc-3517	172	6	dermatol	dermatol	ADJ
dpc-3517	172	7	pract	pract	NOUN
dpc-3517	172	8	concept	concept	NOUN
dpc-3517	172	9	.	.	PUNCT
dpc-3517	173	1	2024;14(1):e2024026	2024;14(1):e2024026	NUM
dpc-3517	173	2	trial	trial	NOUN
dpc-3517	173	3	.	.	PUNCT
dpc-3517	174	1	lancet	lancet	NOUN
dpc-3517	174	2	.	.	PUNCT
dpc-3517	175	1	2022;399(10336):1718	2022;399(10336):1718	NUM
dpc-3517	175	2	-	-	SYM
dpc-3517	175	3	1729	1729	NUM
dpc-3517	175	4	.	.	PUNCT
dpc-3517	176	1	doi:10.1016	doi:10.1016	PROPN
dpc-3517	176	2	/	/	SYM
dpc-3517	177	1	s0140	s0140	ADJ
dpc-3517	177	2	-6736(22)00562	-6736(22)00562	NUM
dpc-3517	177	3	-	-	PUNCT
dpc-3517	177	4	1	1	NUM
dpc-3517	177	5	.	.	PUNCT
dpc-3517	178	1	pmid	pmid	NOUN
dpc-3517	178	2	:	:	PUNCT
dpc-3517	178	3	35367007	35367007	NUM
dpc-3517	178	4	.	.	PUNCT
dpc-3517	179	1	12	12	NUM
dpc-3517	179	2	.	.	PUNCT
dpc-3517	180	1	davis	davis	PROPN
dpc-3517	180	2	kl	kl	PROPN
dpc-3517	180	3	,	,	PUNCT
dpc-3517	180	4	fox	fox	PROPN
dpc-3517	180	5	e	e	PROPN
dpc-3517	180	6	,	,	PUNCT
dpc-3517	180	7	merchant	merchant	NOUN
dpc-3517	180	8	ms	ms	PROPN
dpc-3517	180	9	,	,	PUNCT
dpc-3517	180	10	et	et	PROPN
dpc-3517	180	11	al	al	PROPN
dpc-3517	180	12	.	.	PROPN
dpc-3517	180	13	nivolumab	nivolumab	PROPN
dpc-3517	180	14	in	in	ADP
dpc-3517	180	15	children	child	NOUN
dpc-3517	180	16	and	and	CCONJ
dpc-3517	180	17	young	young	ADJ
dpc-3517	180	18	adults	adult	NOUN
dpc-3517	180	19	with	with	ADP
dpc-3517	180	20	relapsed	relapse	VERB
dpc-3517	180	21	or	or	CCONJ
dpc-3517	180	22	refractory	refractory	NOUN
dpc-3517	180	23	solid	solid	ADJ
dpc-3517	180	24	tumours	tumour	NOUN
dpc-3517	180	25	or	or	CCONJ
dpc-3517	180	26	lymphoma	lymphoma	NOUN
dpc-3517	180	27	(	(	PUNCT
dpc-3517	180	28	advl1412	advl1412	PROPN
dpc-3517	180	29	):	):	PUNCT
dpc-3517	180	30	a	a	DET
dpc-3517	180	31	multicentre	multicentre	NOUN
dpc-3517	180	32	,	,	PUNCT
dpc-3517	180	33	open	open	ADJ
dpc-3517	180	34	-	-	PUNCT
dpc-3517	180	35	label	label	NOUN
dpc-3517	180	36	,	,	PUNCT
dpc-3517	180	37	single	single	ADJ
dpc-3517	180	38	-	-	PUNCT
dpc-3517	180	39	arm	arm	NOUN
dpc-3517	180	40	,	,	PUNCT
dpc-3517	180	41	phase	phase	NOUN
dpc-3517	180	42	1	1	NUM
dpc-3517	180	43	-	-	SYM
dpc-3517	180	44	2	2	NUM
dpc-3517	180	45	trial	trial	NOUN
dpc-3517	180	46	.	.	PUNCT
dpc-3517	181	1	lancet	lancet	PROPN
dpc-3517	181	2	oncol	oncol	PROPN
dpc-3517	181	3	.	.	PUNCT
dpc-3517	182	1	2020;21(4):541	2020;21(4):541	NUM
dpc-3517	182	2	-	-	PUNCT
dpc-3517	182	3	550	550	NUM
dpc-3517	182	4	.	.	PUNCT
dpc-3517	183	1	doi	doi	NOUN
dpc-3517	183	2	:	:	PUNCT
dpc-3517	183	3	10.1016	10.1016	NUM
dpc-3517	183	4	/	/	SYM
dpc-3517	183	5	s1470	s1470	PROPN
dpc-3517	183	6	-	-	PUNCT
dpc-3517	183	7	2045(20)30023	2045(20)30023	NUM
dpc-3517	183	8	-	-	SYM
dpc-3517	183	9	1	1	NUM
dpc-3517	183	10	.	.	PUNCT
dpc-3517	184	1	pmid	pmid	NOUN
dpc-3517	184	2	:	:	PUNCT
dpc-3517	184	3	32192573	32192573	NUM
dpc-3517	184	4	.	.	PUNCT
dpc-3517	185	1	pmcid	pmcid	NOUN
dpc-3517	185	2	:	:	PUNCT
dpc-3517	185	3	pmc7255545	pmc7255545	ADJ
dpc-3517	185	4	.	.	PUNCT
dpc-3517	186	1	13	13	NUM
dpc-3517	186	2	.	.	X
dpc-3517	186	3	geoerger	geoerger	PROPN
dpc-3517	186	4	b	b	PROPN
dpc-3517	186	5	,	,	PUNCT
dpc-3517	186	6	zwaan	zwaan	PROPN
dpc-3517	186	7	cm	cm	PROPN
dpc-3517	186	8	,	,	PUNCT
dpc-3517	186	9	marshall	marshall	PROPN
dpc-3517	186	10	lv	lv	PROPN
dpc-3517	186	11	,	,	PUNCT
dpc-3517	186	12	et	et	PROPN
dpc-3517	186	13	al	al	PROPN
dpc-3517	186	14	.	.	PROPN
dpc-3517	186	15	atezolizumab	atezolizumab	PROPN
dpc-3517	186	16	for	for	ADP
dpc-3517	186	17	children	child	NOUN
dpc-3517	186	18	and	and	CCONJ
dpc-3517	186	19	young	young	ADJ
dpc-3517	186	20	adults	adult	NOUN
dpc-3517	186	21	with	with	ADP
dpc-3517	186	22	previously	previously	ADV
dpc-3517	186	23	treated	treat	VERB
dpc-3517	186	24	solid	solid	ADJ
dpc-3517	186	25	tumours	tumour	NOUN
dpc-3517	186	26	,	,	PUNCT
dpc-3517	186	27	non	non	ADJ
dpc-3517	186	28	-	-	ADJ
dpc-3517	186	29	hodgkin	hodgkin	ADJ
dpc-3517	186	30	lymphoma	lymphoma	NOUN
dpc-3517	186	31	,	,	PUNCT
dpc-3517	186	32	and	and	CCONJ
dpc-3517	186	33	hodgkin	hodgkin	PROPN
dpc-3517	186	34	lymphoma	lymphoma	NOUN
dpc-3517	186	35	(	(	PUNCT
dpc-3517	186	36	imatrix	imatrix	PROPN
dpc-3517	186	37	):	):	PUNCT
dpc-3517	186	38	a	a	DET
dpc-3517	186	39	multicentre	multicentre	NOUN
dpc-3517	186	40	phase	phase	NOUN
dpc-3517	186	41	1	1	NUM
dpc-3517	186	42	-	-	SYM
dpc-3517	186	43	2	2	NUM
dpc-3517	186	44	study	study	NOUN
dpc-3517	186	45	.	.	PUNCT
dpc-3517	187	1	lancet	lancet	PROPN
dpc-3517	187	2	oncol	oncol	PROPN
dpc-3517	187	3	.	.	PUNCT
dpc-3517	188	1	2020;21(1):134	2020;21(1):134	NUM
dpc-3517	188	2	-	-	SYM
dpc-3517	188	3	144	144	NUM
dpc-3517	188	4	.	.	PUNCT
dpc-3517	188	5	doi:10.1016	doi:10.1016	PROPN
dpc-3517	188	6	/	/	SYM
dpc-3517	188	7	s1470	s1470	PROPN
dpc-3517	188	8	-	-	PUNCT
dpc-3517	188	9	2045(19)30693	2045(19)30693	NUM
dpc-3517	188	10	-	-	PUNCT
dpc-3517	188	11	x.	x.	NOUN
dpc-3517	188	12	pmid	pmid	PROPN
dpc-3517	188	13	:	:	PUNCT
dpc-3517	188	14	31780255	31780255	NUM
dpc-3517	188	15	.	.	PUNCT
dpc-3517	189	1	14	14	NUM
dpc-3517	189	2	.	.	PUNCT
dpc-3517	190	1	loeb	loeb	PROPN
dpc-3517	190	2	dm	dm	PROPN
dpc-3517	190	3	,	,	PUNCT
dpc-3517	190	4	lee	lee	PROPN
dpc-3517	190	5	jw	jw	PROPN
dpc-3517	190	6	,	,	PUNCT
dpc-3517	190	7	morgenstern	morgenstern	PROPN
dpc-3517	190	8	da	da	PROPN
dpc-3517	190	9	,	,	PUNCT
dpc-3517	190	10	et	et	PROPN
dpc-3517	190	11	al	al	PROPN
dpc-3517	190	12	.	.	PROPN
dpc-3517	190	13	avelumab	avelumab	PROPN
dpc-3517	190	14	in	in	ADP
dpc-3517	190	15	paediatric	paediatric	ADJ
dpc-3517	190	16	patients	patient	NOUN
dpc-3517	190	17	with	with	ADP
dpc-3517	190	18	refractory	refractory	NOUN
dpc-3517	190	19	or	or	CCONJ
dpc-3517	190	20	relapsed	relapse	VERB
dpc-3517	190	21	solid	solid	ADJ
dpc-3517	190	22	tumours	tumour	NOUN
dpc-3517	190	23	:	:	PUNCT
dpc-3517	190	24	dose	dose	NOUN
dpc-3517	190	25	-	-	PUNCT
dpc-3517	190	26	escalation	escalation	NOUN
dpc-3517	190	27	results	result	NOUN
dpc-3517	190	28	from	from	ADP
dpc-3517	190	29	an	an	DET
dpc-3517	190	30	open	open	ADJ
dpc-3517	190	31	-	-	PUNCT
dpc-3517	190	32	label	label	NOUN
dpc-3517	190	33	,	,	PUNCT
dpc-3517	190	34	single	single	ADJ
dpc-3517	190	35	-	-	PUNCT
dpc-3517	190	36	arm	arm	NOUN
dpc-3517	190	37	,	,	PUNCT
dpc-3517	190	38	phase	phase	NOUN
dpc-3517	190	39	1/2	1/2	NUM
dpc-3517	190	40	trial	trial	NOUN
dpc-3517	190	41	.	.	PUNCT
dpc-3517	191	1	cancer	cancer	NOUN
dpc-3517	191	2	immunol	immunol	PROPN
dpc-3517	191	3	immun	immun	PROPN
dpc-3517	191	4	.	.	PUNCT
dpc-3517	192	1	2022;71(10):2485	2022;71(10):2485	NUM
dpc-3517	192	2	-	-	SYM
dpc-3517	192	3	2495	2495	NUM
dpc-3517	192	4	.	.	PUNCT
dpc-3517	193	1	doi:10.1007	doi:10.1007	VERB
dpc-3517	193	2	/	/	SYM
dpc-3517	194	1	s00262	s00262	NOUN
dpc-3517	194	2	-022	-022	PROPN
dpc-3517	194	3	-	-	PUNCT
dpc-3517	194	4	03159	03159	NUM
dpc-3517	194	5	-	-	PUNCT
dpc-3517	194	6	8	8	NUM
dpc-3517	194	7	.	.	PUNCT
dpc-3517	195	1	pmid	pmid	NOUN
dpc-3517	195	2	:	:	PUNCT
dpc-3517	195	3	35262780	35262780	NUM
dpc-3517	195	4	.	.	PUNCT
dpc-3517	196	1	pmcid	pmcid	NOUN
dpc-3517	196	2	:	:	PUNCT
dpc-3517	196	3	pmc9463244	pmc9463244	NOUN
dpc-3517	196	4	.	.	PUNCT
dpc-3517	197	1	15	15	NUM
dpc-3517	197	2	.	.	X
dpc-3517	197	3	long	long	ADV
dpc-3517	197	4	ah	ah	INTJ
dpc-3517	197	5	,	,	PUNCT
dpc-3517	197	6	morgenstern	morgenstern	PROPN
dpc-3517	197	7	da	da	PROPN
dpc-3517	197	8	,	,	PUNCT
dpc-3517	197	9	leruste	leruste	VERB
dpc-3517	197	10	a	a	PRON
dpc-3517	197	11	,	,	PUNCT
dpc-3517	197	12	bourdeaut	bourdeaut	PROPN
dpc-3517	197	13	f	f	PROPN
dpc-3517	197	14	,	,	PUNCT
dpc-3517	197	15	davis	davis	PROPN
dpc-3517	197	16	kl	kl	PROPN
dpc-3517	197	17	.	.	PROPN
dpc-3517	197	18	checkpoint	checkpoint	NOUN
dpc-3517	197	19	immunotherapy	immunotherapy	NOUN
dpc-3517	197	20	in	in	ADP
dpc-3517	197	21	pediatrics	pediatric	NOUN
dpc-3517	197	22	:	:	PUNCT
dpc-3517	197	23	here	here	ADV
dpc-3517	197	24	,	,	PUNCT
dpc-3517	197	25	gone	go	VERB
dpc-3517	197	26	,	,	PUNCT
dpc-3517	197	27	and	and	CCONJ
dpc-3517	197	28	back	back	ADV
dpc-3517	197	29	again	again	ADV
dpc-3517	197	30	.	.	PUNCT
dpc-3517	198	1	american	american	ADJ
dpc-3517	198	2	society	society	NOUN
dpc-3517	198	3	of	of	ADP
dpc-3517	198	4	clinical	clinical	ADJ
dpc-3517	198	5	oncology	oncology	NOUN
dpc-3517	198	6	educational	educational	ADJ
dpc-3517	198	7	book	book	NOUN
dpc-3517	198	8	.	.	PUNCT
dpc-3517	199	1	2022;(42):781	2022;(42):781	X
dpc-3517	199	2	-	-	SYM
dpc-3517	199	3	794	794	NUM
dpc-3517	199	4	.	.	PUNCT
dpc-3517	200	1	doi:10.1200	doi:10.1200	PROPN
dpc-3517	200	2	/	/	SYM
dpc-3517	200	3	edbk_349799	edbk_349799	PROPN
dpc-3517	200	4	.	.	PUNCT
dpc-3517	201	1	pmid	pmid	NOUN
dpc-3517	201	2	:	:	PUNCT
dpc-3517	201	3	35580293	35580293	NUM
dpc-3517	201	4	.	.	PUNCT
dpc-3517	202	1	16	16	NUM
dpc-3517	202	2	.	.	PUNCT
dpc-3517	203	1	davis	davis	PROPN
dpc-3517	203	2	kl	kl	PROPN
dpc-3517	203	3	,	,	PUNCT
dpc-3517	203	4	fox	fox	PROPN
dpc-3517	203	5	e	e	PROPN
dpc-3517	203	6	,	,	PUNCT
dpc-3517	203	7	reid	reid	PROPN
dpc-3517	203	8	jm	jm	PROPN
dpc-3517	203	9	,	,	PUNCT
dpc-3517	203	10	et	et	PROPN
dpc-3517	203	11	al	al	PROPN
dpc-3517	203	12	.	.	PUNCT
dpc-3517	204	1	advl1412	advl1412	PROPN
dpc-3517	204	2	:	:	PUNCT
dpc-3517	204	3	initial	initial	ADJ
dpc-3517	204	4	results	result	NOUN
dpc-3517	204	5	of	of	ADP
dpc-3517	204	6	a	a	DET
dpc-3517	204	7	phase	phase	NOUN
dpc-3517	204	8	i	i	PRON
dpc-3517	204	9	/	/	SYM
dpc-3517	204	10	ii	ii	PROPN
dpc-3517	204	11	study	study	NOUN
dpc-3517	204	12	of	of	ADP
dpc-3517	204	13	nivolumab	nivolumab	NOUN
dpc-3517	204	14	and	and	CCONJ
dpc-3517	204	15	ipilimumab	ipilimumab	VERB
dpc-3517	204	16	in	in	ADP
dpc-3517	204	17	pediatric	pediatric	ADJ
dpc-3517	204	18	patients	patient	NOUN
dpc-3517	204	19	with	with	ADP
dpc-3517	204	20	relapsed	relapse	VERB
dpc-3517	204	21	/	/	SYM
dpc-3517	204	22	refractory	refractory	NOUN
dpc-3517	204	23	solid	solid	ADJ
dpc-3517	204	24	tumors	tumor	NOUN
dpc-3517	204	25	—	—	PUNCT
dpc-3517	204	26	a	a	DET
dpc-3517	204	27	cog	cog	NOUN
dpc-3517	204	28	study	study	NOUN
dpc-3517	204	29	.	.	PUNCT
dpc-3517	205	1	j	j	PROPN
dpc-3517	205	2	clin	clin	PROPN
dpc-3517	205	3	oncol	oncol	PROPN
dpc-3517	205	4	.	.	PUNCT
dpc-3517	206	1	2017;35(15_suppl):10526	2017;35(15_suppl):10526	NUM
dpc-3517	206	2	-	-	SYM
dpc-3517	206	3	10526	10526	NUM
dpc-3517	206	4	.	.	PUNCT
dpc-3517	207	1	doi:10.1200/	doi:10.1200/	NUM
dpc-3517	207	2	jco.2017.35.15_suppl.10526	jco.2017.35.15_suppl.10526	PROPN
dpc-3517	207	3	.	.	PUNCT
dpc-3517	208	1	17	17	NUM
dpc-3517	208	2	.	.	PUNCT
dpc-3517	209	1	marjanska	marjanska	PROPN
dpc-3517	209	2	a	a	X
dpc-3517	209	3	,	,	PUNCT
dpc-3517	209	4	galazka	galazka	NOUN
dpc-3517	209	5	p	p	NOUN
dpc-3517	209	6	,	,	PUNCT
dpc-3517	209	7	marjanski	marjanski	ADJ
dpc-3517	209	8	m	m	PROPN
dpc-3517	209	9	,	,	PUNCT
dpc-3517	209	10	wysocki	wysocki	PROPN
dpc-3517	209	11	m	m	PROPN
dpc-3517	209	12	,	,	PUNCT
dpc-3517	209	13	styczynski	styczynski	PROPN
dpc-3517	209	14	j.	j.	PROPN
dpc-3517	209	15	efficacy	efficacy	PROPN
dpc-3517	209	16	and	and	CCONJ
dpc-3517	209	17	toxicity	toxicity	NOUN
dpc-3517	209	18	of	of	ADP
dpc-3517	209	19	pembrolizumab	pembrolizumab	NOUN
dpc-3517	209	20	in	in	ADP
dpc-3517	209	21	pediatric	pediatric	ADJ
dpc-3517	209	22	metastatic	metastatic	ADJ
dpc-3517	209	23	recurrent	recurrent	ADJ
dpc-3517	209	24	melanoma	melanoma	NOUN
dpc-3517	209	25	.	.	PUNCT
dpc-3517	210	1	anticancer	anticancer	NOUN
dpc-3517	210	2	res	re	NOUN
dpc-3517	210	3	.	.	PUNCT
dpc-3517	211	1	2019;39(7):3945	2019;39(7):3945	NUM
dpc-3517	211	2	-	-	SYM
dpc-3517	211	3	3947	3947	NUM
dpc-3517	211	4	.	.	PUNCT
dpc-3517	212	1	doi:10.21873	doi:10.21873	PROPN
dpc-3517	212	2	/	/	SYM
dpc-3517	212	3	anticanres.13547	anticanres.13547	PROPN
dpc-3517	212	4	.	.	PUNCT
dpc-3517	213	1	pmid	pmid	NOUN
dpc-3517	213	2	:	:	PUNCT
dpc-3517	213	3	31262925	31262925	NUM
dpc-3517	213	4	.	.	PUNCT
dpc-3517	214	1	4	4	X
dpc-3517	214	2	.	.	X
dpc-3517	214	3	geoerger	geoerger	PROPN
dpc-3517	214	4	b	b	PROPN
dpc-3517	214	5	,	,	PUNCT
dpc-3517	214	6	kang	kang	PROPN
dpc-3517	214	7	hj	hj	PROPN
dpc-3517	214	8	,	,	PUNCT
dpc-3517	214	9	yalon	yalon	PROPN
dpc-3517	214	10	-	-	PUNCT
dpc-3517	214	11	oren	oren	NOUN
dpc-3517	214	12	m	m	PROPN
dpc-3517	214	13	,	,	PUNCT
dpc-3517	214	14	et	et	PROPN
dpc-3517	214	15	al	al	PROPN
dpc-3517	214	16	.	.	PROPN
dpc-3517	214	17	pembrolizumab	pembrolizumab	NOUN
dpc-3517	214	18	in	in	ADP
dpc-3517	214	19	paediatric	paediatric	ADJ
dpc-3517	214	20	patients	patient	NOUN
dpc-3517	214	21	with	with	ADP
dpc-3517	214	22	advanced	advanced	ADJ
dpc-3517	214	23	melanoma	melanoma	NOUN
dpc-3517	214	24	or	or	CCONJ
dpc-3517	214	25	a	a	DET
dpc-3517	214	26	pd	pd	PROPN
dpc-3517	214	27	-	-	PUNCT
dpc-3517	214	28	l1	l1	NOUN
dpc-3517	214	29	-	-	PUNCT
dpc-3517	214	30	positive	positive	ADJ
dpc-3517	214	31	,	,	PUNCT
dpc-3517	214	32	advanced	advanced	ADJ
dpc-3517	214	33	,	,	PUNCT
dpc-3517	214	34	relapsed	relapse	VERB
dpc-3517	214	35	,	,	PUNCT
dpc-3517	214	36	or	or	CCONJ
dpc-3517	214	37	refractory	refractory	NOUN
dpc-3517	214	38	solid	solid	ADJ
dpc-3517	214	39	tumour	tumour	NOUN
dpc-3517	214	40	or	or	CCONJ
dpc-3517	214	41	lymphoma	lymphoma	NOUN
dpc-3517	214	42	(	(	PUNCT
dpc-3517	214	43	keynote-051	keynote-051	ADJ
dpc-3517	214	44	):	):	PUNCT
dpc-3517	214	45	interim	interim	ADJ
dpc-3517	214	46	analysis	analysis	NOUN
dpc-3517	214	47	of	of	ADP
dpc-3517	214	48	an	an	DET
dpc-3517	214	49	open	open	ADJ
dpc-3517	214	50	-	-	PUNCT
dpc-3517	214	51	label	label	NOUN
dpc-3517	214	52	,	,	PUNCT
dpc-3517	214	53	single	single	ADJ
dpc-3517	214	54	-	-	PUNCT
dpc-3517	214	55	arm	arm	NOUN
dpc-3517	214	56	,	,	PUNCT
dpc-3517	214	57	phase	phase	NOUN
dpc-3517	214	58	1	1	NUM
dpc-3517	214	59	-	-	SYM
dpc-3517	214	60	2	2	NUM
dpc-3517	214	61	trial	trial	NOUN
dpc-3517	214	62	.	.	PUNCT
dpc-3517	215	1	lancet	lancet	PROPN
dpc-3517	215	2	oncol	oncol	PROPN
dpc-3517	215	3	.	.	PUNCT
dpc-3517	216	1	2020;21(1):121	2020;21(1):121	NUM
dpc-3517	216	2	-	-	SYM
dpc-3517	216	3	133	133	NUM
dpc-3517	216	4	.	.	PUNCT
dpc-3517	217	1	doi:10.1016	doi:10.1016	PROPN
dpc-3517	217	2	/s1470	/s1470	PROPN
dpc-3517	218	1	-	-	PUNCT
dpc-3517	218	2	2045(19)30671	2045(19)30671	NUM
dpc-3517	218	3	-	-	PUNCT
dpc-3517	218	4	0	0	NUM
dpc-3517	218	5	.	.	PUNCT
dpc-3517	219	1	pmid	pmid	NOUN
dpc-3517	219	2	:	:	PUNCT
dpc-3517	219	3	31812554	31812554	NUM
dpc-3517	219	4	.	.	PUNCT
dpc-3517	220	1	5	5	X
dpc-3517	220	2	.	.	X
dpc-3517	220	3	chao	chao	PROPN
dpc-3517	220	4	mm	mm	PROPN
dpc-3517	220	5	,	,	PUNCT
dpc-3517	220	6	schwartz	schwartz	PROPN
dpc-3517	220	7	jl	jl	PROPN
dpc-3517	220	8	,	,	PUNCT
dpc-3517	220	9	wechsler	wechsler	PROPN
dpc-3517	220	10	ds	ds	PROPN
dpc-3517	220	11	,	,	PUNCT
dpc-3517	220	12	thornburg	thornburg	PROPN
dpc-3517	220	13	cd	cd	PROPN
dpc-3517	220	14	,	,	PUNCT
dpc-3517	220	15	griffith	griffith	PROPN
dpc-3517	220	16	ka	ka	PROPN
dpc-3517	220	17	,	,	PUNCT
dpc-3517	220	18	williams	williams	PROPN
dpc-3517	220	19	ja	ja	PROPN
dpc-3517	220	20	.	.	PUNCT
dpc-3517	220	21	high	high	ADJ
dpc-3517	220	22	-	-	PUNCT
dpc-3517	220	23	risk	risk	NOUN
dpc-3517	220	24	surgically	surgically	ADV
dpc-3517	220	25	resected	resect	VERB
dpc-3517	220	26	pediatric	pediatric	ADJ
dpc-3517	220	27	melanoma	melanoma	NOUN
dpc-3517	220	28	and	and	CCONJ
dpc-3517	220	29	adjuvant	adjuvant	ADJ
dpc-3517	220	30	interferon	interferon	PROPN
dpc-3517	220	31	therapy	therapy	NOUN
dpc-3517	220	32	.	.	PUNCT
dpc-3517	221	1	pediatr	pediatr	ADJ
dpc-3517	221	2	blood	blood	NOUN
dpc-3517	221	3	cancer	cancer	NOUN
dpc-3517	221	4	.	.	PUNCT
dpc-3517	222	1	2005;44(5):441	2005;44(5):441	NUM
dpc-3517	222	2	-	-	SYM
dpc-3517	222	3	448	448	NUM
dpc-3517	222	4	.	.	PUNCT
dpc-3517	222	5	doi:10.1002	doi:10.1002	NOUN
dpc-3517	222	6	/	/	SYM
dpc-3517	222	7	pbc.20168	pbc.20168	PROPN
dpc-3517	222	8	.	.	PUNCT
dpc-3517	223	1	pmid	pmid	NOUN
dpc-3517	223	2	:	:	PUNCT
dpc-3517	223	3	15468307	15468307	NUM
dpc-3517	223	4	.	.	PUNCT
dpc-3517	224	1	6	6	NUM
dpc-3517	224	2	.	.	X
dpc-3517	224	3	ferrari	ferrari	PROPN
dpc-3517	225	1	a	a	X
dpc-3517	225	2	,	,	PUNCT
dpc-3517	225	3	bisogno	bisogno	PROPN
dpc-3517	225	4	g	g	PROPN
dpc-3517	225	5	,	,	PUNCT
dpc-3517	225	6	de	de	X
dpc-3517	225	7	salvo	salvo	NOUN
dpc-3517	225	8	gl	gl	PROPN
dpc-3517	225	9	,	,	PUNCT
dpc-3517	225	10	indolfi	indolfi	VERB
dpc-3517	225	11	p	p	NOUN
dpc-3517	225	12	,	,	PUNCT
dpc-3517	225	13	perilongo	perilongo	NOUN
dpc-3517	225	14	g	g	NOUN
dpc-3517	225	15	,	,	PUNCT
dpc-3517	225	16	cecchetto	cecchetto	NOUN
dpc-3517	225	17	g.	g.	PROPN
dpc-3517	225	18	the	the	DET
dpc-3517	225	19	challenge	challenge	NOUN
dpc-3517	225	20	of	of	ADP
dpc-3517	225	21	very	very	ADV
dpc-3517	225	22	rare	rare	ADJ
dpc-3517	225	23	tumours	tumour	NOUN
dpc-3517	225	24	in	in	ADP
dpc-3517	225	25	childhood	childhood	NOUN
dpc-3517	225	26	:	:	PUNCT
dpc-3517	225	27	the	the	DET
dpc-3517	225	28	italian	italian	ADJ
dpc-3517	225	29	trep	trep	NOUN
dpc-3517	225	30	project	project	NOUN
dpc-3517	225	31	.	.	PUNCT
dpc-3517	226	1	eur	eur	PROPN
dpc-3517	226	2	j	j	PROPN
dpc-3517	226	3	cancer	cancer	NOUN
dpc-3517	226	4	.	.	PUNCT
dpc-3517	227	1	2007;43(4):654	2007;43(4):654	NUM
dpc-3517	227	2	-	-	SYM
dpc-3517	227	3	659	659	NUM
dpc-3517	227	4	.	.	PUNCT
dpc-3517	227	5	doi:10.1016	doi:10.1016	PROPN
dpc-3517	227	6	/	/	SYM
dpc-3517	227	7	j.ejca.2006.08.028	j.ejca.2006.08.028	PROPN
dpc-3517	227	8	.	.	PUNCT
dpc-3517	228	1	pmid	pmid	NOUN
dpc-3517	228	2	:	:	PUNCT
dpc-3517	228	3	17049226	17049226	NUM
dpc-3517	228	4	.	.	PUNCT
dpc-3517	229	1	7	7	X
dpc-3517	229	2	.	.	NOUN
dpc-3517	229	3	pampena	pampena	NOUN
dpc-3517	229	4	r	r	NOUN
dpc-3517	229	5	,	,	PUNCT
dpc-3517	229	6	piccolo	piccolo	NOUN
dpc-3517	229	7	v	v	NOUN
dpc-3517	229	8	,	,	PUNCT
dpc-3517	229	9	muscianese	muscianese	PROPN
dpc-3517	229	10	m	m	PROPN
dpc-3517	229	11	,	,	PUNCT
dpc-3517	229	12	et	et	PROPN
dpc-3517	229	13	al	al	PROPN
dpc-3517	229	14	.	.	PROPN
dpc-3517	229	15	melanoma	melanoma	PROPN
dpc-3517	229	16	in	in	ADP
dpc-3517	229	17	children	child	NOUN
dpc-3517	229	18	:	:	PUNCT
dpc-3517	229	19	a	a	DET
dpc-3517	229	20	systematic	systematic	ADJ
dpc-3517	229	21	review	review	NOUN
dpc-3517	229	22	and	and	CCONJ
dpc-3517	229	23	individual	individual	ADJ
dpc-3517	229	24	patient	patient	ADJ
dpc-3517	229	25	meta	meta	ADJ
dpc-3517	229	26	-	-	PUNCT
dpc-3517	229	27	analysis	analysis	NOUN
dpc-3517	229	28	.	.	PUNCT
dpc-3517	230	1	j	j	PROPN
dpc-3517	230	2	eur	eur	PROPN
dpc-3517	230	3	acad	acad	PROPN
dpc-3517	230	4	dermatol	dermatol	NOUN
dpc-3517	230	5	venereol	venereol	NOUN
dpc-3517	230	6	.	.	PUNCT
dpc-3517	231	1	2023;37(9):1758	2023;37(9):1758	NUM
dpc-3517	231	2	-	-	PUNCT
dpc-3517	231	3	1776	1776	NUM
dpc-3517	231	4	.	.	PUNCT
dpc-3517	232	1	doi:10.1111	doi:10.1111	NOUN
dpc-3517	232	2	/jdv.19220	/jdv.19220	PROPN
dpc-3517	232	3	.	.	PUNCT
dpc-3517	233	1	pmid	pmid	NOUN
dpc-3517	233	2	:	:	PUNCT
dpc-3517	233	3	37210654	37210654	NUM
dpc-3517	233	4	.	.	PUNCT
dpc-3517	234	1	8	8	NUM
dpc-3517	234	2	.	.	PUNCT
dpc-3517	235	1	weber	weber	PROPN
dpc-3517	235	2	j	j	PROPN
dpc-3517	235	3	,	,	PUNCT
dpc-3517	235	4	mandala	mandala	PROPN
dpc-3517	235	5	m	m	PROPN
dpc-3517	235	6	,	,	PUNCT
dpc-3517	235	7	del	del	PROPN
dpc-3517	235	8	vecchio	vecchio	PROPN
dpc-3517	235	9	m	m	PROPN
dpc-3517	235	10	,	,	PUNCT
dpc-3517	235	11	et	et	PROPN
dpc-3517	235	12	al	al	PROPN
dpc-3517	235	13	.	.	PROPN
dpc-3517	236	1	adjuvant	adjuvant	PROPN
dpc-3517	236	2	nivolumab	nivolumab	ADV
dpc-3517	236	3	versus	versus	ADP
dpc-3517	236	4	ipilimumab	ipilimumab	VERB
dpc-3517	236	5	in	in	ADP
dpc-3517	236	6	resected	resect	VERB
dpc-3517	236	7	stage	stage	NOUN
dpc-3517	236	8	iii	iii	NOUN
dpc-3517	236	9	or	or	CCONJ
dpc-3517	236	10	iv	iv	NUM
dpc-3517	236	11	melanoma	melanoma	NOUN
dpc-3517	236	12	.	.	PUNCT
dpc-3517	237	1	n	n	PRON
dpc-3517	237	2	engl	engl	PROPN
dpc-3517	237	3	j	j	PROPN
dpc-3517	237	4	med	med	PROPN
dpc-3517	237	5	.	.	PUNCT
dpc-3517	238	1	2017;377(19):1824	2017;377(19):1824	NUM
dpc-3517	238	2	-	-	SYM
dpc-3517	238	3	1835	1835	NUM
dpc-3517	238	4	.	.	PUNCT
dpc-3517	239	1	doi:10.1056	doi:10.1056	PROPN
dpc-3517	239	2	/	/	SYM
dpc-3517	239	3	nejmoa1	nejmoa1	NOUN
dpc-3517	239	4	709030	709030	NUM
dpc-3517	239	5	.	.	PUNCT
dpc-3517	240	1	pmid	pmid	NOUN
dpc-3517	240	2	:	:	PUNCT
dpc-3517	240	3	28891423	28891423	NUM
dpc-3517	240	4	.	.	PUNCT
dpc-3517	241	1	9	9	X
dpc-3517	241	2	.	.	X
dpc-3517	241	3	eggermont	eggermont	PROPN
dpc-3517	241	4	amm	amm	PROPN
dpc-3517	241	5	,	,	PUNCT
dpc-3517	241	6	blank	blank	PROPN
dpc-3517	241	7	cu	cu	PROPN
dpc-3517	241	8	,	,	PUNCT
dpc-3517	241	9	mandala	mandala	PROPN
dpc-3517	241	10	m	m	PROPN
dpc-3517	241	11	,	,	PUNCT
dpc-3517	241	12	et	et	PROPN
dpc-3517	241	13	al	al	PROPN
dpc-3517	241	14	.	.	PROPN
dpc-3517	241	15	adjuvant	adjuvant	PROPN
dpc-3517	241	16	pembrolizumab	pembrolizumab	NOUN
dpc-3517	241	17	versus	versus	ADP
dpc-3517	241	18	placebo	placebo	NOUN
dpc-3517	241	19	in	in	ADP
dpc-3517	241	20	resected	resect	VERB
dpc-3517	241	21	stage	stage	NOUN
dpc-3517	241	22	iii	iii	NUM
dpc-3517	241	23	melanoma	melanoma	NOUN
dpc-3517	241	24	.	.	PUNCT
dpc-3517	242	1	new	new	ADJ
dpc-3517	242	2	engl	engl	PROPN
dpc-3517	242	3	j	j	PROPN
dpc-3517	242	4	med	med	PROPN
dpc-3517	242	5	.	.	PUNCT
dpc-3517	243	1	2018;378(19):1789	2018;378(19):1789	PROPN
dpc-3517	243	2	-	-	SYM
dpc-3517	243	3	1801	1801	NUM
dpc-3517	243	4	.	.	PUNCT
dpc-3517	244	1	doi:10.1056	doi:10.1056	PROPN
dpc-3517	244	2	/	/	SYM
dpc-3517	244	3	nejmoa	nejmoa	PROPN
dpc-3517	244	4	1802357	1802357	NUM
dpc-3517	244	5	.	.	PUNCT
dpc-3517	245	1	pmid	pmid	NOUN
dpc-3517	245	2	:	:	PUNCT
dpc-3517	245	3	29658430	29658430	NUM
dpc-3517	245	4	.	.	PUNCT
dpc-3517	246	1	10	10	NUM
dpc-3517	246	2	.	.	X
dpc-3517	246	3	eggermont	eggermont	PROPN
dpc-3517	246	4	amm	amm	PROPN
dpc-3517	246	5	,	,	PUNCT
dpc-3517	246	6	blank	blank	PROPN
dpc-3517	246	7	cu	cu	PROPN
dpc-3517	246	8	,	,	PUNCT
dpc-3517	246	9	mandala	mandala	PROPN
dpc-3517	246	10	m	m	PROPN
dpc-3517	246	11	,	,	PUNCT
dpc-3517	246	12	et	et	PROPN
dpc-3517	246	13	al	al	PROPN
dpc-3517	246	14	.	.	PROPN
dpc-3517	247	1	prognostic	prognostic	ADJ
dpc-3517	247	2	and	and	CCONJ
dpc-3517	247	3	predictive	predictive	ADJ
dpc-3517	247	4	value	value	NOUN
dpc-3517	247	5	of	of	ADP
dpc-3517	247	6	ajcc-8	ajcc-8	NUM
dpc-3517	247	7	staging	stage	VERB
dpc-3517	247	8	in	in	ADP
dpc-3517	247	9	the	the	DET
dpc-3517	247	10	phase	phase	NOUN
dpc-3517	247	11	iii	iii	NUM
dpc-3517	247	12	eortc1325	eortc1325	PROPN
dpc-3517	247	13	/keynote-054	/keynote-054	PROPN
dpc-3517	247	14	trial	trial	NOUN
dpc-3517	247	15	of	of	ADP
dpc-3517	247	16	pembrolizumab	pembrolizumab	NOUN
dpc-3517	247	17	vs	vs	ADP
dpc-3517	247	18	placebo	placebo	NOUN
dpc-3517	247	19	in	in	ADP
dpc-3517	247	20	resected	resect	VERB
dpc-3517	247	21	high	high	ADJ
dpc-3517	247	22	-	-	PUNCT
dpc-3517	247	23	risk	risk	NOUN
dpc-3517	247	24	stage	stage	NOUN
dpc-3517	247	25	iii	iii	NUM
dpc-3517	247	26	melanoma	melanoma	NOUN
dpc-3517	247	27	.	.	PUNCT
dpc-3517	248	1	eur	eur	PROPN
dpc-3517	248	2	j	j	PROPN
dpc-3517	248	3	cancer	cancer	NOUN
dpc-3517	248	4	.	.	PUNCT
dpc-3517	249	1	2019;116:148	2019;116:148	NUM
dpc-3517	249	2	-	-	SYM
dpc-3517	249	3	157	157	NUM
dpc-3517	249	4	.	.	PUNCT
dpc-3517	249	5	doi:10.1016	doi:10.1016	PROPN
dpc-3517	249	6	/	/	SYM
dpc-3517	249	7	j.ejca.2019.05.020	j.ejca.2019.05.020	PROPN
dpc-3517	249	8	.	.	PUNCT
dpc-3517	250	1	pmid	pmid	NOUN
dpc-3517	250	2	:	:	PUNCT
dpc-3517	250	3	31200321	31200321	NUM
dpc-3517	250	4	.	.	PUNCT
dpc-3517	251	1	11	11	NUM
dpc-3517	251	2	.	.	PUNCT
dpc-3517	252	1	luke	luke	PROPN
dpc-3517	252	2	jj	jj	PROPN
dpc-3517	252	3	,	,	PUNCT
dpc-3517	252	4	rutkowski	rutkowski	PROPN
dpc-3517	252	5	p	p	X
dpc-3517	252	6	,	,	PUNCT
dpc-3517	252	7	queirolo	queirolo	PROPN
dpc-3517	252	8	p	p	X
dpc-3517	252	9	,	,	PUNCT
dpc-3517	252	10	et	et	PROPN
dpc-3517	252	11	al	al	PROPN
dpc-3517	252	12	.	.	PROPN
dpc-3517	252	13	pembrolizumab	pembrolizumab	NOUN
dpc-3517	252	14	versus	versus	ADP
dpc-3517	252	15	placebo	placebo	NOUN
dpc-3517	252	16	as	as	ADP
dpc-3517	252	17	adjuvant	adjuvant	ADJ
dpc-3517	252	18	therapy	therapy	NOUN
dpc-3517	252	19	in	in	ADP
dpc-3517	252	20	completely	completely	ADV
dpc-3517	252	21	resected	resect	VERB
dpc-3517	252	22	stage	stage	NOUN
dpc-3517	252	23	iib	iib	NOUN
dpc-3517	252	24	or	or	CCONJ
dpc-3517	252	25	iic	iic	PROPN
dpc-3517	252	26	melanoma	melanoma	PROPN
dpc-3517	252	27	(	(	PUNCT
dpc-3517	252	28	keynote-716	keynote-716	NOUN
dpc-3517	252	29	):	):	PUNCT
dpc-3517	252	30	a	a	DET
dpc-3517	252	31	randomised	randomised	ADJ
dpc-3517	252	32	,	,	PUNCT
dpc-3517	252	33	double	double	ADJ
dpc-3517	252	34	-	-	PUNCT
dpc-3517	252	35	blind	blind	ADJ
dpc-3517	252	36	,	,	PUNCT
dpc-3517	252	37	phase	phase	NOUN
dpc-3517	252	38	3	3	NUM